Systems and methods for transposing cargo nucleotide sequences

Through the binding of Cas effector and transposase complex, efficient transposition of cargo nucleotide sequences at target nucleic acid sites is achieved, solving the problem of insufficient transposition efficiency and accuracy of the existing CRISPR/Cas system, and providing An efficient and controllable gene editing method is created.

CN119095974APending Publication Date: 2024-12-06METAGENOMI THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380023368.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-23
Filing Date
2023-02-23
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing CRISPR/Cas systems have problems with insufficient transposition efficiency and accuracy in gene editing and DNA manipulation, especially in the transposition of cargo nucleotide sequences at specific target sites, which are difficult to achieve high efficiency and controllability.

Method used

Provide a system, including Cas effector complexes and recombinant or transposase complexes, to achieve efficient transposition of cargo nucleotide sequences through specific interactions with target nucleic acid sites, Cas effectors and transpositions in the system The non-covalent or covalent binding of the enzyme complex, combining TnsA, TnsB, TnsC and TniQ components, ensures target accuracy.

Benefits of technology

It improves the transposition efficiency and accuracy of cargo nucleotide sequences at target nucleic acid sites, ensures the controllability and efficiency of the transposition process, and is suitable for gene editing and manipulation applications of various cell types.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095974A_ABST
    Figure CN119095974A_ABST
Patent Text Reader

Abstract

The present disclosure provides systems and methods for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid. These systems and methods can include: a double-stranded nucleic acid comprising the cargo nucleotide sequence, where the cargo nucleotide sequence is configured to interact with a recombinase or transposase complex; an effector complex comprising an effector and at least one engineered guide polynucleotide configured to hybridize to the target nucleic acid; and the recombinase or transposase complex, wherein the recombinase or transposase complex is configured to recruit the cargo nucleotide to the target nucleic acid site.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-reference to related applications

[0002] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 313,122, filed on February 23, 2022, which is hereby incorporated by reference in its entirety for all purposes.

[0003] Sequence Listing

[0004] The contents of the electronic sequence listing (MTG-011WO_SL.xml; size: 527,165 bytes; and creation date: February 23, 2023) are incorporated herein by reference in their entirety. Background Art

[0005] Cas enzymes and their associated clustered regularly interspaced short palindromic repeats (CRISPR) guide RNAs appear to be ubiquitous (~45% of bacteria, ~84% of archaea) components of the prokaryotic immune system, serving to protect such microorganisms from non-self nucleic acids, such as infectious viruses and plasmids, through CRISPR-RNA-guided nucleic acid cleavage. While the deoxyribonucleic acid (DNA) elements encoding CRISPR RNA elements may be relatively conserved in structure and length, their CRISPR-associated (Cas) proteins are highly diverse, containing a variety of nucleic acid interaction domains. Although CRISPR DNA elements were observed as early as 1987, the programmable endonuclease cleavage capabilities of the CRISPR / Cas complex were not recognized until recently, leading to the use of recombinant CRISPR / Cas systems in a variety of DNA manipulation and gene editing applications. Summary of the invention

[0006] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site, the system comprising: a first double-stranded nucleic acid, the first double-stranded nucleic acid comprising the cargo nucleotide sequence, wherein the cargo nucleotide sequence is configured to interact with a recombinase or transposase complex; a Cas effector complex, the Cas effector complex comprising 2 types of type II Cas effectors and at least one engineered guide polynucleotide configured to hybridize with the target nucleic acid site; and the recombinase or transposase complex, wherein the recombinase or transposase complex is configured to recruit the cargo nucleotide sequence to the target nucleic acid site. In some embodiments, the recombinase or transposase complex is non-covalently bound to the Cas effector complex. In some embodiments, the recombinase or transposase complex is covalently linked to the Cas effector complex. In some embodiments, the recombinase or transposase complex is fused to the Cas effector complex in a single polypeptide. In some embodiments, the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence. In some embodiments, the system further comprises a second double-stranded nucleic acid comprising the target nucleic acid site. In some embodiments, the system further comprises a PAM sequence compatible with the Cas effector complex adjacent to the target nucleic acid site. In some embodiments, the PAM sequence is located 3' to the target nucleic acid site. In some embodiments, the recombinase or transposase complex is a Tn7-type transposase complex. In some embodiments, the engineered guide polynucleotide is configured to bind to the 2 class II type Cas effectors. In some embodiments, the 2 class II type Cas effectors include a polypeptide comprising a sequence having at least about 80% identity with SEQ ID NO: 1 or a variant thereof. In some embodiments, the recombinase or transposase complex includes at least one, at least two, at least three or four polypeptides comprising a sequence having at least 80% identity with any one of SEQ ID NO: 2-5 or a variant thereof. In some embodiments, the engineered guide polynucleotide includes a sequence comprising at least 60-80 consecutive nucleotides having at least 80% identity with SEQ ID NO: 12 or a variant thereof. In some embodiments, the engineered guide polynucleotide includes a sequence having at least 80% identity with SEQ ID NO: 11 or a variant thereof. In some embodiments, the left recombinase sequence comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 17-18 or variants thereof. In some embodiments, the right recombinase sequence comprises a sequence having at least 80% identity to SEQ ID NO: 19 or variants thereof. In some embodiments, the 2 class II type Cas effectors and the recombinase or transposase complex are encoded by a polynucleotide sequence comprising less than about 10 kilobases.

[0007] In some aspects, the disclosure provides a method for transposing a cargo nucleotide sequence into a target nucleic acid site comprising a target nucleotide sequence, the method comprising expressing the system of any aspect or embodiment described herein in a cell or introducing the system of any aspect or embodiment described herein into a cell.

[0008] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site, the system comprising: a first double-stranded nucleic acid, the first double-stranded nucleic acid comprising a cargo nucleotide sequence configured to interact with a Tn7-type transposase complex; a Cas effector complex, the Cas effector complex comprising 2 types of V-type Cas effectors and an engineered guide polynucleotide, the engineered guide polynucleotide being configured to hybridize with the target nucleotide sequence; and a Tn7-type transposase complex, the Tn7-type transposase complex being configured to bind to the Cas effector complex, wherein the Tn7-type transposase complex comprises a TnsA subunit. In some embodiments, the transposase complex is non-covalently bound to the Cas effector complex. In some embodiments, the transposase complex is covalently linked to the Cas effector complex. In some embodiments, the transposase complex is fused to the Cas effector complex in a single polypeptide. In some embodiments, the 2 types of V-type Cas effectors are not Cas12k effectors. In some embodiments, the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence. In some embodiments, the system further comprises a second double-stranded nucleic acid comprising the target nucleic acid site. In some embodiments, the system further comprises a PAM sequence compatible with the Cas effector complex adjacent to the target nucleic acid site. In some embodiments, the PAM sequence is located 5' of the target nucleic acid site. In some embodiments, the engineered guide polynucleotide is configured to bind to the 2-type V-type Cas effector. In some embodiments, the TnsA subunit comprises a polypeptide having a sequence with at least 80% identity to SEQ ID NO: 7 or a variant thereof. In some embodiments, the Tn7-type transposase complex comprises at least one, at least two or three polypeptides comprising a sequence with at least about 80% identity to any one of SEQ ID NO: 8-10 or a variant thereof. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides having at least 80% identity to any one of SEQ ID NO: 13-16 or a variant thereof. In some embodiments, the left recombinase sequence comprises a sequence with at least about 80% identity to SEQ ID NO: 20 or a variant thereof. In some embodiments, the right recombinase sequence comprises a sequence having at least about 80% identity to SEQ ID NO: 21 or a variant thereof. In some embodiments, the Class 2 Type V Cas effector is not a Cas12k effector. In some embodiments, the Class 2 Type V Cas effector and the Tn7-type transposase complex are encoded by a polynucleotide sequence comprising less than about 10 kilobases.

[0009] In some aspects, the disclosure provides a method for transposing a cargo nucleotide sequence into a target nucleic acid site comprising a target nucleotide sequence, the method comprising expressing the system of any of any aspects or embodiments described herein in a cell or introducing the system of any of the aspects or embodiments described herein into a cell.

[0010] In some aspects, the present disclosure provides a method for transposing a cargo nucleotide sequence into a target nucleic acid site, the method comprising contacting a first double-stranded nucleic acid comprising the cargo nucleotide sequence with: a Cas effector complex comprising 2 class II type Cas effectors and at least one engineered guide polynucleotide configured to hybridize with the target nucleic acid site; a recombinase or transposase complex configured to recruit the cargo nucleotide to the target nucleic acid site; and a second double-stranded nucleic acid comprising the target nucleic acid site. In some embodiments, the recombinase or transposase complex binds to the Cas effector complex non-covalently. In some embodiments, the recombinase or transposase complex is covalently linked to the Cas effector complex. In some embodiments, the recombinase or transposase complex is fused to the Cas effector complex in a single polypeptide. In some embodiments, the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence. In some embodiments, the target nucleic acid further comprises a PAM sequence compatible with the Cas effector complex adjacent to the target nucleic acid site. In some embodiments, the PAM sequence is located 3' of the target nucleic acid site. In some embodiments, the recombinase or transposase complex is a Tn7-type transposase complex. In some embodiments, the engineered guide polynucleotide is configured to bind to the 2nd type II Cas effector. In some embodiments, the 2nd type II Cas effector includes a polypeptide comprising a sequence having at least about 80% identity with SEQ ID NO: 1 or a variant thereof. In some embodiments, the recombinase or transposase complex includes at least one, at least two, at least three or four polypeptides comprising a sequence having at least 80% identity with any one of SEQ ID NO: 2-5 or a variant thereof. In some embodiments, the engineered guide polynucleotide includes a sequence comprising at least 60-80 consecutive nucleotides having at least 80% identity with SEQ ID NO: 12 or a variant thereof. In some embodiments, the engineered guide polynucleotide includes a sequence having at least 80% identity with SEQ ID NO: 11 or a variant thereof. In some embodiments, the left recombinase sequence includes a sequence having at least 80% identity with any one of SEQ ID NO: 17-18 or a variant thereof. In some embodiments, the right recombinase sequence comprises a sequence having at least 80% identity to SEQ ID NO: 19 or a variant thereof. In some embodiments, the 2 class II type Cas effectors and the Tn7 type transposase complex are encoded by a polynucleotide sequence comprising less than about 10 kilobases.

[0011] In some aspects, the present disclosure provides a method for transposing a cargo nucleotide sequence into a target nucleic acid site, the method comprising contacting a first double-stranded nucleic acid comprising the cargo nucleotide sequence with: a Cas effector complex comprising a 2-type V-type Cas effector and at least one engineered guide polynucleotide, the at least one engineered guide polynucleotide being configured to hybridize with the target nucleotide sequence; a Tn7-type transposase complex, the Tn7-type transposase complex being configured to bind to the Cas effector complex, wherein the Tn7-type transposase complex comprises a TnsA subunit; and a second double-stranded nucleic acid comprising the target nucleic acid site. In some embodiments, the transposase complex is non-covalently bound to the Cas effector complex. In some embodiments, the transposase complex is covalently linked to the Cas effector complex. In some embodiments, the transposase complex is fused to the Cas effector complex in a single polypeptide. In some embodiments, the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence. In some embodiments, the target nucleic acid site further comprises a PAM sequence compatible with the Cas effector complex adjacent to the target nucleic acid site. In some embodiments, the PAM sequence is located 3' to the target nucleic acid site. In some embodiments, the engineered guide polynucleotide is configured to bind to the 2-type V-type Cas effector. In some embodiments, the TnsA subunit comprises a polypeptide having a sequence having at least 80% identity with SEQ ID NO:7 or a variant thereof. In some embodiments, the Tn7-type transposase complex comprises at least one, at least two or three polypeptides comprising a sequence having at least about 80% identity with any one of SEQ ID NO:8-10 or a variant thereof. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides having at least 80% identity with any one of SEQ ID NO:13-16 or a variant thereof. In some embodiments, the left recombinase sequence comprises a sequence having at least about 80% identity with SEQ ID NO:20 or a variant thereof. In some embodiments, the right recombinase sequence comprises a sequence having at least about 80% identity with SEQ ID NO:21 or a variant thereof. In some embodiments, the class 2 type V Cas effector is not a Cas12k effector. In some embodiments, the class 2 type V Cas effector and the Tn7 type transposase complex are encoded by a polynucleotide sequence comprising less than about 10 kilobases.

[0012] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site, the system comprising: a first double-stranded nucleic acid, the first double-stranded nucleic acid comprising a cargo nucleotide sequence configured to interact with a Tn7-type transposase complex; a Cas effector complex, the Cas effector complex comprising a class 1 IF-type Cas effector and an engineered guide polynucleotide, the engineered guide polynucleotide being configured to hybridize with the target nucleotide sequence; and a Tn7-type transposase complex, the Tn7-type transposase complex being configured to bind to the Cas effector complex, wherein the Tn7-type transposase complex comprises a TnsA subunit. In some embodiments, the transposase complex is non-covalently bound to the Cas effector complex. In some embodiments, the transposase complex is covalently linked to the Cas effector complex. In some embodiments, the transposase complex is fused to the Cas effector complex in a single polypeptide. In some embodiments, the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence. In some embodiments, the system further comprises a second double-stranded nucleic acid comprising the target nucleic acid site. In some embodiments, the system further comprises a PAM sequence compatible with the Cas effector complex adjacent to the target nucleic acid site. In some embodiments, the PAM sequence is located 3' of the target nucleic acid site. In some embodiments, the PAM sequence is located 5' of the target nucleic acid site. In some embodiments, the engineered guide polynucleotide is configured to bind to the class 1 IF type Cas effector. In some embodiments, the class 1 IF type Cas effector comprises a polypeptide comprising a sequence having at least 80% identity to any one of SEQ ID NOs: 41-43 and 48-50 or a variant thereof. In some embodiments, the Tn7 type transposase complex comprises at least one, at least two or three polypeptides comprising a sequence having at least 80% identity to any one of SEQ ID NOs: 44-46 and 51-53 or a variant thereof.

[0013] In some aspects, the present disclosure provides a method for transposing a cargo nucleotide sequence into a target nucleic acid site comprising a target nucleotide sequence, the method comprising expressing the system of any of the aspects or embodiments described herein in a cell or introducing the system of any of the aspects or embodiments described herein into a cell.

[0014] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site, the system comprising: a first double-stranded nucleic acid, the first double-stranded nucleic acid comprising a cargo nucleotide sequence configured to interact with a Tn7-type transposase complex; a Cas effector complex, the Cas effector complex comprising a 2-type V-type Cas effector and an engineered guide polynucleotide, the engineered guide polynucleotide being configured to hybridize with the target nucleotide sequence; and a Tn7-type transposase complex, the Tn7-type transposase complex being configured to bind to the Cas effector complex, wherein the Tn7-type transposase complex comprises TnsB, TnsC, and TniQ components, wherein: (a) the 2-type V-type Cas effector comprises a polypeptide having a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689, or a variant thereof; or (b) the Tn7-type transposase complex comprises a polypeptide having a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689, or a variant thereof; NO: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343 and 345-347 or a variant thereof having a TnsB, TnsC or TniQ component of a sequence having at least 80% sequence identity. In some embodiments, the transposase complex is non-covalently bound to the Cas effector complex. In some embodiments, the transposase complex is covalently linked to the Cas effector complex. In some embodiments, the transposase complex is fused to the Cas effector complex in a single polypeptide. In some embodiments, the Class 2 V-type Cas effector includes a polypeptide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NO: 22, 26, 30, 34, 55-89, 104, 147, 264-304 and 660-689 or a variant thereof. In some embodiments, the Tn7-type transposase complex includes a TnsB, TnsC or TniQ component comprising a sequence having at least 80% sequence identity with any one of SEQ ID NO: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343 and 345-347 or a variant thereof. In some embodiments, the 2 types of V-type Cas effectors are Cas12k effectors. In some embodiments, the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence. In some embodiments, the system further includes a second double-stranded nucleic acid comprising the target nucleic acid site. In some embodiments, the system further includes a PAM sequence compatible with the Cas effector complex adjacent to the target nucleic acid site.In some embodiments, the PAM sequence is located 5' of the target nucleic acid site. In some embodiments, the PAM sequence comprises 5'-nGTn-3' or 5'-nGTt-3'. In some embodiments, the engineered guide polynucleotide is configured to bind to the class 2 type V Cas effector. In some embodiments, the TnsB, TnsC and TniQ components include a polypeptide having a sequence having at least 80% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343 or 345-347, respectively. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides having at least 80% identity to any one of SEQ ID NOs: 90, 91, 92, 93, 117, 151, 156-181 or 209-234. In some embodiments, the engineered guide polynucleotide comprises a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 111-114, 201-206, 255, 262, 256, 209, 257, 263, 258, 210, 348, or 350-353, or variants thereof. In some embodiments, the left recombinase sequence comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467, or variants thereof. In some embodiments, the right recombinase sequence comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466, and 468, or variants thereof. In some embodiments, the class 2 type V Cas effector and the Tn7-type transposase complex are encoded by a polynucleotide sequence comprising less than about 10 kilobases.In some embodiments: (a) the Class 2 V-type Cas effector comprises a sequence having at least 80% sequence identity to SEQ ID NO: 22 or a variant thereof; (b) the left recombinase sequence comprises a sequence having at least 80% sequence identity to SEQ ID NO: 125 or a variant thereof; (c) the right recombinase sequence comprises a sequence having at least 80% identity to SEQ ID NO: 126 or 155 or a variant thereof; (d) the engineered guide polynucleotide: (i) comprises a sequence having at least 80% sequence identity to at least about 46-60 nucleotides of SEQ ID NO: 90; or (ii) comprises a sequence having at least 80% sequence identity to the non-degenerate nucleotides of any one of SEQ ID NO: 94, 112 or 202; or (e) the TnsB, TnsC and TniQ components comprise a sequence having at least 80% sequence identity to any one of SEQ ID NO: 23-25 ​​or a variant thereof. In some embodiments: (a) the Class 2 V-type Cas effector comprises a sequence having at least 80% sequence identity to SEQ ID NO: 26 or a variant thereof; (b) the left recombinase sequence comprises a sequence having at least 80% sequence identity to SEQ ID NO: 127 or a variant thereof; (c) the right recombinase sequence comprises a sequence having at least 880% identity to SEQ ID NO: 128 or a variant thereof; (d) the engineered guide polynucleotide: (i) comprises a sequence having at least 80% sequence identity to at least about 46-60 nucleotides of any one of SEQ ID NO: 91, 156 or 209; or (ii) comprises a sequence having at least 80% sequence identity to non-degenerate nucleotides of any one of SEQ ID NO: 95, 113 or 203; or (e) the TnsB, TnsC and TniQ components comprise a sequence having at least 80% sequence identity to any one of SEQ ID NO: 27-29 or a variant thereof.In some embodiments: (a) the Class 2 V-type Cas effector comprises a sequence having at least 80% sequence identity with SEQ ID NO: 60 or a variant thereof; (b) the left recombinase sequence comprises a sequence having at least 80% sequence identity with SEQ ID NO: 131 or a variant thereof; (c) the right recombinase sequence comprises a sequence having at least 80% identity with SEQ ID NO: 132 or a variant thereof; (d) the engineered guide polynucleotide: (i) comprises a sequence having at least 80% sequence identity with at least about 46-60 nucleotides of any one of SEQ ID NO: 117, 161 or 214; or (ii) comprises a sequence having at least 80% sequence identity with non-degenerate nucleotides of SEQ ID NO: 119; or (e) the TnsB, TnsC and TniQ components comprise a sequence having at least 80% sequence identity with any one of SEQ ID NO: 101-103 or a variant thereof. In some embodiments: (a) the Class 2 V-type Cas effector comprises a sequence having at least 80% sequence identity to SEQ ID NO: 147 or a variant thereof; (b) the left recombinase sequence comprises a sequence having at least 80% sequence identity to SEQ ID NO: 153 or a variant thereof; (c) the right recombinase sequence comprises a sequence having at least 880% identity to SEQ ID NO: 154 or a variant thereof; (d) the engineered guide polynucleotide: (i) comprises a sequence having at least 80% sequence identity to at least about 46-60 nucleotides of any one of SEQ ID NO: 151, 181 or 234; or (ii) comprises a sequence having at least 80% sequence identity to non-degenerate nucleotides of SEQ ID NO: 152 or 254; or (e) the TnsB, TnsC and TniQ components comprise a sequence having at least 80% sequence identity to any one of SEQ ID NO: 148-150 or a variant thereof.In some embodiments: (a) the Class 2 V-type Cas effector comprises a sequence having at least 80% sequence identity to SEQ ID NO: 34 or a variant thereof; (b) the left recombinase sequence comprises a sequence having at least 80% sequence identity to SEQ ID NO: 129 or a variant thereof; (c) the right recombinase sequence comprises a sequence having at least 880% identity to SEQ ID NO: 130 or a variant thereof; (d) the engineered guide polynucleotide: (i) comprises a sequence having at least 80% sequence identity to at least about 46-60 nucleotides of any one of SEQ ID NO: 93, 157 or 210; or (ii) comprises a sequence having at least 80% sequence identity to non-degenerate nucleotides of any one of SEQ ID NO: 97, 114 or 204; or (e) the TnsB, TnsC and TniQ components comprise a sequence having at least 80% sequence identity to any one of SEQ ID NO: 148-150 or a variant thereof. In some embodiments: (a) the Class 2 V-type Cas effector comprises a sequence having at least 80% sequence identity with SEQ ID NO: 30 or a variant thereof; (b) the left recombinase sequence comprises a sequence having at least 80% sequence identity with SEQ ID NO: 123 or a variant thereof; (c) the right recombinase sequence comprises a sequence having at least 80% identity with SEQ ID NO: 124 or a variant thereof; (d) the engineered guide polynucleotide: (i) comprises a sequence having at least 80% sequence identity with at least about 46-80 nucleotides of SEQ ID NO: 92; or (ii) comprises a sequence having at least 80% identity with non-degenerate nucleotides of SEQ ID NO: 111 or 201; or (e) the TnsB, TnsC and TniQ components comprise a sequence having at least 80% identity with any one of SEQ ID NO: 31, 32 and 33 or a variant thereof; (f) the PAM sequence comprises 5'-nGTn-3' or 5'-nGTt-3'.

[0015] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site, the system comprising: a first double-stranded nucleic acid, the first double-stranded nucleic acid comprising a cargo nucleotide sequence configured to interact with a Tn7-type transposase complex; a Cas effector complex, the Cas effector complex comprising 2 types of V-type Cas effectors and an engineered guide polynucleotide, the engineered guide polynucleotide being configured to hybridize with the target nucleotide sequence; and a Tn7-type transposase complex, the Tn7-type transposase complex being configured to bind to the Cas effector complex, wherein the Tn7-type transposase complex comprises TnsB and TnsC components but does not include TnsA and / or TniQ components. In some embodiments, the transposase complex is non-covalently bound to the Cas effector complex. In some embodiments, the transposase complex is covalently linked to the Cas effector complex. In some embodiments, the transposase complex is fused to the Cas effector complex in a single polypeptide. In some embodiments, the Tn7-type transposase complex comprises a sequenced polypeptide having at least 80% sequence identity to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some embodiments, the TnsB component comprises a polypeptide comprising a sequence having at least 80% sequence identity to SEQ ID NO: 40 or 109. In some embodiments, the TnsC component comprises a polypeptide comprising a sequence having at least 80% sequence identity to SEQ ID NO: 39 or 110. In some embodiments, the Class 2 V-type Cas effector is a Cas12k effector. In some embodiments, the Class 2 V-type Cas effector comprises a sequence having at least 80% sequence identity to SEQ ID NO: 38 or SEQ ID NO: 108. In some embodiments, the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence. In some embodiments, the system further comprises a second double-stranded nucleic acid comprising the target nucleic acid site. In some embodiments, the double-stranded nucleic acid comprising the target nucleic acid site or the system is located within a cell. In some embodiments, the system further comprises a PAM sequence adjacent to the target nucleic acid site that is compatible with the Cas effector complex. In some embodiments, the PAM sequence is located 5' of the target nucleic acid site. In some embodiments, the engineered guide polynucleotide is configured to bind to the Class 2 Type V Cas effector. In some embodiments, the TnsB and TnsC components comprise sequences having at least 80% identity to SEQ ID NOs: 40 and 39 or 109 and 110, respectively.In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides having at least 80% identity to any one of SEQ ID NOs: 118, 182, 183, 235, and 236, or variants thereof. In some embodiments, the engineered guide polynucleotide comprises a sequence having at least 80% identity to non-degenerate nucleotides of any one of SEQ ID NOs: 115, 116, 205, 206, 261, 235, 260, or 236, or variants thereof. In some embodiments, the left recombinase sequence comprises a sequence having at least 80% identity to SEQ ID NO: 134. In some embodiments, the right recombinase sequence comprises a sequence having at least about 80% identity to SEQ ID NO: 135, or variants thereof. In some embodiments, the class 2 type V Cas effector and the Tn7-type transposase complex are encoded by a polynucleotide sequence comprising less than about 10 kilobases. In some embodiments, (a) the Class 2 V-type Cas effector comprises a sequence having at least 80% sequence identity to SEQ ID NO: 38 or a variant thereof; (b) the left recombinase sequence comprises a sequence having at least 80% sequence identity to SEQ ID NO: 134 or a variant thereof; (c) the right recombinase sequence comprises a sequence having at least 80% identity to SEQ ID NO: 135 or a variant thereof; (d) the engineered guide polynucleotide: (i) comprises a sequence having at least 80% sequence identity to at least about 46-80 nucleotides of SEQ ID NO: 182 or 235; or (ii) comprises a sequence having at least 80% identity to non-degenerate nucleotides of SEQ ID NO: 98, 115-116 or 205-206 and 493; or (e) the TnsB and TnsC components comprise polypeptides having a sequence having at least 80% identity to any one of SEQ ID NO: 40 and 39 or a variant thereof.

[0016] In some aspects, the present disclosure provides an engineered nuclease system, the engineered nuclease system comprising: an endonuclease comprising a RuvC domain and a HNH domain, wherein the endonuclease is derived from an uncultured microorganism, wherein the endonuclease is a Class 2 Type II endonuclease, and the Class 2 Type II endonuclease comprises a sequence having at least 80% identity with SEQ ID NO: 1 or a variant thereof; (b) an engineered guide polynucleotide, wherein the engineered guide polynucleotide is configured to form a complex with the endonuclease, and the engineered guide polynucleotide comprises a spacer sequence configured to hybridize with a target nucleic acid sequence. In some embodiments, the engineered guide polynucleotide comprises at least 60-80 consecutive nucleotides having at least 80% identity with SEQ ID NO: 12 or a variant thereof. In some embodiments, the engineered guide polynucleotide comprises a sequence having at least 80% identity with SEQ ID NO: 11 or a variant thereof.

[0017] In some aspects, the present disclosure provides an engineered nuclease system comprising: an endonuclease comprising a RuvC domain, wherein the endonuclease is derived from an uncultured microorganism, and wherein the endonuclease is a Class 2 V-type endonuclease having at least 80% identity to SEQ ID NO: 5; an engineered guide polynucleotide, wherein the engineered guide polynucleotide is configured to form a complex with the endonuclease, and the engineered guide RNA comprises a spacer sequence configured to hybridize to a target nucleic acid sequence. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides having at least 80% identity to any one of SEQ ID NO: 13-16 or a variant thereof.

[0018] In some aspects, the present disclosure provides an engineered nuclease system, comprising: a nuclease comprising a RuvC domain, wherein the nuclease is derived from an uncultured microorganism, and wherein the nuclease is a Class 2 V-type nuclease having at least 80% identity with any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689, or a variant thereof; and an engineered guide polynucleotide, wherein the engineered guide polynucleotide is configured to form a complex with the nuclease, and the engineered guide RNA comprises a spacer sequence configured to hybridize to a target nucleic acid sequence. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides having at least 80% identity to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739, or variants thereof. In some embodiments, the engineered guide polynucleotide comprises a sequence having at least 80% sequence identity to non-degenerate nucleotides of any one of SEQ ID NOs: 111-114, 201-206, 255, 262, 256, 209, 257, 263, 258, 210, 348, or 350-353, or variants thereof.

[0019] In some aspects, the present disclosure provides an engineered nuclease system, the engineered nuclease system comprising: a nuclease comprising a RuvC domain, wherein the nuclease is derived from an uncultured microorganism, and wherein the nuclease is a Class 2 VK-type nuclease with at least 80% identity to SEQ ID NO: 38 or SEQ ID NO: 108 or a variant thereof; and an engineered guide polynucleotide, wherein the engineered guide polynucleotide is configured to form a complex with the nuclease, and the engineered guide RNA comprises a spacer sequence configured to hybridize to a target nucleic acid sequence. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides with at least 80% identity to any one of SEQ ID NO: 118, 182, 183, 235 and 236 or a variant thereof. In some embodiments, the engineered guide polynucleotide comprises a sequence that is at least 80% identical to non-degenerate nucleotides of any one of SEQ ID NOs: 111-114, 201-206, 255, 262, 256, 209, 257, 263, 258, 210, 115, 116, 205, 206, 261, 235, 260, 236, 348, or 350-353, or variants thereof.

[0020] In some aspects, the present disclosure provides an engineered nuclease system, comprising: a Class I IF-type Cas endonuclease, comprising at least one Cas6, Cas7 or Cas8 polypeptide comprising a sequence having at least 80% identity to any one of SEQ ID NOs: 41-43 and 48-50 or a variant thereof; and an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease, and the engineered guide RNA comprises a spacer sequence configured to hybridize to a target nucleic acid sequence. In some embodiments, the engineered guide polynucleotide comprises a sequence having at least 80% identity to a non-degenerate nucleotide of any one of SEQ ID NOs: 121, 122, 207 and 208.

[0021] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a Cas effector complex comprising 2 class II type Cas effectors, a small prokaryotic ribosomal protein subunit S15, and an engineered guide polynucleotide configured to hybridize to the target nucleic acid site; a recombinase or transposase complex configured to bind to the Cas effector complex; and a double-stranded nucleic acid configured to interact with the recombinase or transposase complex and comprising a cargo nucleotide sequence.

[0022] In some embodiments, the Cas effector complex is non-covalently bound to a recombinase or transposase complex. In some embodiments, the Cas effector complex is covalently linked to a recombinase or transposase complex. In some embodiments, the Cas effector complex is fused to a recombinase or transposase complex. In some embodiments, the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence recognized by a recombinase or transposase complex. In some embodiments, the left recombinase sequence includes a sequence having at least 80% identity to any one of SEQ ID NOs: 17-18. In some embodiments, the right recombinase sequence includes a sequence having at least 80% identity to SEQ ID NO: 19.

[0023] In some embodiments, the target nucleic acid includes a PAM sequence that is compatible with the Cas effector complex. In some embodiments, the PAM sequence is located about 50 to about 70 base pairs from the target nucleic acid site. In some embodiments, the PAM sequence is located 3' of the target nucleic acid site. In some embodiments, the PAM sequence is located 5' of the target nucleic acid site.

[0024] In some embodiments, the 2nd class II type Cas effector is not a Cas12k effector. In some embodiments, the 2nd class II type Cas effector includes a polypeptide comprising a sequence having at least 80% identity with SEQ ID NO: 1. In some embodiments, the 2nd class II type Cas effector includes a polypeptide comprising a sequence having at least 90% identity with SEQ ID NO: 1. In some embodiments, the 2nd class II type Cas effector includes a polypeptide comprising a sequence of SEQ ID NO: 1. In some embodiments, the recombinase or transposase complex includes at least one polypeptide comprising a sequence having at least 80% identity with any one of SEQ ID NO: 2-5. In some embodiments, the recombinase or transposase complex includes at least one polypeptide comprising a sequence having at least 90% identity with any one of SEQ ID NO: 2-5. In some embodiments, the recombinase or transposase complex includes at least one polypeptide comprising a sequence having at least 90% identity with any one of SEQ ID NO: 2-5. In some embodiments, the recombinase or transposase complex includes at least one polypeptide comprising a sequence of any one of SEQ ID NO: 2-5.

[0025] In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides having at least 80% identity to SEQ ID NO: 12. In some embodiments, the engineered guide polynucleotide comprises a sequence having at least 80% sequence identity to SEQ ID NO:11.

[0026] In some embodiments, the small prokaryotic ribosomal protein subunit S15 comprises a sequence having at least 80% sequence identity to any one of any one of SEQ ID NOs: 494-659. In some embodiments, the Class 2 type II Cas effector and recombinase or transposase complex is encoded by a polynucleotide sequence comprising less than about 10 kilobases.

[0027] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a Cas effector complex, the Cas effector complex comprising a class 2 type V Cas effector, a small prokaryotic ribosomal protein subunit S15, and an engineered guide polynucleotide configured to hybridize to the target nucleic acid site; a Tn7-type transposase complex, the Tn7-type transposase complex being configured to bind to the Cas effector complex and comprising TnsA, TnsB, TnsC, and TniQ components; and a double-stranded nucleic acid, the double-stranded nucleic acid being configured to interact with the Tn7-type transposase complex and comprising a cargo nucleotide sequence.

[0028] In some embodiments, the Cas effector complex is non-covalently bound to a Tn7-type transposase complex. In some embodiments, the Cas effector complex is covalently linked to a Tn7-type transposase complex. In some embodiments, the Cas effector complex is fused to a Tn7-type transposase complex. In some embodiments, the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence recognized by a recombinase or transposase complex. In some embodiments, the left recombinase sequence comprises a sequence having at least 80% identity to any one of SEQ ID NO: 20. In some embodiments, the right recombinase sequence comprises a sequence having at least 80% identity to SEQ ID NO: 21.

[0029] In some embodiments, the target nucleic acid includes a PAM sequence that is compatible with the Cas effector complex. In some embodiments, the PAM sequence is located about 50 to about 70 base pairs from the target nucleic acid site. In some embodiments, the PAM sequence is located 3' of the target nucleic acid site. In some embodiments, the PAM sequence is located 5' of the target nucleic acid site.

[0030] In some embodiments, the Class 2 V-type Cas effector is not a Cas12k effector. In some embodiments, the TnsA component comprises a polypeptide comprising a sequence having at least 80% identity to SEQ ID NO: 7. In some embodiments, the Tn7-type transposase complex comprises at least one polypeptide comprising a sequence having at least 80% identity to any one of SEQ ID NOs: 8-10.

[0031] In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides having at least 80% identity to any one of SEQ ID NOs: 13-16. In some embodiments, the small prokaryotic ribosomal protein subunit S15 comprises a sequence having at least 80% sequence identity to any one of any one of SEQ ID NOs: 494-659.

[0032] In some embodiments, the Class 2 Type II Cas effector and recombinase or transposase complex is encoded by a polynucleotide sequence comprising less than about 10 kilobases.

[0033] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a Cas effector complex, the Cas effector complex comprising a class 1 IF-type Cas effector, a small prokaryotic ribosomal protein subunit S15, and an engineered guide polynucleotide configured to hybridize to the target nucleic acid site; a Tn7-type transposase complex, the Tn7-type transposase complex being configured to bind to the Cas effector complex and comprising TnsA, TnsB, TnsC, and TniQ components; and a double-stranded nucleic acid, the double-stranded nucleic acid being configured to interact with the Tn7-type transposase complex and comprising a cargo nucleotide sequence.

[0034] In some embodiments, the Cas effector complex is non-covalently bound to a Tn7-type transposase complex. In some embodiments, the Cas effector complex is covalently linked to a Tn7-type transposase complex. In some embodiments, the Cas effector complex is fused to a Tn7-type transposase complex. In some embodiments, the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence recognized by a recombinase or transposase complex. In some embodiments, the left recombinase sequence comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 136 and 138. In some embodiments, the right recombinase sequence comprises a sequence having at least 80% identity to SEQ ID NOs: 137 and 139.

[0035] In some embodiments, the target nucleic acid includes a PAM sequence that is compatible with the Cas effector complex. In some embodiments, the PAM sequence is located about 50 to about 70 base pairs from the target nucleic acid site. In some embodiments, the PAM sequence is located 3' of the target nucleic acid site. In some embodiments, the PAM sequence is located 5' of the target nucleic acid site.

[0036] In some embodiments, the class 1 IF-type Cas effector comprises a polypeptide comprising a sequence having at least 80% identity to any one of SEQ ID NOs: 41-43 and 48-50. In some embodiments, the class 1 IF-type Cas effector comprises a polypeptide comprising a sequence having at least 90% identity to any one of SEQ ID NOs: 41-43 and 48-50. In some embodiments, the class 1 IF-type Cas effector comprises a polypeptide comprising a sequence of any one of SEQ ID NOs: 41-43 and 48-50. In some embodiments, the Tn7-type transposase complex comprises at least one polypeptide comprising a sequence having at least 80% identity to any one of SEQ ID NOs: 44-47 and 51-54. In some embodiments, the Tn7-type transposase complex comprises at least one polypeptide comprising a sequence having at least 90% identity to any one of SEQ ID NOs: 44-47 and 51-54. In some embodiments, the Tn7-type transposase complex comprises at least one polypeptide comprising a sequence of any one of SEQ ID NOs: 44-47 and 51-54. In some embodiments, the small prokaryotic ribosomal protein subunit S15 comprises a sequence having at least 80% sequence identity to any one of any one of SEQ ID NOs: 494-659. In some embodiments, the Class 2 type II Cas effector and recombinase or transposase complex is encoded by a polynucleotide sequence comprising less than about 10 kilobases.

[0037] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a Cas effector complex configured to hybridize to the target nucleic acid site and comprising: i) a Class 2 type V Cas effector comprising a polypeptide having a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689; and ii) an engineered guide polynucleotide comprising a polypeptide having a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689; NO:90-93, 111-114, 117, 151, 156-181, 201-204, 209-234, 255-258, 262, 263, 348, 350-353, 417-460, 491-492 and 715-739 have at least 80% sequence identity; a Tn7-type transposase complex configured to bind to a Cas effector complex and comprising TnsB, TnsC and TniQ components, wherein the TnsB, TnsC or TniQ components include the same as SEQ ID NO:90-93, 111-114, 117, 151, 156-181, 201-204, 209-234, 255-258, 262, 263, 348, 350-353, 417-460, 491-492 and 715-739; NO:23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343 and 345-347 having at least 80% identity; and a double-stranded nucleic acid configured to interact with a Tn7-type transposase complex and comprising, in 5' to 3' order: i) a left recombinase sequence comprising a sequence having at least 80% sequence identity to any one of SEQ ID NO:123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465 and 467; ii) a cargo nucleotide sequence; and iii) a right recombinase sequence comprising a sequence having at least 80% sequence identity to any one of SEQ ID NO:123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465 and 467; Any one of NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466 and 468 has a sequence with at least 80% identity.

[0038] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site, the system comprising: a Cas effector complex configured to hybridize to the target nucleic acid site and comprising: i) a Class 2 V-type Cas effector, the Class 2 V-type Cas effector comprising a polypeptide having a sequence having at least 80% sequence identity to SEQ ID NO: 22; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 90, 112, and 202; a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsB, TnsC, and TniQ components, the TnsB, TnsC, or TniQ components comprising a sequence having at least 80% sequence identity to SEQ ID NO: 22; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 90, 112, and 202; and NO:23-25 ​​having at least 80% identity; and a double-stranded nucleic acid configured to interact with a Tn7-type transposase complex and comprising, in 5' to 3' order: i) a left-side recombinase sequence comprising a sequence having at least 80% identity to SEQ ID NO:125; ii) a cargo nucleotide sequence; and iii) a right-side recombinase sequence comprising a sequence having at least 80% identity to any one of SEQ ID NO:126 and 155.

[0039] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site of a target nucleic acid, the system comprising: a Cas effector complex configured to hybridize to the target nucleic acid site and comprising: i) a Class 2 V-type Cas effector, the Class 2 V-type Cas effector comprising a polypeptide having a sequence having at least 80% sequence identity to SEQ ID NO: 26; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 91, 113, 156, 203, and 209; a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsB, TnsC, and TniQ components, the TnsB, TnsC, or TniQ components comprising a sequence having at least 80% sequence identity to SEQ ID NO: 26; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 91, 113, 156, 203, and 209; NO:27-29 having at least 80% identity; and a double-stranded nucleic acid configured to interact with a Tn7-type transposase complex and comprising, in 5' to 3' order: i) a left-side recombinase sequence comprising a sequence having at least 80% sequence identity to SEQ ID NO:127; ii) a cargo nucleotide sequence; and iii) a right-side recombinase sequence comprising a sequence having at least 80% identity to SEQ ID NO:128.

[0040] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site of a target nucleic acid, the system comprising: a Cas effector complex configured to hybridize to the target nucleic acid site and comprising: i) a Class 2 V-type Cas effector, the Class 2 V-type Cas effector comprising a polypeptide having a sequence having at least 80% sequence identity to SEQ ID NO: 60; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 117, 119, 161, and 214; a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsB, TnsC, and TniQ components, the TnsB, TnsC, or TniQ components comprising a sequence having at least 80% sequence identity to SEQ ID NO: 117, 119, 161, and 214; NO:101-103 having at least 80% identity; and a double-stranded nucleic acid configured to interact with a Tn7-type transposase complex and comprising, in 5' to 3' order: i) a left-side recombinase sequence comprising a sequence having at least 80% sequence identity to SEQ ID NO:131; ii) a cargo nucleotide sequence; and iii) a right-side recombinase sequence comprising a sequence having at least 80% identity to SEQ ID NO:132.

[0041] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site of a target nucleic acid, the system comprising: a Cas effector complex configured to hybridize to the target nucleic acid site and comprising: i) a Class 2 V-type Cas effector, the Class 2 V-type Cas effector comprising a polypeptide having a sequence having at least 80% sequence identity to SEQ ID NO: 147; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 151, 181, and 234; a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsB, TnsC, and TniQ components, the TnsB, TnsC, or TniQ components comprising a sequence having at least 80% sequence identity to SEQ ID NO: 147; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 151, 181, and 234; and NO:148-150 having at least 80% identity; and a double-stranded nucleic acid configured to interact with a Tn7-type transposase complex and comprising, in 5' to 3' order: i) a left-side recombinase sequence comprising a sequence having at least 80% sequence identity to SEQ ID NO:153; ii) a cargo nucleotide sequence; and iii) a right-side recombinase sequence comprising a sequence having at least 80% identity to SEQ ID NO:154.

[0042] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site, the system comprising: a Cas effector complex configured to hybridize to a target nucleic acid site in a target nucleic acid and comprising: i) a Class 2 V-type Cas effector, the Class 2 V-type Cas effector comprising a polypeptide having a sequence having at least 80% sequence identity to SEQ ID NO: 34; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 93, 114, 157, 204, and 210; a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsB, TnsC, and TniQ components, the TnsB, TnsC, or TniQ components comprising a sequence having at least 80% sequence identity to SEQ ID NO: 34; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 93, 114, 157, 204, and 210; and NO:148-150 having at least 80% identity; and a double-stranded nucleic acid configured to interact with a Tn7-type transposase complex and comprising, in 5' to 3' order: i) a left-side recombinase sequence comprising a sequence having at least 80% sequence identity to SEQ ID NO:129; ii) a cargo nucleotide sequence; and iii) a right-side recombinase sequence comprising a sequence having at least 80% identity to SEQ ID NO:130.

[0043] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site of a target nucleic acid, the system comprising: a Cas effector complex configured to hybridize to the target nucleic acid site and comprising: i) a Class 2 V-type Cas effector, the Class 2 V-type Cas effector comprising a polypeptide having a sequence having at least 80% sequence identity to SEQ ID NO: 30; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 92, 111, and 201; a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsB, TnsC, and TniQ components, the TnsB, TnsC, or TniQ components comprising a sequence having at least 80% sequence identity to SEQ ID NO: 30; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 92, 111, and 201; and a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsB, TnsC, and TniQ components, the TnsB, TnsC, or TniQ components comprising a sequence having at least 80% sequence identity to SEQ ID NO: NO:31-33 having at least 80% identity; and a double-stranded nucleic acid configured to interact with a Tn7-type transposase complex and comprising, in 5' to 3' order: i) a left-side recombinase sequence comprising a sequence having at least 80% sequence identity to SEQ ID NO:123; ii) a cargo nucleotide sequence; and iii) a right-side recombinase sequence comprising a sequence having at least 80% identity to SEQ ID NO:124.

[0044] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site of a target nucleic acid, the system comprising: a Cas effector complex configured to hybridize to the target nucleic acid site and comprising: i) a Class 2 V-type Cas effector, the Class 2 V-type Cas effector comprising a polypeptide having a sequence having at least 80% sequence identity to SEQ ID NO: 38; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 98, 115-116, 182, 205-206, 235, and 493; a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsB, TnsC, and TniQ components, the TnsB, TnsC, or TniQ components comprising a sequence having at least 80% sequence identity to SEQ ID NO: NO:39 and 40 have a sequence with at least 80% identity; and a double-stranded nucleic acid configured to interact with a Tn7-type transposase complex and comprising, in 5' to 3' order: i) a left-side recombinase sequence, the left-side recombinase sequence comprising a sequence with at least 80% sequence identity to SEQ ID NO:134; ii) a cargo nucleotide sequence; and iii) a right-side recombinase sequence, the right-side recombinase sequence comprising a sequence with at least 80% identity to SEQ ID NO:135.

[0045] In some embodiments, the 2nd type V Cas effector is a Cas12k effector. In some embodiments, the target nucleic acid includes a PAM sequence compatible with the Cas effector complex. In some embodiments, the PAM sequence is located 5' of the target nucleic acid site. In some embodiments, the PAM sequence includes 5'-nGTn-3' or 5'-nGTt-3'.

[0046] In some embodiments, the Cas effector complex further comprises a small prokaryotic ribosomal protein subunit S15. In some embodiments, the small prokaryotic ribosomal protein subunit S15 comprises a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 494-659. In some embodiments, the class 2 type V Cas effector and Tn7 type transposase complex are encoded by a polynucleotide sequence comprising less than about 10 kilobases.

[0047] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a Cas effector complex, the Cas effector complex comprising a class 2 type V Cas effector, a small prokaryotic ribosomal protein subunit S15, and an engineered guide polynucleotide configured to hybridize to the target nucleic acid site; a Tn7-type transposase complex, the Tn7-type transposase complex being configured to bind to the Cas effector complex and comprising TnsB and TnsC components but not TnsA and / or TniQ components; and a double-stranded nucleic acid, the double-stranded nucleic acid being configured to interact with the Tn7-type transposase complex and comprising a cargo nucleotide sequence.

[0048] In some embodiments, the Cas effector complex is non-covalently bound to a Tn7-type transposase complex. In some embodiments, the Cas effector complex is covalently linked to a Tn7-type transposase complex. In some embodiments, the Cas effector complex is fused to a Tn7-type transposase complex. In some embodiments, the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence recognized by a recombinase or transposase complex. In some embodiments, the left recombinase sequence comprises a sequence having at least 80% identity to any one of SEQ ID NO: 134. In some embodiments, the right recombinase sequence comprises a sequence having at least 80% identity to SEQ ID NO: 135.

[0049] In some embodiments, the target nucleic acid includes a PAM sequence that is compatible with the Cas effector complex. In some embodiments, the PAM sequence is located about 50 to about 70 base pairs from the target nucleic acid site. In some embodiments, the PAM sequence is located 3' of the target nucleic acid site. In some embodiments, the PAM sequence is located 5' of the target nucleic acid site.

[0050] In some embodiments, the Class 2 type V Cas effector is a Cas12k effector. In some embodiments, the Class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least 80% identity to any one of SEQ ID NOs: 38 and 108. In some embodiments, the Class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least 90% identity to any one of SEQ ID NOs: 38 and 108. In some embodiments, the Class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least 90% identity to any one of SEQ ID NOs: 38 and 108. In some embodiments, the Class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least 80% identity to any one of SEQ ID NOs: 38 and 108. In some embodiments, the TnsB subunit comprises a polypeptide comprising a sequence having at least 80% sequence identity to SEQ ID NOs: 40 or 109. In some embodiments, the TnsC subunit comprises a polypeptide comprising a sequence having at least 80% sequence identity to SEQ ID NOs: 39 or 110. In some embodiments, the Tn7-type transposase complex comprises at least one polypeptide comprising a sequence having at least 80% identity to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some embodiments, the engineered guide polynucleotide comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 115, 116, 205, 206, 261, 235, 260, and 236. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides having at least 80% identity to any one of SEQ ID NOs: 118, 182, 183, 235, and 236.

[0051] In some embodiments, the small prokaryotic ribosomal protein subunit S15 comprises a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 494-659. In some embodiments, the Class 2 type II Cas effector and recombinase or transposase complex is encoded by a polynucleotide sequence comprising less than about 10 kilobases.

[0052] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a Cas effector complex, the Cas effector complex comprising 2 class II type Cas effectors, a small prokaryotic ribosomal protein subunit S15, and an engineered guide polynucleotide, the engineered guide polynucleotide being capable of hybridizing with a target nucleic acid; a recombinase or transposase complex, the recombinase or transposase complex being operably linked to the Cas effector complex; and a double-stranded nucleic acid, the double-stranded nucleic acid comprising, in 5' to 3' order: i) a left recombinase recognition sequence; ii) a cargo nucleotide sequence; and iii) a right recombinase recognition sequence, the left recombinase recognition sequence and the right recombinase recognition sequence being capable of being recognized by the recombinase or transposase complex.

[0053] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a Cas effector complex, the Cas effector complex comprising a class 2 type V Cas effector, a small prokaryotic ribosomal protein subunit S15, and an engineered guide polynucleotide, the engineered guide polynucleotide being capable of hybridizing with a target nucleic acid; a Tn7-type transposase complex, the Tn7-type transposase complex being operably linked to the Cas effector complex and comprising TnsA, TnsB, TnsC, and TniQ components; and a double-stranded nucleic acid comprising, in 5' to 3' order: i) a left recombinase recognition sequence; ii) a cargo nucleotide sequence; and iii) a right recombinase recognition sequence, wherein the left recombinase recognition sequence and the right recombinase recognition sequence are capable of being recognized by the Tn7-type transposase complex.

[0054] In some aspects, the present disclosure provides a system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a Cas effector complex, the Cas effector complex comprising a class 1 IF-type Cas effector, a small prokaryotic ribosomal protein subunit S15, and an engineered guide polynucleotide, the engineered guide polynucleotide being capable of hybridizing with a target nucleic acid; a Tn7-type transposase complex, the Tn7-type transposase complex being operably linked to the Cas effector complex and comprising TnsA, TnsB, TnsC, and TniQ components; and a double-stranded nucleic acid comprising, in 5' to 3' order: i) a left recombinase recognition sequence; ii) a cargo nucleotide sequence; and iii) a right recombinase recognition sequence, the left recombinase recognition sequence and the right recombinase recognition sequence being capable of being recognized by the Tn7-type transposase complex.

[0055] In some aspects, the present disclosure provides an engineered nuclease system, the engineered nuclease system comprising: an endonuclease comprising a RuvC domain and a HNH domain, wherein the endonuclease is derived from an uncultured microorganism, wherein the endonuclease is a Class 2 Type II endonuclease, and the Class 2 Type II endonuclease comprises a sequence having at least 80% identity with SEQ ID NO: 1; and an engineered guide polynucleotide, wherein the engineered guide RNA is configured to form a complex with the endonuclease, and the engineered guide RNA comprises a spacer sequence configured to hybridize with a target nucleic acid sequence. In some embodiments, the engineered guide polynucleotide comprises at least about 60-80 consecutive nucleotides having at least 80% identity with SEQ ID NO: 12. In some embodiments, the engineered guide polynucleotide comprises a sequence having at least 80% identity with SEQ ID NO: 11.

[0056] In some aspects, the present disclosure provides an engineered nuclease system comprising: an endonuclease comprising a RuvC domain, wherein the endonuclease is derived from an uncultured microorganism, and wherein the endonuclease is a Class 2 V-type endonuclease with at least 80% identity to SEQ ID NO: 6; and an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease, and the engineered guide RNA comprises a spacer sequence configured to hybridize to a target nucleic acid sequence. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides with at least 80% identity to any one of SEQ ID NO: 13-16.

[0057] In some aspects, the present disclosure provides an engineered nuclease system, the engineered nuclease system comprising: a nuclease comprising a RuvC domain, wherein the nuclease is derived from an uncultured microorganism, and wherein the nuclease is a Class 2 VK-type nuclease with at least 80% identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689; and an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the nuclease, and the engineered guide RNA comprises a spacer sequence configured to hybridize with a target nucleic acid sequence. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides with at least 80% identity to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739. In some embodiments, the engineered guide polynucleotide comprises a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 111-114, 201-206, 209, 210, 255-258, 262, 263, 348, 350-353, and 473-492.

[0058] In some aspects, the present disclosure provides an engineered nuclease system comprising: an endonuclease comprising a RuvC domain, wherein the endonuclease is derived from an uncultured microorganism, and wherein the endonuclease is a Class 2 VK-type endonuclease having at least 80% identity to SEQ ID NO: 38 or SEQ ID NO: 108; and an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease, and the engineered guide RNA comprises a spacer sequence configured to hybridize to a target nucleic acid sequence. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides having at least 80% identity to any one of SEQ ID NO: 118, 182, 183, 235, and 236. In some embodiments, the engineered guide polynucleotide comprises a sequence at least 80% identical to any one of SEQ ID NOs: 111-114, 115, 116, 201-206, 209, 210, 235, 236, 255-258, 260-263, 348, and 350-353.

[0059] In some aspects, the present disclosure provides an engineered nuclease system, comprising: a Class 1 IF-type Cas endonuclease, the Class 1 IF-type Cas endonuclease comprising at least one Cas6, Cas7 or Cas8 polypeptide comprising a sequence having at least 80% identity to any one of SEQ ID NOs: 41-43 and 48-50; and an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease, and the engineered guide RNA comprises a spacer sequence configured to hybridize with a target nucleic acid sequence. In some embodiments, the engineered guide polynucleotide comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 121, 122, 207 and 208.

[0060] In some aspects, the present disclosure provides a method for transposing a cargo nucleotide sequence into a target nucleic acid site, the method comprising introducing a system of the present disclosure into a cell.

[0061] In some aspects, the present disclosure provides a cell, which includes a system of the present disclosure. In some embodiments, the cell is a eukaryotic cell. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is an immortalized cell. In some embodiments, the cell is an insect cell. In some embodiments, the cell is a yeast cell. In some embodiments, the cell is a plant cell. In some embodiments, the cell is a fungal cell. In some embodiments, the cell is a prokaryotic cell. In some embodiments, the cell is A549, HEK-293, HEK-293T, BHK, CHO, HeLa, MRC5, Sf9, Cos-1, Cos-7, Vero, BSC 1, BSC 40, BMT 10, WI38, HeLa, Saos, C2C12, L cell, HT1080, HepG2, Huh7, K562, primary cell or its derivative. In some embodiments, the cell is an engineered cell. In some embodiments, the cell is a stable cell.

[0062] For those skilled in the art, further aspects and advantages of the present disclosure will become apparent through the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be appreciated, the present disclosure is capable of other and different embodiments, and its several details can be modified in various obvious aspects, all without departing from the present disclosure. Therefore, the drawings and description will be regarded as illustrative rather than restrictive in nature. BRIEF DESCRIPTION OF THE DRAWINGS

[0063] The novel features of the present disclosure are particularly set forth in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description setting forth illustrative embodiments in which the principles of the present disclosure are utilized, and in the accompanying drawings (also referred to herein as "Figures (Figure / FIG.)"):

[0064] Figure 1 Example organizations of different species and types of CRISPR / Cas loci are depicted.

[0065] Figure 2 Depicted is the architecture of the native Class 2 type II crRNA / tracrRNA pair compared to the hybrid sgRNA in which the crRNA and tracrRNA are linked.

[0066] Figure 3 Two pathways found in Tn7 and Tn7-like elements are depicted.

[0067] Figures 4A-4C The genomic context of type II Tn7-reduced CASTs of the MG36 family is depicted. Figure 4AThe MG36-5CAST system is shown to include a CRISPR array (CRISPR repeats), a type II nuclease with RuvC and HNH endonuclease domains, and four predicted transposase protein open reading frames. The catalytic transposase TnsB is encoded as two subunits. Figure 4B Two transposon ends (TIR-1 and TIR-2) predicted by the CAST system for MG36-1 are shown. Figure 4C The alignment of the predicted left end (LE) and right end (RE) sequences of the type II Tn7-reduced CAST transposon is shown, with arrows indicating annotated repeat sequences. The left and right ends are labeled according to their orientation.

[0068] Figure 5A-5B The genomic context of the V-type Tn7 CAST of the MG39 family is depicted. Figure 5A The MG39-1 CAST system is shown to consist of a V-type nuclease, four predicted transposon proteins (TnsABC and TniQ), and a CRISPR array. Transposon ends (TIR-1) are predicted for the MG39-1 CAST system. Figure 5B An alignment of the predicted left (LE) and right (RE) end sequences of the V-type Tn7 CAST transposon is shown, with arrows indicating annotated inverted repeat sequences.

[0069] Figure 6 and Figure 7 The predicted structures of the corresponding sgRNAs of the CAST systems described herein (eg, predicted in Example 3) are depicted.

[0070] Figure 8 The genomic context of the system MG108-1 described herein is depicted. This candidate is a Cas12K CAST that naturally lacks TniQ. Genes in the genomic fragment are indicated by arrows.

[0071] Fig. 9 A phylogenetic gene tree of Cas12k effector sequences is depicted. The tree is inferred from a multiple sequence alignment of 64 Cas12k sequences (orange and black branches) recovered here and 229 reference Cas12k sequences (grey branches) from public databases. The orange branches indicate Cas12k effectors that have been confirmed to be associated with CAST transposon components.

[0072] Figures 10A-10C MG110 Cascade CAST is depicted. Fig. 10AThe genomic context of MG110-1 Cascade CAST is shown. The complete Tn7 suite (TnsA, TnsB, TnsC / TniB, TniQ) and the defective Cascade suite (Cas6, Cas7, fused Cas5-Cas8) are indicated by orange arrows. The TIRs flanking the CAST transposon are indicated by connected arrows. Fig. 10B Repeated secondary structures are shown indicating the stem-loop structure of the crRNA. Fig. 10C Sequence alignment of CRISPR repeats from A. wodanis, V. cholerae, and MG110 family CASTs shows conserved motifs indicative of crRNA stem-loop secondary structures.

[0073] Fig.11A The MG64-3 CRISPR locus is depicted. The tracrRNA is encoded upstream of the CRISPR array, while the transposon end is encoded downstream (inner black box). The sequence corresponding to part of the 3' CRISPR repeat sequence and part of the spacer are encoded within the transposon (outer frame). The self-matching spacer is encoded outside the transposon end.

[0074] Fig. 11B The tracrRNA sequence alignment of various CASTs provided herein is depicted. The alignment of tracrRNA sequences shows the conserved region. Specifically, the sequence "TGCTTTC" at sequence positioning 92-98 (top frame) may be important for sgRNA tertiary structure and non-continuous repeat-anti-repeat pairing with crRNA. The hairpin "CYCC (n6) GGRG" at positioning 265-278 (bottom frame) may be important for function, such as by positioning the downstream sequence of crRNA pairing.

[0075] Fig. 11C Shown are repeat-antirepeat (RAR) motifs present in, for example, the MG64-2, MG64-4, MG64-5, MG64-6, MG64-7, and MG108-1 families.

[0076] Fig. 12A The predicted structure of the MG64-2 sgRNA is depicted.

[0077] Fig. 12B The predicted structure of the MG64-4 sgRNA is depicted.

[0078] Fig. 12C The predicted structure of the MG64-6 sgRNA is depicted.

[0079] Fig.12D The predicted structure of the MG64-7 sgRNA is depicted.

[0080] Fig.12E The predicted structure of MG108-1 sgRNA is depicted.

[0081] Figures 13A-13C Depict MG64-6 has active PCR, PAM and Sanger sequencing data in vitro.Use described in vitro targeted integrase activity scheme, express effector protein and its TnsB, TnsC and TniQ protein in in vitro transcription / translation system.After translation, target DNA, cargo DNA and sgRNA are added to reaction buffer.Integration is determined by PCR across target / donor junction. Fig.13A Gel images of PCRs showing transposition of apo (no sgRNA) and 64-6 with sgRNA (64-6sgRNA) are depicted. PCR 3 detects RE junction, PAM distal. PCR 4 is LE junction, PAM distal. PCR 5 is RE junction, PAM proximal. PCR 6 is LE junction, PAM proximal. PCRs are paired across different possible orientations (PCR 3 and 6 with PCR 4 and 5). LE-PAM proximal and RE-PAM distal orientations are preferred. Fig. 13B PAMs from the in vitro transposition assay are depicted, and PCRs 5 and 6 were sequenced. Fig. 13C Described are Sanger data showing the junction of the transposition where cleavage occurs in the donor DNA. The first panel shows PCR 3 and 5 (RE). The second panel shows PCR 4 and 6 (LE). The Sanger sequencing reaction is a reaction of the donor-target product, so when the junction occurs, sequencing stops matching the donor DNA (dark bar below the sequencing peak)

[0082] Fig.14 Depicted are the results of next generation sequencing (NGS) of in vitro transposition products, which reveal insertion site preferences. NGS reads processed in CRISPResso2 were compared to a reference sequence with transposition at position 60. Insertions therein correspond to transpositions earlier or later than this arbitrary reference sequence.

[0083] Fig.15Electrophoretic mobility shift assay (EMSA) results of 64-2TnsB and its RE DNA sequence are depicted. EMSA results confirmed binding and TnsB recognition. TnsB protein was expressed in an in vitro transcription / translation system, incubated with FAM-labeled DNA containing the RE sequence, and then separated on a native 5% TBE gel. Binding was observed as an upward shift in the labeled band. Multiple TnsB binding sites resulted in multiple shifts in the EMSA. Lane 1: FAM-labeled DNA only. Lane 2: FAM DNA plus in vitro transcription / translation system (no TnsB protein). Lane 3: FAM DNA plus TnsB. The upward shift of the labeled band in lane 3 indicates that TnsB binds to the RE sequence, indicating that it contains an active RE transposition sequence.

[0084] Figures 16A-16B Cas12k effector diversity is profiled. Fig.16A The Cas12k CAST genomic context is depicted. The transposon is characterized by: terminal inverted repeats (TIR, light orange bars), Tn7-like transposon genes (colored arrows), death effector Cas12k (orange arrows), tracrRNA (pink half arrows), and CRISPR arrays. The "TAAA" target site repeat (TDS) was observed to be flanked by TIR. Middle panel: MG64-1 noncoding region illustration, showing tracrRNA (a pseudo-repeat sequence and self-targeting spacer), CRISPR array, and transposon left end TIR. Bottom panel: Multiple alignments of pseudo-repeat sequences and self-targeting spacers in a group of CAST homologs. Fig. 16B Depicted is an unrooted phylogenetic tree of Cas12k effectors. Cas12k effectors as described herein are shown in orange (confirmed transposons in the genome) and black branches, while reference Cas12k sequences are shown in gray. Reference sequences ShCas12k and AcCas12k are shown with red arrows.

[0085] Figures 17A-17B Depicts the right end of CAST ( Fig.17A ) and the left end ( Fig. 17B ). The transposon end inverted motif "TGTNNA" is highlighted with a box.

[0086] Fig.18 Depicted is the alignment of Cas12k CAST tracrRNA sequences, showing regions of sequence and structural conservation. Specifically, the sequence "TGCTTTC" at sequence location 90 (top box) may be important for sgRNA tertiary structure and non-continuous repeat-anti-repeat pairing with crRNA. The hairpin "CYCC (n6) GGRG" at location 331 (bottom box) may be important for function, such as by locating the downstream sequence of crRNA pairing.

[0087] Fig.19 Depicted is the single guide RNA folding of the active MG64-6 CAST system.

[0088] Figures 20A-20B Depicted is an in vitro screen for CAST transposition using a PAM library. Fig. 20A The screening setup of the in vitro PAM assay is depicted. Fig. 20B A schematic diagram of junction PCR for detection of transposition products is depicted.

[0089] Fig.21A The transposition junction of MG64-6 CAST amplified by PCR is depicted.

[0090] Fig. 21B SeqLogo representation of detected PAMs of MG64-6 is depicted.

[0091] Fig. 21C Depicted are the integrated frequencies plotted by distance at proximal and distal distances of MG64-6.

[0092] Figures 22A-22C The results of E. coli integration with MG64-6 are depicted. Fig.22A Depicted is a schematic representation of the introduction of the CAST system into E. coli. Fig. 22B Depicted are NGS data showing editing efficiency greater than 80%. Fig. 22C Depicted is an off-target analysis showing no off-target integrations greater than 1% of all transposition events added were detected.

[0093] Figures 23A-23B Insertion rates at various endogenous loci of the E. coli genome are depicted. Fig.23A The local insertion rates of various endogenous loci of the E. coli genome are depicted. Fig. 23B The off-target rates of insertions into various endogenous loci in the E. coli genome are depicted.

[0094] Fig.24NLS screening of MG64-6 CAST components is depicted. All CAST components were synthesized with NLS tags at both the N-terminus and the C-terminus and expressed in vitro. All components were then tested in an in vitro transposition reaction with the MG64-6 donor PCR fragment, single guide RNA, and target plasmid. Row A: Lane 1 = All WT 64-6 CAST components without any NLS tags under apo conditions (without single guide). Lane 2 = All WT 64-6 CAST components without any NLS tags under holo conditions (with single guide). Lane 3 = In vitro transposition with NLS-MG64-6-Cas12k, Lane 4 = In vitro transposition with MG64-6-Cas12k-NLS, Lane 5 = NLS-MG64-6-B, Lane 6 = MG64-6-B-NLS, Lane 7 = NLS-MG64-6-C, Lane 8 = MG64-6-C-NLS, Lane 9 = NLS MG64-6-Q, Lane 10 = MG64-6-NLS. Row B: CAST components were tested in combinations to find in vitro active agglutinins. All reactions were holo conditions (with single guides) except Lane 2. Lane 1 = All WT 64-6 CAST components without any NLS tag under apo conditions (no single guide). Lane 2 = All WT 64-6CAST components without any NLS tag under holo conditions (with single guide), lane 3 = NLS-MG64-6-Cas12k, NLS-MG64-6-B, NLS-MG64-6-C, NLS-MG64-6-Q, lane 4 = NLS-MG64-6-Cas12k, NLS-MG64-6-B, NLS-MG64-6-C, MG64-6-Q-NLS, lane 5 = NLS-MG64-6-Cas12k, MG64-6-B-NLS, NLS-MG64-6-C, NLS-MG64-6-Q, lane 6 = NLS-MG64-6-Cas12k, MG64-6-B-NLS, NLS-MG64-6- 6-C, MG64-6-Q-NLS, Lane 7 = MG64-6-Cas12k-NLS, NLS-MG64-6-B, NLS-MG64-6-C, NLS-MG64-6-Q, Lane 8 = MG64-6-Cas12k-NLS, NLS-MG64-6-B, NLS-MG64-6-C, MG64-6-Q-NLS, Lane 9 = MG64-6-Cas12k-NLS, MG64-6-B-NLS, NLS-MG64-6-C, NLS-MG64-6-Q, Lane 10 = MG64-6-Cas12k-NLS, MG64-6-B-NLS, NLS-MG64-6-C, MG64-6-Q-NLS

[0095] Fig.25 Gel images depicting PCR junctions of in vitro transposition reactions with in vitro expressed CAST components. Cell-derived material was extracted from cell lines transduced with lentiviruses having expressed CAST NLS components. For each cell extract, both cytoplasmic and nuclear fractions were tested with a set of WT CAST complement components. The boxed lanes are not relevant for this experiment. Row A: Lane 1 = all in vitro expressed CAST components, apo conditions (no single guide added), Lane 2 = all in vitro expressed CAST components, holo conditions (no single guide added), Lane 3 = cytoplasmic NLS-MG64-6-Cas12k, Lane 4 = cytoplasmic MG64-6-Cas12k-NLS, Lane 5 = cytoplasmic NLS-MG64-6-B, Lane 6 = cytoplasmic MG64-6-B-NLS, Lane 7 = cytoplasmic NLS-MG64-6-C, Lane 8 = cytoplasmic NLS-MG64-6-Q. Row B: Lane 1 = cytoplasmic MG64-6-Q-NLS, Lane 2 = nucleoplasmic NLS-MG64-6-Cas12k, Lane 3 = nucleoplasmic MG64-6-Cas12k-NLS, Lane 4 = nucleoplasmic NLS-MG64-6-B, Lane 5 = nucleoplasmic MG64-6-B-NLS, Lane 6 = nucleoplasmic NLS-MG64-6-C, Lane 7 = nucleoplasmic NLS-MG64-6-Q, Lane 8 = nucleoplasmic MG64-6-Q-NLS. Row C: Lane 1 = all CAST components expressed in vitro, apo conditions (no single guide added), Lane 2 = all CAST components expressed in vitro, holo conditions (no single guide added), Lane 3 = skipped, Lane 4 = skipped, Lane 5 = cytoplasmic polycistronic NLS-MG64-6-B and NLS-MG64-6-C, Lane 6 = cytoplasmic polycistronic MG64-6-B-NLS and NLS-MG64-6-C, Lane 7 = skipped, Lane 8 = skipped, Lane 9 = nucleoplasmic polycistronic NLS-MG64-6-B and NLS-MG64-6-C, Lane 6 = nucleoplasmic polycistronic MG64-6-B-NLS and NLS-MG64-6-C

[0096] Figures 26A-26B Depicted are Sanger sequencing data of the integrated PCR products, demonstrating that MG64-6 is active in vitro. The reaction is that of the donor-target product, and sequencing stops when the junction occurs matching the donor DNA (dark bars below the sequencing peak). Fig.26A Sanger sequencing data for PCR reactions 3 and 5 (RE) are depicted. Fig.26B Sanger sequencing data for PCR reactions 4 and 6 (LE) are depicted.

[0097] Figures 27A-27CIn vitro screening of MG64-6 Cas12kCAST transposition using cognate Cas12k sgRNA and effectors is demonstrated. Fig.27A A schematic representation of junction PCR for detecting transposition products is depicted. A target substrate with a 5' PAM followed by a protospacer (target, Rxn#1) was targeted with the CAST system to integrate cargo DNA (Rxn#2). After successful integration, a junction PCR reaction was performed with primers to amplify four putative integration reactions based on the orientation of cargo integration. Fig.27B Junction PCR reactions depicting transposition activity of MG64-6 with cognate sgRNAs. Left gel: Rxn#3. Lane 4: Ladder. Lanes 1-3: Transposition reactions with sgRNAs from effectors MG64-57, MG108-1, and MG108-2. Right gel: Lane 10: Ladder. Lanes 1-3: Rxn#5 from transposition reactions with sgRNAs from effectors MG64-57, MG108-1, and MG108-2. Lanes 7-9: Rxn#6 from transposition reactions with sgRNAs from effectors MG64-57, MG108-1, and MG108-2. Boxed lanes are not relevant to this experiment. Fig.27C Junction PCR reactions of transposition activity of MG64-6 with cognate Cas12k effectors are depicted. Lane 13: Ladder. Lanes 1-12: Rxn#5 from transposition reactions with Cas12k effector MG64-57 and MG64-6 transposase protein. 6Tns: MG64-6 TnsB, TnsC, and TniQ. 6B: MG64-6 TnsB. 6C: MG64-6TnsC. 6Q: MG64-6TniQ.

[0098] Fig.28 Immunofluorescence staining results for the localization of Cas12k CAST components in human cells are depicted. All rows: CAST proteins were labeled with HA tags (Cas12k and TnsB) or FLAG tags (TnsC and TniQ). Anti-HA or anti-FLAG antibodies were used for protein detection. DAPI was used to stain DNA (nuclei, first row). The merged DAPI and anti-tag channels indicate protein localization (row 2). MG64-6 Cas12k, TnsB, and TniQ are localized in the nucleus, while TnsC is localized in both the nucleus and cytoplasm (row 3).

[0099] Fig.29A and 29B The design and testing of an engineered minimal LE and RE for MG64-6 are described. Fig.29A Depicted is a schematic representation of the inverted repeats across the WT64-6 terminal inverted repeat (TIR) ​​and the minimal LE / RE design. Fig.29B The PCR results of the junction of RE1 to the PAM target (Min) and the wild-type RE (WT) are depicted. The shift in the size of the PCR amplified band indicates a smaller RE in the expected final transposition fragment.

[0100] Fig.30 A schematic illustration depicting the identification of ribosomal protein S15 homologs in Cyanobacteria genomic fragments. Candidate sequences from the same sample from which Cas12k effectors were recovered are highlighted with black dots. Reference S15 from Escherichia coli is indicated with an arrow.

[0101] Brief Description of Sequence Listing

[0102] The sequence listing submitted herewith provides exemplary polynucleotide and polypeptide sequences for use in the methods, compositions and systems according to the present disclosure.Below is an exemplary description of the sequences therein.

[0103] MG36

[0104] SEQ ID NO: 1 shows the full-length peptide sequence of the MG36 Cas effector.

[0105] SEQ ID NO: 2-5 shows the peptide sequence of MG36 transposase protein, which may include a recombinase or transposase complex associated with MG36Cas effector. -B1, -B2, -T1 and -C are added to the end of the tag to indicate similarity to TnsB1, TnsB2, TnsT1 and TniC proteins of the Tn7-like system, respectively.

[0106] SEQ ID NO: 11 shows the nucleotide sequence of the sgRNA engineered to function with the MG36 Cas effector.

[0107] SEQ ID NO: 12 shows the nucleotide sequence of the MG36 tracrRNA derived from the same locus as the MG36 Cas effector.

[0108] SEQ ID NOs: 17-18 show the nucleotide sequences of the left-side transposase recognition sequences associated with the MG36 system.

[0109] SEQ ID NO: 19 shows the nucleotide sequence of the right transposase recognition sequence associated with the MG36 system.

[0110] MG39

[0111] SEQ ID NO:6 shows the full-length peptide sequence of the MG39-1 Cas effector.

[0112] SEQ ID NOs:7-10 show the peptide sequences of the MG39-1 transposase protein, which may include a recombinase or transposase complex associated with the MG39-1 Cas effector.

[0113] SEQ ID NOs: 13-16 show the nucleotide sequences of MG39 tracrRNA derived from the same locus as the MG39 Cas effector.

[0114] SEQ ID NO: 20 shows the nucleotide sequence of the left-side transposase recognition sequence associated with the MG39 system.

[0115] SEQ ID NO: 21 shows the nucleotide sequence of the right transposase recognition sequence associated with the MG39 system.

[0116] MG64

[0117] SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, 660-689 show the full-length peptide sequences of the MG64 Cas effectors.

[0118] SEQ ID NO: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343 and 345-347 show peptide sequences of MG64 transposase proteins, which may include a recombinase or transposase complex associated with an MG64 Cas effector. -A, -B, -C and -Q are added to the end of the marker to indicate similarity to the TnsA, TnsB, TnsC and TniQ proteins of the Tn7-like system, respectively.

[0119] SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739 show the nucleotide sequences of MG64 tracrRNAs derived from the same locus as the MG64 effector.

[0120] SEQ ID NOs:94-97, 119, 152 and 184-200 show the nucleotide sequences of the MG64 target CRISPR repeat sequences.

[0121] SEQ ID NOs: 237-259, 364-416 and 690-714 show the nucleotide sequence of MG64 crRNA.

[0122] SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353 and 473-492 show the nucleotide sequences of single guide RNAs engineered to function with the MG64 Cas effector.

[0123] SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465 and 467 show the nucleotide sequences of the left-sided transposase recognition sequences associated with the MG64 system.

[0124] SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466 and 468 show the nucleotide sequences of the right transposase recognition sequences associated with the MG64 system.

[0125] SEQ ID NO:349 shows the nucleotide sequence of the protospacer adjacent motif (PAM) of the MG64 Cas effector.

[0126] MG108

[0127] SEQ ID NOs: 38 and 108 show the full-length peptide sequence of the MG108 Cas effector.

[0128] SEQ ID NOs: 39-40, 109-110 and 344 show peptide sequences of MG108 transposase proteins, which may include a recombinase or transposase complex associated with an MG108 Cas effector. -A, -B, -C and -Q are added to the end of the marker to indicate similarity to the TnsA, TnsB, TnsC and TniQ proteins of the Tn7-like system, respectively.

[0129] SEQ ID NOs:98 and 120 show the nucleotide sequence of the MG108 target CRISPR repeat sequence.

[0130] SEQ ID NOs:260-261 show the nucleotide sequence of MG108 crRNA.

[0131] SEQ ID NOs: 115-116, 205-206 and 493 show the nucleotide sequences of single guide RNAs engineered to function with the MG108 Cas effector.

[0132] SEQ ID NOs: 118, 182-183, and 235-236 show the nucleotide sequences derived from the MG108 tracrRNA having the same locus as the MG108 Cas effector.

[0133] SEQ ID NO: 134 shows the nucleotide sequence of the left-side transposase recognition sequence associated with the MG108 system.

[0134] SEQ ID NO: 135 shows the nucleotide sequence of the right transposase recognition sequence associated with the MG108 system.

[0135] MG110

[0136] SEQ ID NOs: 41-43 and 48-50 show the full-length peptide sequences of the MG110 Cas effectors. The addition of -6, -7 and -8 to the end of the markers indicates similarity to the cas6, cas7 and cas8 proteins of the class I IF system, respectively.

[0137] SEQ ID NOs: 44-47 and 51-54 show peptide sequences of MG110 transposase proteins, which may include a recombinase or transposase complex associated with an MG110 Cas effector. -A, -B, -C, and -Q are added to the end of the marker to indicate similarity to the TnsA, TnsB, TnsC, and TniQ proteins of the Tn7-like system, respectively.

[0138] SEQ ID NOs:99-100 show the nucleotide sequences of the MG110 target CRISPR repeat sequences.

[0139] SEQ ID NOs: 121-122 and 207-208 show the nucleotide sequence of MG110 crRNA.

[0140] SEQ ID NOs: 136 and 138 show the nucleotide sequences of the left-side transposase recognition sequences associated with the MG110 system.

[0141] SEQ ID NOs: 137 and 139 show the nucleotide sequences of the right transposase recognition sequences associated with the MG110 system.

[0142] MG190

[0143] SEQ ID NOs: 494-659 show the peptide sequences of MG190 ribosomal protein.

[0144] Other sequences

[0145] SEQ ID NOs: 140-141, 471-472 and 740-755 show the peptide sequences of nuclear localization signals.

[0146] SEQ ID NOs: 142-143 and 470 show the peptide sequences of the linkers.

[0147] SEQ ID NOs: 144-146 show the peptide sequences of the epitope tags.

[0148] SEQ ID NO:469 shows the peptide sequence of the E. coli promoter. DETAILED DESCRIPTION

[0149] Although various embodiments of the present disclosure have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided by way of example only. Various changes, modifications and substitutions may be envisioned by those skilled in the art without departing from the present disclosure. It should be understood that various alternatives to the embodiments of the present disclosure described herein may be employed.

[0150] Unless otherwise indicated, the practice of certain methods disclosed herein employs techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics and recombinant DNA. See, e.g., Sambrook and Green et al., Molecular Cloning: A Laboratory Manual, 4th edition (2012); the book series Current Protocols in Molecular Biology (FM Ausubel et al., eds.); the book series Methods In Enzymology (Academic Press, Inc.), PCR 2: A Practical Approach (MJ MacPherson, BD Hames and GR Taylor, eds. (1995)), Harlow and Lane, eds. (1988) Antibodies, A Laboratory Manual, and Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications, 6th edition (RI Freshney, ed., (2010)).

[0151] As used herein, the singular forms "a / an", and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. In addition, where the terms "including", "include", "having", "has", "with" or variations thereof are used in the detailed description and / or claims, such terms are intended to be inclusive in a manner similar to the term "comprising".

[0152] The term "about" or "approximately" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" may mean within one or more than one standard deviation, as practiced in the art. Alternatively, "about" may mean a range of up to 20%, up to 15%, up to 10%, up to 5%, or up to 1% of a given value.

[0153] As used herein, "cell" refers to a biological cell. A cell can be the basic structural, functional and / or biological unit of a living organism. A cell can be derived from any organism having one or more cells. Some non-limiting examples include: prokaryotic cells, eukaryotic cells, bacterial cells, archaeal cells, cells of unicellular eukaryotic organisms, protozoan cells, cells from plants (e.g., cells from cultivated crops, fruits, vegetables, grains, soybeans, corn, maize, wheat, seeds, tomatoes, rice, cassava, sugar cane, pumpkin, hay, potatoes, cotton, hemp, tobacco, flowering plants, conifers, gymnosperms, ferns, lycopodiella, hornwort, liverwort, mosses), algal cells (e.g., Botryococcus braunii, Chlamydomonas reinhardtii, Nannochloropsis gaditana, Chlorella pyrenoidosa, C. agardh Sargassum pampatens C. Agardh, etc.), algae (e.g., kelp), fungal cells (e.g., yeast cells, cells from mushrooms), animal cells, cells from invertebrates (e.g., fruit flies, cnidarians, echinoderms, nematodes, etc.), cells from vertebrates (e.g., fish, amphibians, reptiles, birds, mammals), cells from mammals (e.g., pigs, cows, goats, sheep, rodents, rats, mice, non-human primates, humans, etc.), etc. Sometimes, the cell is not derived from a natural organism (e.g., the cell can be synthetically manufactured, sometimes referred to as an artificial cell).

[0154] As used herein, the term "nucleotide" refers to a base-sugar-phosphate combination. Nucleotides may include synthetic nucleotides. Nucleotides may include synthetic nucleotide analogs. Nucleotides may be monomeric units of nucleic acid sequences (e.g., deoxyribonucleic acid (DNA) and ribonucleic acid (RNA)). The term nucleotide may include: ribonucleoside triphosphates, adenosine triphosphate (ATP), uridine triphosphate (UTP), cytosine triphosphate (CTP), guanosine triphosphate (GTP); and deoxyribonucleoside triphosphates, such as dATP, dCTP, dITP, dUTP, dGTP, dTTP or derivatives thereof. Such derivatives may include, for example, [αS] dATP, 7-deaza-dGTP and 7-deaza-dATP, as well as nucleotide derivatives that confer nuclease resistance to nucleic acid molecules containing them. As used herein, the term nucleotide may refer to dideoxyribonucleoside triphosphates (ddNTP) and derivatives thereof. Illustrative examples of dideoxyribonucleoside triphosphates may include, but are not limited to: ddATP, ddCTP, ddGTP, ddITP and ddTTP. Nucleotide can be unlabeled or detectably labeled, such as using a portion including an optically detectable portion (e.g., a fluorophore). It can also be labeled with quantum dots. Detectable labels can include, for example, radioisotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels, and enzyme labels. The fluorescent labeling of nucleotides can include, but is not limited to, fluorescein, 5-carboxyfluorescein (FAM), 2'7'-dimethoxy-4'5-dichloro-6-carboxyfluorescein (JOE), rhodamine, 6-carboxyrhodamine (R6G), N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), 6-carboxyl-X-rhodamine (ROX), 4-(4'dimethylaminophenylazo)benzoic acid (DABCYL), waterfall blue, Oregon green, Texas red, cyanine, and 5-(2'-aminoethyl)aminonaphthalene-1-sulfonic acid (EDANS).Specific examples of fluorescently labeled nucleotides can include [R6G]dUTP, [TAMRA]dUTP, [R110]dCTP, [R6G]dCTP, [TAMRA]dCTP, [JOE]ddATP, [R6G]ddATP, [FAM]ddCTP, [R110]ddCTP, [TAMRA]ddGTP, [ROX]ddTTP, [dR6G]ddATP, [dR110]ddCTP, [dTAMRA]ddGTP, and [dROX]ddTTP, available from Perkin Elmer, Foster City, Calif.; FluoroLink deoxynucleotides, FluoroLink Cy3-dCTP, FluoroLink Cy5-dCTP, FluoroLink FluorX-dCTP, FluoroLink Cy3-dUTP, and FluoroLink Cy5-dUTP; fluorescein-15-dATP, fluorescein-12-dUTP, tetramethyl-rhodamine-6-dUTP, IR770-9-dATP, fluorescein-12-ddUTP, fluorescein-12-UTP, and fluorescein-15-2′-dATP available from Boehringer Mannheim, Indianapolis, Ind.; and fluorescein-15-dATP, available from Molecular Probes, Inc., Eugene, Oregon. Probes, Eugene, Oreg), BODIPY-FL-14-UTP, BODIPY-FL-4-UTP, BODIPY-TMR-14-UTP, BODIPY-TMR-14-dUTP, BODIPY-TR-14-UTP, BODIPY-TR-14-dUTP, Cascade Blue-7-UTP, Cascade Blue-7-dUTP, fluorescein-12-UTP, fluorescein-12-dUTP, Oregon Green 488-5-dUTP, Rhodamine Green-5-UTP, Rhodamine Green-5-dUTP, Tetramethylrhodamine-6-UTP, Tetramethylrhodamine-6-dUTP, Texas Red-5-UTP, Texas Red-5-dUTP and Texas Red-12-dUTP. Nucleotides can also be labeled or marked by chemical modification. The chemically modified single nucleotide may be a biotin-dNTP.Some non-limiting examples of biotinylated dNTPs can include biotin-dATP (e.g., bio-N6-ddATP, biotin-14-dATP), biotin-dCTP (e.g., biotin-11-dCTP, biotin-14-dCTP), and biotin-dUTP (e.g., biotin-11-dUTP, biotin-16-dUTP, biotin-20-dUTP).

[0155] The terms "polynucleotide", "oligonucleotide" and "nucleic acid" are used interchangeably to refer to a polymeric form of nucleotides of any length, deoxyribonucleotides or ribonucleotides or their analogs, in single-stranded, double-stranded or multi-stranded form. The polynucleotide can be exogenous or endogenous to the cell. The polynucleotide can be present in a cell-free environment. The polynucleotide can be a gene or a fragment thereof. The polynucleotide can be DNA. The polynucleotide can be RNA. The polynucleotide can have any three-dimensional structure and can perform any function. In a polynucleotide, when T is mentioned, T means U (uracil) in RNA and T (thymine) in DNA. The polynucleotide can include one or more analogs (e.g., altered backbones, sugars or nucleobases). If present, modifications to the nucleotide structure can be imparted before or after the polymer is assembled. Some non-limiting examples of analogs include: 5-bromouracil, peptide nucleic acids, heterologous nucleic acids, morpholinos, locked nucleic acids, glycerol nucleic acids, threose nucleic acids, dideoxynucleotides, cordycepin, 7-deaza-GTP, fluorophores (e.g., rhodamine or fluorescein linked to a sugar), thiol-containing nucleotides, biotin-linked nucleotides, fluorescent base analogs, CpG islands, methyl-7-guanosine, methylated nucleotides, inosine, thiouridine, pseudouridine, dihydrouridine, braided nucleotides, and wyosine. Non-limiting examples of polynucleotides include coding or non-coding regions of genes or gene fragments, multiple loci (one locus) defined according to linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), short interfering RNA (siRNA), short hairpin RNA (shRNA), micro RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, cell-free polynucleotides including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), nucleic acid probes and primers. The nucleotide sequence may be interspersed with non-nucleotide components.

[0156] The term "transfection" or "transfected" refers to the introduction of nucleic acid into cells by non-viral or viral-based methods. The nucleic acid molecule can be a gene sequence encoding a complete protein or a functional portion thereof. See, for example, Sambrook et al. (1989), Molecular Cloning: A Laboratory Manual, 18.1-18.88.

[0157] The terms "peptide", "polypeptide" and "protein" are used interchangeably herein to refer to a polymer of at least two amino acid residues connected by a peptide bond. This term does not indicate the specific length of the polymer, nor is it intended to imply or distinguish whether the peptide is produced using recombinant technology, chemical or enzymatic synthesis, or is naturally present. The term is applicable to naturally occurring amino acid polymers and amino acid polymers including at least one modified amino acid. In some cases, the polymer may be interspersed with non-amino acids. The term includes amino acid chains of any length, including full-length proteins and proteins with or without secondary and / or tertiary structures (e.g., domains). The term also encompasses amino acid polymers that have been modified; for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, oxidation, and any other operations, such as conjugation with a labeling component. As used herein, the terms "amino acid" and "amino acids" refer to natural and non-natural amino acids, including but not limited to modified amino acids and amino acid analogs. Modified amino acids may include natural and non-natural amino acids that have been chemically modified to include groups or chemical moieties that are not naturally present on amino acids. Amino acid analogs may refer to amino acid derivatives. The term "amino acid" encompasses D-amino acids and L-amino acids.

[0158] As used herein, "non-natural" may refer to nucleic acids or polypeptide sequences not found in natural nucleic acids or proteins. Non-natural may refer to affinity tags. Non-natural may refer to fusions. Non-natural may refer to naturally occurring nucleic acids or polypeptide sequences including mutations, insertions and / or deletions. Non-natural sequences may exhibit and / or encode activities (e.g., enzymatic activity, methyltransferase activity, acetyltransferase activity, kinase activity, ubiquitination activity, etc.) that may also be exhibited by nucleic acids and / or polypeptide sequences fused to non-natural sequences. Non-natural nucleic acids or polypeptide sequences may be connected to naturally occurring nucleic acids or polypeptide sequences (or variants thereof) by genetic engineering to produce chimeric nucleic acids and / or polypeptide sequences encoding chimeric nucleic acids and / or polypeptides.

[0159] As used herein, the term "promoter" refers to a regulatory DNA region that controls polynucleotide (e.g., gene) transcription or expression and can be located adjacent to or overlaps with a nucleotide or nucleotide region that initiates RNA transcription. A promoter may contain a specific DNA sequence that binds a protein factor (commonly referred to as a transcription factor) that promotes the binding of RNA polymerase to DNA, thereby causing gene transcription. 'Basic promoter', also referred to as 'core promoter', may refer to a promoter containing all the basic essential elements that promote the transcriptional expression of an operably linked polynucleotide. Eukaryotic basal promoters typically (although not necessarily) contain a TATA box and / or a CAAT box. In certain embodiments, different promoters direct the expression of genes in different tissues or cell types, or at different developmental stages, or in response to different environmental or physiological conditions or inducer molecules. Promoters that make genes expressed in most cell types at most times are generally referred to as "constitutive promoters". Promoters that make genes expressed in specific cells and tissue types are generally referred to as "cell-specific promoters" or "tissue-specific promoters", respectively. Promoters that make genes expressed at specific stages of development or cell differentiation are generally referred to as "developmental-specific promoters" or "cell differentiation-specific promoters". Promoters that are induced and result in gene expression following exposure or treatment of cells with an agent, biomolecule, chemical, ligand, light, etc. that induces the promoter are generally referred to as "inducible promoters" or "regulatable promoters." It is further recognized that in some embodiments, promoter activity is identical for DNA fragments of different lengths, as the exact boundaries of regulatory sequences have not been completely defined in most cases.

[0160] As used herein, the term "expression" refers to the process of transcribing a nucleic acid sequence or polynucleotide from a DNA template (e.g., into mRNA or other RNA transcripts) and / or the subsequent translation of the transcribed mRNA into a peptide, polypeptide, or protein. Transcripts and encoded polypeptides may be collectively referred to as "gene products." If the polynucleotide is derived from genomic DNA, expression may include splicing of mRNA in eukaryotic cells.

[0161] As used herein, "operably connected", "operably connected", "operably connected" or its grammatical equivalent refers to genetic elements, such as the arrangement of promoters, enhancers, polyadenylation sequences, etc., wherein the operation (for example, movement or activation) of the first genetic element has some influence on the second genetic element. The influence on the second genetic element can be but need not be the same type as the operation of the first genetic element. For example, if the movement of the first element causes the activation of the second element, the two genetic elements are operably connected. For example, if the regulatory element helps to start the transcription of the coding sequence, the regulatory element that can include promoters and / or enhancer sequences is operably connected to the coding region. As long as this functional relationship is maintained, there will be an insertion residue between the regulatory element and the coding region.

[0162] As used herein, "vector" refers to a macromolecule or macromolecular association that includes or associates with a polynucleotide and can be used to mediate the delivery of the polynucleotide to a cell. Examples of vectors include plasmids, viral vectors, liposomes, and other gene delivery vehicles. Vectors typically include genetic elements, such as regulatory elements, that are operably linked to a gene to promote expression of the gene in a target.

[0163] As used herein, "expression cassette" and "nucleic acid cassette" are used interchangeably to refer to a combination of nucleic acid sequences or elements that are expressed together or operably linked for expression. In some cases, an expression cassette refers to a combination of a regulatory element and one or more genes to which it is operably linked for expression.

[0164] A "functional fragment" of a DNA or protein sequence refers to a fragment that retains a biological activity (function or structure) substantially similar to that of the full-length DNA or protein sequence. The biological activity of a DNA sequence may be its ability to affect expression in a manner attributed to the full-length sequence.

[0165] The terms "engineered," "synthetic," and "artificial" are used interchangeably herein to refer to objects that have been modified by human intervention. For example, the terms may refer to a non-naturally occurring polynucleotide or polypeptide. An engineered peptide may have, but need not have, low sequence identity (e.g., less than 50% sequence identity, less than 25% sequence identity, less than 10% sequence identity, less than 5% sequence identity, less than 1% sequence identity) with a naturally occurring human protein. For example, the VPR and VP64 domains are synthetic transactivation domains. For example, the VPR and VP64 domains are synthetic transactivation domains. According to non-limiting examples: a nucleic acid may be modified by changing its sequence to a sequence that does not exist in nature; a nucleic acid may be modified by connecting it to a nucleic acid that is not associated with it in nature, so that the connection product has a function that does not exist in the original nucleic acid; an engineered nucleic acid may be synthesized in vitro with a sequence that does not exist in nature; a protein may be modified by changing its amino acid sequence to a sequence that does not exist in nature; an engineered protein may acquire a new function or property. An "engineered" system includes at least one engineered component.

[0166] The term "tracrRNA" or "tracr sequence" means trans-activating CRISPR RNA. TracrRNA interacts with CRISPR (cr) RNA to form a guide nucleic acid (e.g., guide RNA or gRNA) that can hybridize with a target nucleic acid and thereby guides the relevant nuclease to the target nucleic acid. If tracrRNA is engineered, it may have about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100% sequence identity and / or sequence similarity with a wild-type exemplary tracrRNA sequence (e.g., tracrRNA from Streptococcus pyogenes (S.pyogenes), Staphylococcus aureus (S.aureus or SEQ ID NO: *_*), etc.). TracrRNA may refer to a modified form of tracrRNA, which may include nucleotide changes, such as deletions, insertions or substitutions, variants, mutations or chimeras. TracrRNA may refer to a nucleic acid that may be at least about 60% identical to a wild-type exemplary tracrRNA (e.g., tracrRNA from Streptococcus pyogenes, Staphylococcus aureus, etc.) sequence over an extension of at least 6 consecutive nucleotides. For example, a tracrRNA sequence may be at least about 60% identical, at least about 65% identical, at least about 70% identical, at least about 75% identical, at least about 80% identical, at least about 85% identical, at least about 90% identical, at least about 95% identical, at least about 98% identical, at least about 99% identical, or 100% identical to a wild-type exemplary tracrRNA (e.g., tracrRNA from Streptococcus pyogenes, Staphylococcus aureus, etc.) sequence over an extension of at least 6 consecutive nucleotides. Type II tracrRNA sequences may be predicted on genomic sequences by identifying regions that are complementary to partial repeat sequences in adjacent CRISPR arrays.

[0167] As used herein, "guide nucleic acid" or "guide polynucleotide" refers to a nucleic acid that can hybridize with a target nucleic acid and thereby guide the relevant nuclease to the target nucleic acid. The guide nucleic acid can be RNA (guide RNA or gRNA). The guide nucleic acid can be DNA. The guide nucleic acid can be a mixture of RNA and DNA. The guide nucleic acid can include crRNA or tracrRNA or a combination of the two. The guide nucleic acid can be engineered. The guide nucleic acid can be programmed to specifically bind to the target nucleic acid. A portion of the target nucleic acid can be complementary to a portion of the guide nucleic acid. The chain of the double-stranded target polynucleotide that is complementary to and hybridized with the guide nucleic acid can be referred to as a complementary chain. The chain of the double-stranded target polynucleotide that is complementary to the complementary chain and therefore may not be complementary to the guide nucleic acid can be referred to as a non-complementary chain. The guide nucleic acid can include a polynucleotide chain and can be referred to as a "single guide nucleic acid". The guide nucleic acid can include two polynucleotide chains and can be referred to as a "double guide nucleic acid". If not otherwise specified, the term "guide nucleic acid" can be inclusive, referring to both single guide nucleic acids and double guide nucleic acids. The guide nucleic acid can include a segment that can be referred to as a "nucleic acid targeting segment", "nucleic acid targeting sequence" or "spacer". The nucleic acid targeting segment may include sub-segments, which may be referred to as "protein binding segments" or "protein binding sequences" or "Cas protein binding segments."

[0168] As used herein, the terms "gene editing" and "genome editing" can be used interchangeably. Gene editing or genome editing means changing the nucleic acid sequence of a gene or genome. Genome editing can include, for example, insertions, deletions, and mutations.

[0169] In the context of two or more nucleic acid or polypeptide sequences, the term "sequence identity" or "percent identity" refers to sequences that are identical or have a specific percentage of amino acid residues or nucleotides that are identical (e.g., in a pairwise alignment) or more (e.g., in a multiple sequence alignment) when compared and aligned for maximum correspondence within a local or global comparison window, as measured using a sequence comparison algorithm. Suitable sequence comparison algorithms for polypeptide sequences include, for example, BLASTP using a word length (W) of 3, an expected value (E) of 10, and a BLOSUM62 scoring matrix with gap penalties set to 11 for presence, 1 for extension, and using a conditional composition scoring matrix adjustment for polypeptide sequences longer than 30 residues; BLASTP using a word length (W) of 2, an expected value (E) of 1000000, and a PAM30 scoring matrix (for sequences less than 30 residues, the gap penalty is set to 9 to open a gap, and to 1 to extend a gap) (these are the parameters of the BLAST suite BLASTP with default parameters, available at https: / / blast.ncbi.nlm.nih.gov); CLUSTALW with parameters; Smith-Waterman homology search algorithm with the following parameters: matches of 2, mismatches of -1, and gaps of -1; MUSCLE with default parameters; MAFFT with the following parameters: retree of 2 and maxiterations of 1000; Novafold with default parameters; HMMER hmmalign with default parameters.

[0170] The present disclosure includes variants of any enzyme in the enzymes described herein with one or more conservative amino acid substitutions. Such conservative substitutions can be carried out in the amino acid sequence of a polypeptide without destroying the three-dimensional structure or function of the polypeptide. Conservative substitutions can be completed by replacing each other with amino acids having similar hydrophobicity, polarity, and R chain length. Additionally or alternatively, by comparing the alignment sequences of homologous proteins from different species, conservative substitutions can be identified by locating the amino acid residues (e.g., non-conservative residues) that have mutated between species without changing the basic function of the encoded protein. Such conservatively substituted variants may include variants with at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% identity with any of the systems described herein (e.g., MG36 or MG39 systems described herein). In some embodiments, such conservatively substituted variants are functional variants. Such functional variants may encompass sequences with substitutions so that the activity of the key active site residues of the endonuclease is not destroyed. In some embodiments, the functional variants of any of the systems described herein lack substitutions of at least one of the conservative residues or functional residues shown in Figures 4 and 5. In some embodiments, functional variants of any of the systems described herein lack substitutions of all of the conserved or functional residues shown in Figures 4 and 5.

[0171] Conservative substitution tables providing functionally similar amino acids are available from various references (see, e.g., Creighton, Proteins: Structures and Molecular Properties (WH Freeman & Co.; 2nd ed. (December 1993)). The following eight groups each contain amino acids that are conservatively substituted for each other:

[0172] 1) Alanine (A), glycine (G);

[0173] 2) Aspartic acid (D), glutamic acid (E);

[0174] 3) Asparagine (N), glutamine (Q);

[0175] 4) Arginine (R), Lysine (K);

[0176] 5) Isoleucine (I), leucine (L), methionine (M), valine (V);

[0177] 6) Phenylalanine (F), tyrosine (Y), tryptophan (W);

[0178] 7) serine (S), threonine (T); and

[0179] 8) Cysteine ​​(C), methionine (M).

[0180] As used herein, the term "RuvC_III domain" refers to the third discontinuous segment of the RuvC nuclease domain (the RuvC nuclease domain includes three discontinuous segments, RuvC_I, RuvC_II and RuvC_III). RuvC domains or their segments can usually be identified by comparing with recorded domain sequences, with the structural alignment of proteins with annotated domains, or by comparing with a Hidden Markov Model (HMM) constructed based on recorded domain sequences (e.g., Pfam HMM PF18541 of RuvC_III).

[0181] As used herein, the term "HNH domain" refers to an endonuclease domain having characteristic histidine and asparagine residues. HNH domains can generally be identified by comparison with recorded domain sequence alignments, with structural alignments of proteins with annotated domains, or by comparison with a hidden Markov model (HMM) constructed based on recorded domain sequences (e.g., Pfam HMM PF01844 for domain HNH).

[0182] As used herein, the term "recombinase" refers to an enzyme that mediates the recombination of DNA fragments located between recombinase recognition sequences, which results in excision, insertion, inversion, exchange or translocation of the DNA fragments located between the recombinase recognition sequences.

[0183] As used herein, in the context of nucleic acid modification (e.g., genomic modification), the term "recombination" refers to the process of modifying two or more nucleic acid molecules or two or more regions of a single nucleic acid molecule by the action of a recombinase protein. Recombination may particularly result in excision, insertion, inversion, exchange or translocation of nucleic acid sequences, such as in or between one or more nucleic acid molecules.

[0184] As used herein, the term "transposon" or "transposable element" refers to a nucleic acid sequence in a genome, which is a mobile genetic element that can change its location in the genome. In some cases, transposons transport additional "cargo DNA" excised from the genome. Transposons include, for example, retrotransposons, DNA transposons, autonomous and non-autonomous transposons, and class III transposons. Transposon nucleic acid sequences include, for example, genes encoding homologous transposases, one or more transposase recognition sequences, or a combination thereof. In some cases, these transposons are different in the nucleic acid type of transposition, the type of repetition at the end of the transposon, the type of cargo to be carried, or the transposition mode (i.e., self-repair or host repair) of the transposition. As used herein, the term "transposase (transposase or transposases)" refers to an enzyme that is combined with the recognition sequence of a transposon and catalyzes its movement to another part of the genome. In some cases, movement is carried out by cutting and pasting a mechanism or copying a transposition.

[0185] As used herein, the term "Tn7" or "Tn7-like transposase" refers to a family of transposases that includes three major components: a heteropolymer transposase (TnsA and / or TnsB) and a regulatory protein (TnsC). In addition to the TnsABC transposase, the Tn7 element can encode specialized target site selection proteins, TnsD and TnsE. In combination with TnsABC, the sequence-specific DNA binding protein TnsD guides transposition to a conserved site known as the "Tn7 attachment site," i.e., attTn7. TnsD is a member of a large family of proteins that also includes TniQ. TniQ has been shown to target transposition in the resolution site of a plasmid.

[0186] As used herein, the term "complex" refers to the connection of at least two components. The two components can each retain the characteristics / activity they had before forming the complex. The connection can be carried out by covalent bonding, non-covalent bonding (i.e., hydrogen bonding, ionic interactions, Van der Waals interactions, and hydrophobic bonds), using a linker, fusion, or any other suitable method. In some cases, the components in the complex are polynucleotides, polypeptides, or combinations thereof. For example, the complex can include a Cas protein and a guide nucleic acid.

[0187] In some cases, the CAST system described herein includes one or more Tn7 or Tn7-like transposases. In certain example embodiments, Tn7 or Tn7-like transposases include multimeric protein complexes. In certain example embodiments, multimeric protein complexes include TnsA, TnsB, TnsC or TniQ. In these combinations, transposases (TnsA, TnsB, TnsC, TniQ) can form complexes or fusion proteins with each other.

[0188] In some cases, the CAST system described herein includes one or more Tn5053 or Tn5053-like transposases. In certain example embodiments, Tn5053 or Tn5053-like transposases include multimeric protein complexes. In certain example embodiments, the multimeric protein complexes include TnsA, TnsB, TnsC or TniQ. In these combinations, transposases (TnsA, TnsB, TnsC, TniQ) can form complexes or fusion proteins with each other.

[0189] As used herein, the term "Cas12k" (alternatively, "class 2 VK type") refers to a subtype of a V-type CRISPR system that has been found to be defective in nuclease activity (e.g., it may include at least one defective RuvC domain that lacks at least one catalytic residue important for DNA cleavage). This effector subtype is typically associated with a CAST system.

[0190] As used herein, the term "IF-type" (alternatively Class 1 IF-type CRISPR) refers to a subtype of a Class 1 Type I CRISPR system. Such systems typically include a multi-component CRISPR effector consisting of Cas8, Cas7, and Cas6 proteins. In some cases, such systems are found to be associated with CAST systems. In some cases, the IF-type CRISPR system includes a crRNA comprising: an 8-nt 5' handle for Cas8 and / or Cas5 binding; a 32-nt spacer bound by six copies of Cas7 for target identification; or a 20-nt 3' hairpin for Cas6 binding and pre-crRNA processing. In some cases, the F-type system utilizes a 5'-CC PAM on a non-target strand for target binding.

[0191] In accordance with IUPAC conventions, the following abbreviations are used in various examples:

[0192] A = Adenine

[0193] C = cytosine

[0194] G = Guanine

[0195] T = thymine

[0196] R = adenine or guanine

[0197] Y = cytosine or thymine

[0198] S = guanine or cytosine

[0199] W = adenine or thymine

[0200] K = guanine or thymine

[0201] M = adenine or cytosine

[0202] B=C, G or T

[0203] D=A, G or T

[0204] H=A、C or T

[0205] V=A、C or G

[0206] Overview

[0207] The discovery of new Cas enzymes with unique functions and structures may offer the potential to further disrupt deoxyribonucleic acid (DNA) editing technologies, thereby improving speed, specificity, functionality, and ease of use. Relative to the predicted prevalence of clustered regularly interspaced short palindromic repeat (CRISPR) systems in microorganisms and the sheer diversity of microbial species, there are relatively few functionally characterized CRISPR / Cas enzymes in the literature. This is in part because a large number of microbial species may not be easily cultured under laboratory conditions. Metagenomic sequencing of natural environmental niches representing a large number of microbial species may offer the potential to substantially increase the number of new CRISPR / Cas systems documented and accelerate the discovery of new oligonucleotide editing functions. A recent example of the fruitfulness of this approach was demonstrated by the discovery of the CasX / CasY CRISPR system in 2016 through metagenomic analysis of natural microbial communities.

[0208] The CRISPR / Cas system is an RNA-guided nuclease complex that has been described as acting as an adaptive immune system in microorganisms. In the natural environment of the CRISPR / Cas system, the CRISPR / Cas system appears in a CRISPR (clustered regularly spaced short palindromic repeats) operon or locus, which generally includes two parts: (i) an array of short repeats (30-40bp) separated by equally short spacer sequences, which encodes RNA-based targeting elements; and (ii) an ORF encoding Cas, which encodes a nuclease polypeptide guided by RNA-based targeting elements together with an auxiliary protein / enzyme. Efficient nuclease targeting of a specific target nucleic acid sequence generally requires the following two: (i) complementary hybridization between the first 6-8 nucleic acids of the target (target seed) and the crRNA guide; and (ii) the presence of a protospacer adjacent motif (PAM) sequence near the definition of the target seed (PAM is usually a sequence not often represented in the host genome). Depending on the exact function and organization of the system, CRISPR-Cas systems are generally classified into 2 categories, 5 types, and 16 subtypes based on shared functional features and evolutionary similarities (see Figure 1 ).

[0209] Class 1 CRISPR-Cas systems have large multi-subunit effector complexes and include types I, III, and IV.

[0210] Type I CRISPR-Cas systems are considered to have medium complexity in terms of components. In type I CRISPR-Cas systems, the array of RNA targeting elements is transcribed into long precursor crRNA (pre-crRNA), which is processed at the repeat element to release short mature crRNA, when followed by a suitable short consensus sequence known as the protospacer adjacent motif (PAM), the short mature crRNA guides the nuclease complex to the nucleic acid target. This treatment is carried out by the endoribonuclease subunit (Cas6) of the large endonuclease complex called cascade, and the endonuclease complex also includes the nuclease (Cas3) protein component of the nuclease complex guided by crRNA. Cas I nuclease mainly serves as DNA nuclease.

[0211] Type III CRISPR systems may be characterized by the presence of a central nuclease called Cas10 and repeat-associated mysterious proteins (RAMPs) including Csm or Cmr protein subunits. As in type I systems, mature crRNAs are processed by crRNA precursors using a Cas6-like enzyme. Unlike type I and type II systems, type III systems appear to target and cleave DNA-RNA duplexes (such as DNA chains used as templates for RNA polymerases).

[0212] Type IV CRISPR-Cas systems have an effector complex consisting of a highly reduced large subunit nuclease (csf1), two genes for the Cas5 (csf3) and Cas7 (csf2) groups of RAMP proteins, and in some cases a gene for a predicted small subunit; such systems are often found on endogenous plasmids.

[0213] Class 2 CRISPR-Cas systems typically have single-polypeptide multi-domain nuclease effectors and include types II, V, and VI.

[0214] Type II CRISPR-Cas systems are considered to be the simplest in terms of components. In type II CRISPR-Cas systems, the CRISPR array is processed into mature crRNA without the presence of special endonuclease subunits, but requires a small trans-encoded crRNA (tracrRNA), whose region is complementary to the array repeat sequence; tracrRNA interacts with its corresponding effector nuclease (e.g., Cas9) and repeat sequence to form a precursor dsRNA structure, which is cut by endogenous RNase III, thereby generating a mature effector enzyme loaded with both tracrRNA and crRNA. Cas II nucleases are referred to as DNA nucleases. Type 2 effectors generally exhibit a structure consisting of a RuvC-like endonuclease domain, which is folded using RNase H, wherein an unrelated HNH nuclease domain is inserted into the fold of the RuvC-like nuclease domain. The RuvC-like domain is responsible for the cutting of the target (e.g., crRNA complementary) DNA chain, and the HNH domain is responsible for the cutting of the replaced DNA chain.

[0215] The V-type CRISPR-Cas system is characterized by a nuclease effector (e.g., Cas12) structure similar to that of the type II effector including a RuvC-like domain. Similar to type II, most (but not all) V-type CRISPR systems use tracrRNA to process pre-crRNA into mature crRNA; however, unlike the type II system that requires RNase III to cut pre-crRNA into multiple crRNAs, the V-type system is able to use the effector nuclease itself to cut pre-crRNA. Like the type II CRISPR-Cas system, the V-type CRISPR-Cas system is again referred to as a DNA nuclease. Unlike the type II CRISPR-Cas system, some V-type enzymes (e.g., Cas12a) appear to have a strong single-stranded nonspecific deoxyribonuclease activity activated by the first crRNA-directed cutting of the double-stranded target sequence.

[0216] Type VI CRIPSR-Cas systems have RNA-guided RNA endonucleases. The single polypeptide effector of a type VI system (e.g., Cas13) includes two HEPN ribonuclease domains, rather than a RuvC-like domain. Unlike type II and type V systems, type VI systems also do not appear to require tracrRNA to process pre-crRNA into crRNA. However, similar to type V systems, some type VI systems (e.g., C2C2) appear to have powerful single-stranded nonspecific nuclease (ribonuclease) activity activated by the first crRNA-directed cutting of the target RNA.

[0217] Class 2 CRISPR-Cas has been most widely used in engineering and development as a designer nuclease / genome editing application due to its simpler architecture.

[0218] One of the early adaptations of this system to in vitro used (i) recombinantly expressed, purified full-length Cas9 (e.g., class 2, type II Cas enzyme) isolated from Streptococcus pyogenes SF370; (ii) purified mature, approximately 42 nt crRNA carrying an approximately 20 nt 5' sequence complementary to the target DNA sequence desired to be cleaved, followed by a 3' tracr binding sequence (the entire crRNA was in vitro transcribed from a synthetic DNA template carrying a T7 promoter sequence); (iii) purified tracrRNA in vitro transcribed from a synthetic DNA template carrying a T7 promoter sequence; and (iv) Mg 2+ A later improved engineered system involves the crRNA of (ii) being linked to the 5' end of (iii) via a linker (e.g., GAAA) to form a single fused synthetic guide RNA (sgRNA) that can itself guide Cas9 to the target (compare Figure 2 ).

[0219] Such an engineered system can be adapted for mammalian cells by providing a DNA vector encoding: (i) an ORF encoding a codon-optimized Cas9 (e.g., a class 2 type II Cas enzyme) under a suitable mammalian promoter with a C-terminal nuclear localization sequence (e.g., SV40 NLS) and a suitable polyadenylation signal (e.g., TK pA signal); and (ii) an ORF encoding an sgRNA (having a 5' sequence starting with G followed by a 20 nt complementary targeting nucleic acid sequence linked to a 3' tracr binding sequence, a linker, and a tracrRNA sequence) under a suitable polymerase III promoter (e.g., U6 promoter).

[0220] Transposons are mobile elements that can move between locations in the genome. Such transposons have evolved to limit their negative impact on the host. A variety of regulatory mechanisms are used to maintain low-frequency transpositions, and sometimes also coordinate transpositions with various cellular processes. Some prokaryotic transposons can also mobilize functions that are beneficial to the host or otherwise help maintain the element. Some transposons may also evolve a strict control mechanism for target site selection, with the most notable example being the Tn7 family.

[0221] Transposon Tn7 and similar elements may be reservoirs for antibiotic resistance and pathogenesis functions in clinical settings, as well as encoding other adaptive functions in natural environments. For example, the Tn7 system has evolved mechanisms to almost completely avoid integration into important host genes but also to maximize dispersion of the element by recognizing mobile plasmids and phages that can move Tn7 between host bacteria.

[0222] Tn7 and Tn7-like elements can control the location and timing of their insertion, with one pathway directing insertion into a single conserved location in the bacterial genome and a second pathway that appears to be adapted to maximize targeting of mobile plasmids capable of transporting the element between bacteria (see Figure 3 The association between Tn7-like transposons and CRISPR-Cas systems suggests that transposons may hijack CRISPR effectors to generate R-loops in target loci and facilitate transposon spread via plasmids and phages.

[0223] MG36 System

[0224] In some embodiments, provided herein is a MG36 system for transposing a cargo nucleotide sequence into a target nucleic acid site. Figures 4A-4C . In some embodiments, the system comprises a double-stranded nucleic acid. In some embodiments, the cargo nucleotide sequence is configured to interact with a recombinase complex. In some embodiments, the system comprises a Cas effector complex. In some embodiments, the Cas effector complex comprises 2 types of type II Cas effectors and at least one engineered guide polynucleotide configured to hybridize with a target nucleic acid site. In some embodiments, the 2 types of type II Cas effectors comprise a RuvC domain and a HNH domain. In some embodiments, the system comprises a recombinase or transposase complex, wherein the recombinase or transposase complex is configured to recruit the cargo nucleotide sequence to the target nucleic acid site.

[0225] In some cases, the cargo nucleotide sequence is flanked by a left transposase recognition sequence. In some cases, the cargo nucleotide sequence is flanked by a right transposase recognition sequence. In some cases, the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence.

[0226] In some cases, the target nucleic acid includes a target nucleic acid site. In some cases, the target nucleic acid includes a PAM sequence that is compatible with the Cas effector complex adjacent to the target nucleic acid site. In some cases, the PAM sequence is located at 3' of the target nucleic acid site. In some cases, the PAM sequence is located at 5' of the target nucleic acid site.

[0227] In some cases, the engineered guide polynucleotide is configured to bind to Class 2 Type II Cas effectors. In some cases, Class 2 Type II Cas effectors include polypeptides having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to SEQ ID NO: 1. In some cases, Class 2 Type II Cas effectors include polypeptides comprising a sequence having at least about 70% identity to SEQ ID NO: 1. In some cases, 2 class II type Cas effectors include polypeptides comprising a sequence having at least about 75% identity to SEQ ID NO: 1. In some cases, 2 class II type Cas effectors include polypeptides comprising a sequence having at least about 80% identity to SEQ ID NO: 1. In some cases, 2 class II type Cas effectors include polypeptides comprising a sequence having at least about 85% identity to SEQ ID NO: 1. In some cases, 2 class II type Cas effectors include polypeptides comprising a sequence having at least about 90% identity to SEQ ID NO: 1. In some cases, 2 class II type Cas effectors include polypeptides comprising a sequence having at least about 91% identity to SEQ ID NO: 1. In some cases, 2 class II type Cas effectors include polypeptides comprising a sequence having at least about 92% identity to SEQ ID NO: 1. In some cases, 2 class II type Cas effectors include polypeptides comprising a sequence having at least about 93% identity to SEQ ID NO: 1. In some cases, 2 class II type Cas effectors include polypeptides comprising a sequence having at least about 94% identity to SEQ ID NO: 1. In some cases, 2 class II type Cas effectors include polypeptides comprising a sequence having at least about 95% identity to SEQ ID NO: 1. In some cases, 2 class II type Cas effectors include polypeptides comprising a sequence having at least about 96% identity to SEQ ID NO: 1. In some cases, 2 class II type Cas effectors include polypeptides comprising a sequence having at least about 97% identity to SEQ ID NO: 1. In some cases, 2 class II type Cas effectors include polypeptides comprising a sequence having at least about 98% identity to SEQ ID NO: 1. In some cases, 2 class II type Cas effectors include polypeptides comprising a sequence having at least about 99% identity to SEQ ID NO: 1.In some cases, the Class 2 type II Cas effector includes a polypeptide comprising a sequence with 100% identity to SEQ ID NO:1.

[0228] In some cases, the recombinase or transposase complex includes at least one polypeptide (e.g., at least 1, 2, 3, 4, 5, 6, or more than 6 polypeptides) comprising a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex includes at least one polypeptide comprising a sequence having at least about 70% identity to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex includes at least one polypeptide comprising a sequence having at least about 75% identity to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex includes at least one polypeptide comprising a sequence having at least about 80% identity to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex includes at least one polypeptide comprising a sequence having at least about 85% identity to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex includes at least one polypeptide comprising a sequence having at least about 90% identity to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex includes at least one polypeptide comprising a sequence having at least about 91% identity to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex includes at least one polypeptide comprising a sequence having at least about 92% identity to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex includes at least one polypeptide including a sequence that is at least about 93% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex includes at least one polypeptide including a sequence that is at least about 94% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex includes at least one polypeptide including a sequence that is at least about 95% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex includes at least one polypeptide including a sequence that is at least about 96% identical to any one of SEQ ID NOs: 2-5.In some cases, the recombinase or transposase complex includes at least one polypeptide including a sequence that is at least about 97% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex includes at least one polypeptide including a sequence that is at least about 98% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex includes at least one polypeptide including a sequence that is at least about 99% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex includes at least one polypeptide including a sequence that is 100% identical to any one of SEQ ID NOs: 2-5.

[0229] In some cases, the recombinase or transposase complex comprises at least a first polypeptide and a second polypeptide, each independently comprising a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex comprises at least a first polypeptide and a second polypeptide, each independently comprising a polypeptide having a sequence having at least about 70% identity to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex comprises at least a first polypeptide and a second polypeptide, each of which independently comprises a polypeptide having a sequence at least about 75% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex comprises at least a first polypeptide and a second polypeptide, each of which independently comprises a polypeptide having a sequence at least about 80% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex comprises at least a first polypeptide and a second polypeptide, each of which independently comprises a polypeptide having a sequence at least about 85% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex comprises at least a first polypeptide and a second polypeptide, each of which independently comprises a polypeptide having a sequence at least about 90% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex comprises at least a first polypeptide and a second polypeptide, each independently comprising a polypeptide having a sequence at least about 91% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex comprises at least a first polypeptide and a second polypeptide, each independently comprising a polypeptide having a sequence at least about 92% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex comprises at least a first polypeptide and a second polypeptide, each independently comprising a polypeptide having a sequence at least about 93% identical to any one of SEQ ID NOs: 2-5.In some cases, the recombinase or transposase complex comprises at least a first polypeptide and a second polypeptide, each independently comprising a polypeptide having a sequence at least about 94% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex comprises at least a first polypeptide and a second polypeptide, each independently comprising a polypeptide having a sequence at least about 95% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex comprises at least a first polypeptide and a second polypeptide, each independently comprising a polypeptide having a sequence at least about 96% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex comprises at least a first polypeptide and a second polypeptide, each independently comprising a polypeptide having a sequence at least about 97% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex comprises at least a first polypeptide and a second polypeptide, each independently comprising a polypeptide having a sequence at least about 98% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex comprises at least a first polypeptide and a second polypeptide, each independently comprising a polypeptide having a sequence at least about 99% identical to any one of SEQ ID NOs: 2-5. In some cases, the recombinase or transposase complex comprises at least a first polypeptide and a second polypeptide, each independently comprising a polypeptide having a sequence 100% identical to any one of SEQ ID NOs: 2-5.

[0230] In some cases, the recombinase or transposase complex comprises a TnsB1 polypeptide comprising a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NO: 2. In some cases, the recombinase or transposase complex comprises a TnsB1 polypeptide comprising a sequence having at least about 70% identity to SEQ ID NO: 2. In some cases, the recombinase or transposase complex comprises a TnsB1 polypeptide comprising a sequence having at least about 75% identity to SEQ ID NO: 2. In some cases, the recombinase or transposase complex includes a TnsB1 polypeptide comprising a sequence having at least about 80% identity to SEQ ID NO: 2. In some cases, the recombinase or transposase complex includes a TnsB1 polypeptide comprising a sequence having at least about 85% identity to SEQ ID NO: 2. In some cases, the recombinase or transposase complex includes a TnsB1 polypeptide comprising a sequence having at least about 90% identity to SEQ ID NO: 2. In some cases, the recombinase or transposase complex includes a TnsB1 polypeptide comprising a sequence having at least about 91% identity to SEQ ID NO: 2. In some cases, the recombinase or transposase complex includes a TnsB1 polypeptide comprising a sequence having at least about 92% identity to SEQ ID NO: 2. In some cases, the recombinase or transposase complex includes a TnsB1 polypeptide comprising a sequence having at least about 93% identity to SEQ ID NO: 2. In some cases, the recombinase or transposase complex includes a TnsB1 polypeptide comprising a sequence having at least about 94% identity to SEQ ID NO: 2. In some cases, the recombinase or transposase complex includes a TnsB1 polypeptide comprising a sequence having at least about 95% identity to SEQ ID NO: 2. In some cases, the recombinase or transposase complex includes a TnsB1 polypeptide comprising a sequence having at least about 96% identity to SEQ ID NO: 2. In some cases, the recombinase or transposase complex includes a TnsB1 polypeptide comprising a sequence having at least about 97% identity to SEQ ID NO: 2. In some cases, the recombinase or transposase complex includes a TnsB1 polypeptide comprising a sequence having at least about 98% identity to SEQ ID NO: 2.In some cases, the recombinase or transposase complex includes a TnsB1 polypeptide comprising a sequence at least about 99% identical to SEQ ID NO: 2. In some cases, the recombinase or transposase complex includes a TnsB1 polypeptide comprising a sequence 100% identical to SEQ ID NO:2.

[0231] In some cases, the recombinase or transposase complex comprises a TnsB2 polypeptide comprising a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NO: 3. In some cases, the recombinase or transposase complex comprises a TnsB2 polypeptide comprising a sequence having at least about 70% identity to SEQ ID NO: 3. In some cases, the recombinase or transposase complex comprises a TnsB2 polypeptide comprising a sequence having at least about 75% identity to SEQ ID NO: 3. In some cases, the recombinase or transposase complex includes a TnsB2 polypeptide comprising a sequence with at least about 80% identity to SEQ ID NO: 3. In some cases, the recombinase or transposase complex includes a TnsB2 polypeptide comprising a sequence with at least about 85% identity to SEQ ID NO: 3. In some cases, the recombinase or transposase complex includes a TnsB2 polypeptide comprising a sequence with at least about 90% identity to SEQ ID NO: 3. In some cases, the recombinase or transposase complex includes a TnsB2 polypeptide comprising a sequence with at least about 91% identity to SEQ ID NO: 3. In some cases, the recombinase or transposase complex includes a TnsB2 polypeptide comprising a sequence with at least about 92% identity to SEQ ID NO: 3. In some cases, the recombinase or transposase complex includes a TnsB2 polypeptide comprising a sequence with at least about 93% identity to SEQ ID NO: 3. In some cases, the recombinase or transposase complex includes a TnsB2 polypeptide comprising a sequence with at least about 94% identity to SEQ ID NO: 3. In some cases, the recombinase or transposase complex includes a TnsB2 polypeptide comprising a sequence having at least about 95% identity to SEQ ID NO: 3. In some cases, the recombinase or transposase complex includes a TnsB2 polypeptide comprising a sequence having at least about 96% identity to SEQ ID NO: 3. In some cases, the recombinase or transposase complex includes a TnsB2 polypeptide comprising a sequence having at least about 97% identity to SEQ ID NO: 3. In some cases, the recombinase or transposase complex includes a TnsB2 polypeptide comprising a sequence having at least about 98% identity to SEQ ID NO: 3.In some cases, the recombinase or transposase complex includes a TnsB2 polypeptide comprising a sequence at least about 99% identical to SEQ ID NO: 3. In some cases, the recombinase or transposase complex includes a TnsB2 polypeptide comprising a sequence 100% identical to SEQ ID NO:3.

[0232] In some cases, the recombinase or transposase complex includes a TnsT1 polypeptide comprising a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to SEQ ID NO: 4. In some cases, the recombinase or transposase complex includes a TnsT1 polypeptide comprising a sequence having at least about 70% identity to SEQ ID NO: 4. In some cases, the recombinase or transposase complex includes a TnsT1 polypeptide comprising a sequence having at least about 75% identity to SEQ ID NO: 4. In some cases, the recombinase or transposase complex includes a TnsT1 polypeptide comprising a sequence having at least about 80% identity to SEQ ID NO: 4. In some cases, the recombinase or transposase complex includes a TnsT1 polypeptide comprising a sequence having at least about 85% identity to SEQ ID NO: 4. In some cases, the recombinase or transposase complex includes a TnsT1 polypeptide comprising a sequence having at least about 90% identity to SEQ ID NO: 4. In some cases, the recombinase or transposase complex includes a TnsT1 polypeptide comprising a sequence having at least about 91% identity to SEQ ID NO: 4. In some cases, the recombinase or transposase complex includes a TnsT1 polypeptide comprising a sequence having at least about 92% identity to SEQ ID NO: 4. In some cases, the recombinase or transposase complex includes a TnsT1 polypeptide comprising a sequence having at least about 93% identity to SEQ ID NO: 4. In some cases, the recombinase or transposase complex includes a TnsT1 polypeptide comprising a sequence having at least about 94% identity to SEQ ID NO: 4. In some cases, the recombinase or transposase complex includes a TnsT1 polypeptide comprising a sequence having at least about 95% identity to SEQ ID NO: 4. In some cases, the recombinase or transposase complex includes a TnsT1 polypeptide comprising a sequence having at least about 96% identity to SEQ ID NO: 4. In some cases, the recombinase or transposase complex includes a TnsT1 polypeptide comprising a sequence having at least about 97% identity to SEQ ID NO: 4. In some cases, the recombinase or transposase complex includes a TnsT1 polypeptide comprising a sequence having at least about 98% identity to SEQ ID NO: 4. In some cases, the recombinase or transposase complex includes a TnsT1 polypeptide comprising a sequence having at least about 99% identity to SEQ ID NO: 4.In some cases, the recombinase or transposase complex includes a TnsT1 polypeptide comprising a sequence that is 100% identical to SEQ ID NO:4.

[0233] In some cases, the recombinase or transposase complex includes a TnsC component comprising a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to SEQ ID NO: 5. In some cases, the recombinase or transposase complex includes a TnsC component comprising a sequence having at least about 70% identity to SEQ ID NO: 5. In some cases, the recombinase or transposase complex includes a TnsC component comprising a sequence having at least about 75% identity to SEQ ID NO: 5. In some cases, the recombinase or transposase complex includes a TnsC component comprising a sequence having at least about 80% identity to SEQ ID NO: 5. In some cases, the recombinase or transposase complex includes a TnsC component comprising a sequence having at least about 85% identity to SEQ ID NO: 5. In some cases, the recombinase or transposase complex includes a TnsC component comprising a sequence having at least about 90% identity to SEQ ID NO: 5. In some cases, the recombinase or transposase complex includes a TnsC component comprising a sequence having at least about 91% identity to SEQ ID NO: 5. In some cases, the recombinase or transposase complex includes a TnsC component comprising a sequence having at least about 92% identity to SEQ ID NO: 5. In some cases, the recombinase or transposase complex includes a TnsC component comprising a sequence having at least about 93% identity to SEQ ID NO: 5. In some cases, the recombinase or transposase complex includes a TnsC component comprising a sequence having at least about 94% identity to SEQ ID NO: 5. In some cases, the recombinase or transposase complex includes a TnsC component comprising a sequence having at least about 95% identity to SEQ ID NO: 5. In some cases, the recombinase or transposase complex includes a TnsC component comprising a sequence having at least about 96% identity to SEQ ID NO: 5. In some cases, the recombinase or transposase complex includes a TnsC component comprising a sequence having at least about 97% identity to SEQ ID NO: 5. In some cases, the recombinase or transposase complex includes a TnsC component comprising a sequence having at least about 98% identity to SEQ ID NO: 5. In some cases, the recombinase or transposase complex includes a TnsC component comprising a sequence having at least about 99% identity to SEQ ID NO: 5.In some cases, the recombinase or transposase complex includes a TnsC component comprising a sequence that is 100% identical to SEQ ID NO:5.

[0234] In some embodiments, the systems disclosed herein include at least one engineered guide polynucleotide, such as a gRNA.

[0235] In some embodiments, provided herein are engineered guide polynucleotides, such as guide RNA (gRNA).

[0236] In some cases, the engineered guide polynucleotide comprises a sequence comprising at least about 60-80 consecutive nucleotides having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to SEQ ID NO: 11. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 60-80 consecutive nucleotides having at least about 70% identity to SEQ ID NO: 11. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 60-80 consecutive nucleotides having at least about 75% identity to SEQ ID NO: 11. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 60-80 consecutive nucleotides that are at least about 80% identical to SEQ ID NO: 11. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 60-80 consecutive nucleotides that are at least about 85% identical to SEQ ID NO: 11. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 60-80 consecutive nucleotides that are at least about 90% identical to SEQ ID NO: 11. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 60-80 consecutive nucleotides that are at least about 91% identical to SEQ ID NO: 11. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 60-80 consecutive nucleotides that are at least about 92% identical to SEQ ID NO: 11. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 60-80 consecutive nucleotides that are at least about 93% identical to SEQ ID NO: 11. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 60-80 consecutive nucleotides that are at least about 94% identical to SEQ ID NO: 11. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 60-80 contiguous nucleotides that are at least about 95% identical to SEQ ID NO: 11. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 60-80 contiguous nucleotides that are at least about 96% identical to SEQ ID NO: 11. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 60-80 contiguous nucleotides that are at least about 97% identical to SEQ ID NO: 11.In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 60-80 consecutive nucleotides that are at least about 98% identical to SEQ ID NO: 11. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 60-80 consecutive nucleotides that are at least about 99% identical to SEQ ID NO: 11. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 60-80 consecutive nucleotides that are 100% identical to SEQ ID NO: 11.

[0237] In some embodiments, the guide RNA includes various structural elements, including but not limited to: a spacer sequence, crRNA, and optional tracrRNA that binds to the original spacer sequence (target sequence). In some embodiments, the guide RNA includes a crRNA that includes a spacer sequence. In some embodiments, the guide RNA additionally includes tracrRNA or modified tracrRNA.

[0238] In some embodiments, the system provided herein includes one or more guide RNAs. In some embodiments, the guide RNA includes a sense sequence. In some embodiments, the guide RNA includes an antisense sequence. In some embodiments, the guide RNA includes a nucleotide sequence other than a region complementary to or substantially complementary to a region of a target sequence. For example, crRNA is or is considered to be part of a guide RNA, or is included in a guide RNA, such as a crRNA:tracrRNA chimera.

[0239] In some embodiments, the guide RNA comprises synthetic nucleotides or modified nucleotides. In some embodiments, the guide RNA comprises one or more internucleoside linkers modified by natural phosphodiester. In some embodiments, all internucleoside linkers of the guide RNA or its continuous nucleotide sequence are modified. For example, in some embodiments, the internucleoside bond comprises sulfur (S), such as a thiophosphate internucleoside bond.

[0240] In some embodiments, the guide RNA includes modifications to ribose sugar or nucleobase. In some embodiments, the guide RNA includes one or more nucleosides, the nucleosides including modified sugar moieties, wherein when compared to the ribose sugar moieties present in deoxyribonucleic acid (DNA) and RNA, the modified glucose moieties are modifications of sugar moieties. In some embodiments, the modification is within the ribose ring structure. Exemplary modifications include but are not limited to substitution with a hexose ring (HNA), a bicyclic ring (e.g., locked nucleic acid (LNA)) having a diradical bridge between the C2 carbon and the C4 carbon on the ribose ring, or an unconnected ribose ring (e.g., UNA) that lacks a bond between the C2 carbon and the C3 carbon. In some embodiments, sugar-modified nucleosides include bicyclic hexose nucleic acids or tricyclic nucleic acids. In some embodiments, modified nucleosides include nucleosides in which the sugar moiety is replaced by a non-sugar moiety, such as a peptide nucleic acid (PNA) or a morpholino nucleic acid.

[0241] In some embodiments, the guide RNA includes one or more modified sugars. In some embodiments, sugar modifications include modifications by changing the substituents on the ribose ring to groups other than hydrogen or 2'-OH groups naturally present in DNA and RNA nucleosides. In some embodiments, the substituents are introduced at 2', 3', 4' or 5' positions or combinations thereof. In some embodiments, nucleosides with modified sugar moieties include 2' modified nucleosides, such as 2' substituted nucleosides. In some embodiments, 2' sugar-modified nucleosides are nucleosides with substituents other than -H or -OH (2' substituted nucleosides) or including 2' connected diradicals at 2' positions, and include 2' substituted nucleosides and LNA (2'-4' diradical bridged) nucleosides. Examples of 2'-substituted modified nucleosides include, but are not limited to, 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-fluoro-RNA and 2'-F-ANA nucleosides. In some embodiments, the modification in the ribose group comprises a modification at the 2' position of the ribose group. In some embodiments, the modification at the 2' position of the ribose group is selected from the group consisting of: 2'-O-methyl, 2'-fluoro, 2'-deoxy, and 2'-O-(2-methoxyethyl).

[0242] In some embodiments, the guide RNA includes one or more modified sugars. In some embodiments, the guide RNA includes only modified sugars. In certain embodiments, the guide RNA includes greater than about 10%, 25%, 50%, 75% or 90% modified sugars. In some embodiments, the modified sugar is a bicyclic sugar. In some embodiments, the modified sugar includes 2'-O-methoxyethyl. In some embodiments, the guide RNA includes both internucleoside linker modifications and nucleoside modifications.

[0243] In some cases, the guide RNA includes a sequence complementary to a eukaryotic, fungal, plant, mammalian or human genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a eukaryotic genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a fungal genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a plant genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a mammalian genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a human genome polynucleotide sequence.

[0244] In some embodiments, the guide RNA is 30-250 nucleotides in length. In some embodiments, the guide RNA is more than 90 nucleotides in length. In some embodiments, the guide RNA is less than 245 nucleotides in length. In some embodiments, the guide RNA is 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, or more than 240 nucleotides in length. In some embodiments, the guide RNA is about 30 to about 40, about 30 to about 50, about 30 to about 60, about 30 to about 70, about 30 to about 80, about 30 to about 90, about 30 to about 100, about 30 to about 120, about 30 to about 140, about 30 to about 160, about 30 to about 180, about 30 to about 200, about 30 to about 220, about 30 to about 240, about 50 to about 60, about 50 to about 70, about 50 to about 80, about 50 to about 90, about 50 to about 100, about 30 to about 120, about 30 to about 140, about 30 to about 160, about 30 to about 180, about 30 to about 200, about 30 to about 220, about 30 to about 240, about 50 to about 60, about 50 to about 70, about 50 to about 80, about 50 to about 90, about 50 to about 100 In the present invention, the present invention relates to a polypeptide having at least one nucleotide sequence and at least one nucleotide sequence. In the present invention, the present invention relates to a polypeptide having at least one nucleotide sequence and at least one nucleotide sequence. In the present invention, the present invention relates to a polypeptide having at least one nucleotide sequence and at least one nucleotide sequence.

[0245] In some cases, the left recombinase sequence includes a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% identity to any one of SEQ ID NOs: 17-18. In some cases, the left recombinase sequence includes a sequence having at least about 70% identity to any one of SEQ ID NOs: 17-18. In some cases, the left recombinase sequence includes a sequence having at least about 75% identity to any one of SEQ ID NOs: 17-18. In some cases, the left recombinase sequence includes a sequence with at least about 80% identity to any one of SEQ ID NOs: 17-18. In some cases, the left recombinase sequence includes a sequence with at least about 85% identity to any one of SEQ ID NOs: 17-18. In some cases, the left recombinase sequence includes a sequence with at least about 90% identity to any one of SEQ ID NOs: 17-18. In some cases, the left recombinase sequence includes a sequence with at least about 91% identity to any one of SEQ ID NOs: 17-18. In some cases, the left recombinase sequence includes a sequence with at least about 92% identity to any one of SEQ ID NOs: 17-18. In some cases, the left recombinase sequence includes a sequence with at least about 93% identity to any one of SEQ ID NOs: 17-18. In some cases, the left recombinase sequence includes a sequence with at least about 94% identity to any one of SEQ ID NOs: 17-18. In some cases, the left recombinase sequence includes a sequence with at least about 95% identity to any one of SEQ ID NO: 17-18. In some cases, the left recombinase sequence includes a sequence with at least about 96% identity to any one of SEQ ID NO: 17-18. In some cases, the left recombinase sequence includes a sequence with at least about 97% identity to any one of SEQ ID NO: 17-18. In some cases, the left recombinase sequence includes a sequence with at least about 98% identity to any one of SEQ ID NO: 17-18. In some cases, the left recombinase sequence includes a sequence with at least about 99% identity to any one of SEQ ID NO: 17-18. In some cases, the left recombinase sequence includes a sequence with 100% identity to any one of SEQ ID NO: 17-18.

[0246] In some cases, the right recombinase sequence comprises a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NO: 19. In some cases, the right recombinase sequence comprises a sequence having at least about 70% identity to SEQ ID NO: 19. In some cases, the right recombinase sequence comprises a sequence having at least about 75% identity to SEQ ID NO: 19. In some cases, the right recombinase sequence comprises a sequence having at least about 80% identity to SEQ ID NO: 19. In some cases, the right recombinase sequence includes a sequence having at least about 85% identity to SEQ ID NO: 19. In some cases, the right recombinase sequence includes a sequence having at least about 90% identity to SEQ ID NO: 19. In some cases, the right recombinase sequence includes a sequence having at least about 91% identity to SEQ ID NO: 19. In some cases, the right recombinase sequence includes a sequence having at least about 92% identity to SEQ ID NO: 19. In some cases, the right recombinase sequence includes a sequence having at least about 93% identity to SEQ ID NO: 19. In some cases, the right recombinase sequence includes a sequence having at least about 94% identity to SEQ ID NO: 19. In some cases, the right recombinase sequence includes a sequence having at least about 95% identity to SEQ ID NO: 19. In some cases, the right recombinase sequence includes a sequence having at least about 96% identity to SEQ ID NO: 19. In some cases, the right recombinase sequence includes a sequence having at least about 97% identity to SEQ ID NO: 19. In some cases, the right recombinase sequence comprises a sequence having at least about 98% identity to SEQ ID NO: 19. In some cases, the right recombinase sequence comprises a sequence having at least about 99% identity to SEQ ID NO: 19. In some cases, the right recombinase sequence comprises a sequence having 100% identity to SEQ ID NO: 19.

[0247] In some cases, the Class 2 Type II Cas effector and recombinase or transposase complex is encoded by a polynucleotide sequence comprising less than about 20 kilobases, less than about 15 kilobases, less than about 10 kilobases, or less than about 5 kilobases.

[0248] MG39 System

[0249] In some embodiments, provided herein is the MG39 system for transposing a cargo nucleotide sequence into a target nucleic acid site. Figure 5A-5B , in some embodiments, the system includes a double-stranded nucleic acid. In some embodiments, the cargo nucleotide sequence is configured to interact with a Tn7-type transposase complex. In some embodiments, the system includes a Cas effector complex. In some embodiments, the Cas effector complex includes 2 types of V-type Cas effectors and an engineered guide polynucleotide configured to hybridize with a target nucleotide sequence. In some embodiments, the 2 types of V-type Cas effectors include a RuvC domain. In some embodiments, the system includes a Tn7 transposase complex, the transposase complex being configured to bind to a Cas effector complex, wherein the Tn7-type transposase complex includes a TnsA subunit.

[0250] In some cases, the cargo nucleotide sequence is flanked by a left transposase recognition sequence. In some cases, the cargo nucleotide sequence is flanked by a right transposase recognition sequence. In some cases, the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence.

[0251] In some cases, the target nucleic acid includes a target nucleic acid site. In some cases, the target nucleic acid includes a PAM sequence that is compatible with the Cas effector complex adjacent to the target nucleic acid site. In some cases, the PAM sequence is located at 3' of the target nucleic acid site. In some cases, the PAM sequence is located at 5' of the target nucleic acid site.

[0252] In some cases, the engineered guide polynucleotide is configured to bind to the 2nd class V-type Cas effector. In some cases, the 2nd class V-type Cas effector includes a polypeptide comprising a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NO: 6. In some cases, the 2nd class V-type Cas effector includes a polypeptide comprising a sequence having at least about 70% identity to SEQ ID NO: 6. In some cases, the 2nd class V-type Cas effector includes a polypeptide comprising a sequence having at least about 75% identity to SEQ ID NO:6. In some cases, the 2nd class V-type Cas effector includes a polypeptide comprising a sequence having at least about 80% identity to SEQ ID NO:6. In some cases, the 2nd class V-type Cas effector includes a polypeptide comprising a sequence having at least about 85% identity to SEQ ID NO:6. In some cases, the 2nd class V-type Cas effector includes a polypeptide comprising a sequence having at least about 90% identity to SEQ ID NO:6. In some cases, the 2nd class V-type Cas effector includes a polypeptide comprising a sequence having at least about 91% identity to SEQ ID NO:6. In some cases, the 2nd class V-type Cas effector includes a polypeptide comprising a sequence having at least about 92% identity to SEQ ID NO:6. In some cases, the 2nd class V-type Cas effector includes a polypeptide comprising a sequence having at least about 93% identity to SEQ ID NO:6. In some cases, the 2nd class V-type Cas effector includes a polypeptide comprising a sequence having at least about 94% identity to SEQ ID NO:6. In some cases, the 2nd class V-type Cas effector includes a polypeptide comprising a sequence having at least about 95% identity to SEQ ID NO:6. In some cases, the 2nd class V-type Cas effector includes a polypeptide comprising a sequence having at least about 96% identity to SEQ ID NO:6. In some cases, the 2nd class V-type Cas effector includes a polypeptide comprising a sequence having at least about 97% identity to SEQ ID NO:6. In some cases, the 2nd class V-type Cas effector includes a polypeptide comprising a sequence having at least about 98% identity to SEQ ID NO:6. In some cases, the 2nd class V-type Cas effector includes a polypeptide comprising a sequence having at least about 99% identity to SEQ ID NO:6.In some cases, the Class 2 type V Cas effector includes a polypeptide comprising a sequence with 100% identity to SEQ ID NO:6.

[0253] In some cases, the Tn7-type transposase complex includes at least one polypeptide (e.g., at least 1, 2, 3, 4, 5, 6, or more than 6 polypeptides) that includes a sequence at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least one polypeptide comprising a sequence having at least about 70% identity with any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least one polypeptide comprising a sequence having at least about 75% identity with any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least one polypeptide comprising a sequence having at least about 80% identity with any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least one polypeptide comprising a sequence having at least about 85% identity with any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least one polypeptide comprising a sequence having at least about 90% identity with any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least one polypeptide comprising a sequence having at least about 91% identity with any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 92% identical to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 93% identical to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 94% identical to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 95% identical to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 96% identical to any one of SEQ ID NOs: 8-10.In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 97% identical to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 98% identical to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 99% identical to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is 100% identical to any one of SEQ ID NOs: 8-10.

[0254] In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, each independently comprising a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, each independently comprising a sequence having at least about 70% identity to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, each independently including a sequence having at least about 75% identity to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, each independently including a sequence having at least about 80% identity to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, each independently including a sequence having at least about 85% identity to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, each independently including a sequence having at least about 90% identity to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, each independently comprising a sequence having at least about 91% identity to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, each independently comprising a sequence having at least about 92% identity to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, each independently comprising a sequence having at least about 93% identity to any one of SEQ ID NOs: 8-10.In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, each independently including a sequence having at least about 94% identity to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, each independently including a sequence having at least about 95% identity to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, each independently including a sequence having at least about 96% identity to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, each independently including a sequence having at least about 97% identity to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, each independently including a sequence having at least about 98% identity to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, each independently including a sequence having at least about 99% identity to any one of SEQ ID NOs: 8-10. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, each independently including a sequence having 100% identity to any one of SEQ ID NOs: 8-10.

[0255] In some cases, the Tn7-type transposase complex includes a TnsA component comprising a sequence that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NO: 7. In some cases, the Tn7-type transposase complex includes a TnsA component comprising a sequence that is at least about 70% identical to SEQ ID NO: 7. In some cases, the Tn7-type transposase complex includes a TnsA component comprising a sequence that is at least about 75% identical to SEQ ID NO: 7. In some cases, the Tn7-type transposase complex includes a TnsA component comprising a sequence having at least about 80% identity to SEQ ID NO: 7. In some cases, the Tn7-type transposase complex includes a TnsA component comprising a sequence having at least about 85% identity to SEQ ID NO: 7. In some cases, the Tn7-type transposase complex includes a TnsA component comprising a sequence having at least about 90% identity to SEQ ID NO: 7. In some cases, the Tn7-type transposase complex includes a TnsA component comprising a sequence having at least about 91% identity to SEQ ID NO: 7. In some cases, the Tn7-type transposase complex includes a TnsA component comprising a sequence having at least about 92% identity to SEQ ID NO: 7. In some cases, the Tn7-type transposase complex includes a TnsA component comprising a sequence having at least about 93% identity to SEQ ID NO: 7. In some cases, the Tn7-type transposase complex includes a TnsA component comprising a sequence having at least about 94% identity to SEQ ID NO: 7. In some cases, the Tn7-type transposase complex includes a TnsA component comprising a sequence that is at least about 95% identical to SEQ ID NO: 7. In some cases, the Tn7-type transposase complex includes a TnsA component comprising a sequence that is at least about 96% identical to SEQ ID NO: 7. In some cases, the Tn7-type transposase complex includes a TnsA component comprising a sequence that is at least about 97% identical to SEQ ID NO: 7. In some cases, the Tn7-type transposase complex includes a TnsA component comprising a sequence that is at least about 98% identical to SEQ ID NO: 7. In some cases, the Tn7-type transposase complex includes a TnsA component comprising a sequence that is at least about 99% identical to SEQ ID NO: 7.In some cases, the Tn7-type transposase complex includes a TnsA component comprising a sequence that is 100% identical to SEQ ID NO:7.

[0256] In some cases, the Tn7-type transposase complex includes a TnsB component comprising a sequence that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NO: 8. In some cases, the Tn7-type transposase complex includes a TnsB component comprising a sequence that is at least about 70% identical to SEQ ID NO: 8. In some cases, the Tn7-type transposase complex includes a TnsB component comprising a sequence that is at least about 75% identical to SEQ ID NO: 8. In some cases, the Tn7-type transposase complex includes a TnsB component comprising a sequence having at least about 80% identity to SEQ ID NO: 8. In some cases, the Tn7-type transposase complex includes a TnsB component comprising a sequence having at least about 85% identity to SEQ ID NO: 8. In some cases, the Tn7-type transposase complex includes a TnsB component comprising a sequence having at least about 90% identity to SEQ ID NO: 8. In some cases, the Tn7-type transposase complex includes a TnsB component comprising a sequence having at least about 91% identity to SEQ ID NO: 8. In some cases, the Tn7-type transposase complex includes a TnsB component comprising a sequence having at least about 92% identity to SEQ ID NO: 8. In some cases, the Tn7-type transposase complex includes a TnsB component comprising a sequence having at least about 93% identity to SEQ ID NO: 8. In some cases, the Tn7-type transposase complex includes a TnsB component comprising a sequence having at least about 94% identity to SEQ ID NO: 8. In some cases, the Tn7-type transposase complex includes a TnsB component comprising a sequence that is at least about 95% identical to SEQ ID NO: 8. In some cases, the Tn7-type transposase complex includes a TnsB component comprising a sequence that is at least about 96% identical to SEQ ID NO: 8. In some cases, the Tn7-type transposase complex includes a TnsB component comprising a sequence that is at least about 97% identical to SEQ ID NO: 8. In some cases, the Tn7-type transposase complex includes a TnsB component comprising a sequence that is at least about 98% identical to SEQ ID NO: 8. In some cases, the Tn7-type transposase complex includes a TnsB component comprising a sequence that is at least about 99% identical to SEQ ID NO: 8.In some cases, the Tn7-type transposase complex includes a TnsB component comprising a sequence with 100% identity to SEQ ID NO:8.

[0257] In some cases, the Tn7-type transposase complex includes a TnsC component comprising a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NO: 9. In some cases, the Tn7-type transposase complex includes a TnsC component comprising a sequence having at least about 70% identity to SEQ ID NO: 9. In some cases, the Tn7-type transposase complex includes a TnsC component comprising a sequence having at least about 75% identity to SEQ ID NO: 9. In some cases, the Tn7-type transposase complex includes a TnsC component comprising a sequence having at least about 80% identity to SEQ ID NO: 9. In some cases, the Tn7-type transposase complex includes a TnsC component comprising a sequence having at least about 85% identity to SEQ ID NO: 9. In some cases, the Tn7-type transposase complex includes a TnsC component comprising a sequence having at least about 90% identity to SEQ ID NO: 9. In some cases, the Tn7-type transposase complex includes a TnsC component comprising a sequence having at least about 91% identity to SEQ ID NO: 9. In some cases, the Tn7-type transposase complex includes a TnsC component comprising a sequence having at least about 92% identity to SEQ ID NO: 9. In some cases, the Tn7-type transposase complex includes a TnsC component comprising a sequence having at least about 93% identity to SEQ ID NO: 9. In some cases, the Tn7-type transposase complex includes a TnsC component comprising a sequence having at least about 94% identity to SEQ ID NO: 9. In some cases, the Tn7-type transposase complex includes a TnsC component comprising a sequence having at least about 95% identity to SEQ ID NO: 9. In some cases, the Tn7-type transposase complex includes a TnsC component comprising a sequence having at least about 96% identity to SEQ ID NO: 9. In some cases, the Tn7-type transposase complex includes a TnsC component comprising a sequence having at least about 97% identity to SEQ ID NO: 9. In some cases, the Tn7-type transposase complex includes a TnsC component comprising a sequence having at least about 98% identity to SEQ ID NO: 9. In some cases, the Tn7-type transposase complex includes a TnsC component comprising a sequence having at least about 99% identity to SEQ ID NO: 9.In some cases, the Tn7-type transposase complex includes a TnsC component comprising a sequence with 100% identity to SEQ ID NO:9.

[0258] In some cases, the Tn7-type transposase complex includes a TniQ polypeptide comprising a sequence at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NO: 10. In some cases, the Tn7-type transposase complex includes a TniQ polypeptide comprising a sequence at least about 70% identical to SEQ ID NO: 10. In some cases, the Tn7-type transposase complex includes a TniQ polypeptide comprising a sequence that is at least about 75% identical to SEQ ID NO: 10. In some cases, the Tn7-type transposase complex includes a TniQ polypeptide comprising a sequence that is at least about 80% identical to SEQ ID NO: 10. In some cases, the Tn7-type transposase complex includes a TniQ polypeptide comprising a sequence that is at least about 85% identical to SEQ ID NO: 10. In some cases, the Tn7-type transposase complex includes a TniQ polypeptide comprising a sequence that is at least about 90% identical to SEQ ID NO: 10. In some cases, the Tn7-type transposase complex includes a TniQ polypeptide comprising a sequence that is at least about 91% identical to SEQ ID NO: 10. In some cases, the Tn7-type transposase complex includes a TniQ polypeptide comprising a sequence that is at least about 92% identical to SEQ ID NO: 10. In some cases, the Tn7-type transposase complex includes a TniQ polypeptide comprising a sequence that is at least about 93% identical to SEQ ID NO: 10. In some cases, the Tn7-type transposase complex includes a TniQ polypeptide comprising a sequence that is at least about 94% identical to SEQ ID NO: 10. In some cases, the Tn7-type transposase complex includes a TniQ polypeptide comprising a sequence that is at least about 95% identical to SEQ ID NO: 10. In some cases, the Tn7-type transposase complex includes a TniQ polypeptide comprising a sequence that is at least about 96% identical to SEQ ID NO: 10. In some cases, the Tn7-type transposase complex includes a TniQ polypeptide comprising a sequence that is at least about 97% identical to SEQ ID NO: 10. In some cases, the Tn7-type transposase complex includes a TniQ polypeptide comprising a sequence that is at least about 98% identical to SEQ ID NO: 10.In some cases, the Tn7-type transposase complex includes a TniQ polypeptide comprising a sequence at least about 99% identical to SEQ ID NO: 10. In some cases, the Tn7-type transposase complex includes a TniQ polypeptide comprising a sequence 100% identical to SEQ ID NO:10.

[0259] In some embodiments, the systems disclosed herein include at least one engineered guide polynucleotide, such as a gRNA.

[0260] In some embodiments, provided herein are engineered guide polynucleotides, such as guide RNA (gRNA).

[0261] In some cases, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NOs: 13-16. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides having at least about 70% identity to any one of SEQ ID NOs: 13-16. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides that are at least about 75% identical to any one of SEQ ID NOs: 13-16. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides that are at least about 80% identical to any one of SEQ ID NOs: 13-16. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides that are at least about 85% identical to any one of SEQ ID NOs: 13-16. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides that are at least about 90% identical to any one of SEQ ID NOs: 13-16. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides that are at least about 91% identical to any one of SEQ ID NOs: 13-16. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides that are at least about 92% identical to any one of SEQ ID NOs: 13-16. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides that are at least about 93% identical to any one of SEQ ID NOs: 13-16. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides that are at least about 94% identical to any one of SEQ ID NOs: 13-16. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides that are at least about 95% identical to any one of SEQ ID NOs: 13-16. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides that are at least about 96% identical to any one of SEQ ID NOs: 13-16.In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides that are at least about 97% identical to any one of SEQ ID NOs: 13-16. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides that are at least about 98% identical to any one of SEQ ID NOs: 13-16. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides that are at least about 99% identical to any one of SEQ ID NOs: 13-16. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides that are 100% identical to any one of SEQ ID NOs: 13-16.

[0262] In some embodiments, the guide RNA includes various structural elements, including but not limited to: a spacer sequence, crRNA, and optional tracrRNA that binds to the original spacer sequence (target sequence). In some embodiments, the guide RNA includes a crRNA that includes a spacer sequence. In some embodiments, the guide RNA additionally includes tracrRNA or modified tracrRNA.

[0263] In some embodiments, the system provided herein includes one or more guide RNAs. In some embodiments, the guide RNA includes a sense sequence. In some embodiments, the guide RNA includes an antisense sequence. In some embodiments, the guide RNA includes a nucleotide sequence other than a region complementary to or substantially complementary to a region of a target sequence. For example, crRNA is or is considered to be part of a guide RNA, or is included in a guide RNA, such as a crRNA:tracrRNA chimera.

[0264] In some embodiments, the guide RNA comprises synthetic nucleotides or modified nucleotides. In some embodiments, the guide RNA comprises one or more internucleoside linkers modified by natural phosphodiester. In some embodiments, all internucleoside linkers of the guide RNA or its continuous nucleotide sequence are modified. For example, in some embodiments, the internucleoside bond comprises sulfur (S), such as a thiophosphate internucleoside bond.

[0265] In some embodiments, the guide RNA includes modifications to ribose sugar or nucleobase. In some embodiments, the guide RNA includes one or more nucleosides, the nucleosides including modified sugar moieties, wherein when compared to the ribose sugar moieties present in deoxyribonucleic acid (DNA) and RNA, the modified glucose moieties are modifications of sugar moieties. In some embodiments, the modification is within the ribose ring structure. Exemplary modifications include but are not limited to substitution with a hexose ring (HNA), a bicyclic ring (e.g., locked nucleic acid (LNA)) having a diradical bridge between the C2 carbon and the C4 carbon on the ribose ring, or an unconnected ribose ring (e.g., UNA) that lacks a bond between the C2 carbon and the C3 carbon. In some embodiments, sugar-modified nucleosides include bicyclic hexose nucleic acids or tricyclic nucleic acids. In some embodiments, modified nucleosides include nucleosides in which the sugar moiety is replaced by a non-sugar moiety, such as a peptide nucleic acid (PNA) or a morpholino nucleic acid.

[0266] In some embodiments, the guide RNA includes one or more modified sugars. In some embodiments, sugar modifications include modifications by changing the substituents on the ribose ring to groups other than hydrogen or 2'-OH groups naturally present in DNA and RNA nucleosides. In some embodiments, the substituents are introduced at 2', 3', 4' or 5' positions or combinations thereof. In some embodiments, nucleosides with modified sugar moieties include 2' modified nucleosides, such as 2' substituted nucleosides. In some embodiments, 2' sugar-modified nucleosides are nucleosides with substituents other than -H or -OH (2' substituted nucleosides) or including 2' connected diradicals at 2' positions, and include 2' substituted nucleosides and LNA (2'-4' diradical bridged) nucleosides. Examples of 2'-substituted modified nucleosides include, but are not limited to, 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-fluoro-RNA and 2'-F-ANA nucleosides. In some embodiments, the modification in the ribose group comprises a modification at the 2' position of the ribose group. In some embodiments, the modification at the 2' position of the ribose group is selected from the group consisting of: 2'-O-methyl, 2'-fluoro, 2'-deoxy, and 2'-O-(2-methoxyethyl).

[0267] In some embodiments, the guide RNA includes one or more modified sugars. In some embodiments, the guide RNA includes only modified sugars. In certain embodiments, the guide RNA includes greater than about 10%, 25%, 50%, 75% or 90% modified sugars. In some embodiments, the modified sugar is a bicyclic sugar. In some embodiments, the modified sugar includes 2'-O-methoxyethyl. In some embodiments, the guide RNA includes both internucleoside linker modifications and nucleoside modifications.

[0268] In some cases, the guide RNA includes a sequence complementary to a eukaryotic, fungal, plant, mammalian or human genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a eukaryotic genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a fungal genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a plant genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a mammalian genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a human genome polynucleotide sequence.

[0269] In some embodiments, the guide RNA is 30-250 nucleotides in length. In some embodiments, the guide RNA is more than 90 nucleotides in length. In some embodiments, the guide RNA is less than 245 nucleotides in length. In some embodiments, the guide RNA is 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, or more than 240 nucleotides in length. In some embodiments, the guide RNA is about 30 to about 40, about 30 to about 50, about 30 to about 60, about 30 to about 70, about 30 to about 80, about 30 to about 90, about 30 to about 100, about 30 to about 120, about 30 to about 140, about 30 to about 160, about 30 to about 180, about 30 to about 200, about 30 to about 220, about 30 to about 240, about 50 to about 60, about 50 to about 70, about 50 to about 80, about 50 to about 90, about 50 to about 100, about 30 to about 120, about 30 to about 140, about 30 to about 160, about 30 to about 180, about 30 to about 200, about 30 to about 220, about 30 to about 240, about 50 to about 60, about 50 to about 70, about 50 to about 80, about 50 to about 90, about 50 to about 100 In the present invention, the present invention relates to a polypeptide having at least one nucleotide sequence and at least one nucleotide sequence. In the present invention, the present invention relates to a polypeptide having at least one nucleotide sequence and at least one nucleotide sequence. In the present invention, the present invention relates to a polypeptide having at least one nucleotide sequence and at least one nucleotide sequence.

[0270] In some cases, the left recombinase sequence comprises a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NO: 20. In some cases, the left recombinase sequence comprises a sequence having at least about 70% identity to SEQ ID NO: 20. In some cases, the left recombinase sequence comprises a sequence having at least about 75% identity to SEQ ID NO: 20. In some cases, the left recombinase sequence comprises a sequence having at least about 80% identity to SEQ ID NO: 20. In some cases, the left recombinase sequence includes a sequence having at least about 85% identity to SEQ ID NO: 20. In some cases, the left recombinase sequence includes a sequence having at least about 90% identity to SEQ ID NO: 20. In some cases, the left recombinase sequence includes a sequence having at least about 91% identity to SEQ ID NO: 20. In some cases, the left recombinase sequence includes a sequence having at least about 92% identity to SEQ ID NO: 20. In some cases, the left recombinase sequence includes a sequence having at least about 93% identity to SEQ ID NO: 20. In some cases, the left recombinase sequence includes a sequence having at least about 94% identity to SEQ ID NO: 20. In some cases, the left recombinase sequence includes a sequence having at least about 95% identity to SEQ ID NO: 20. In some cases, the left recombinase sequence includes a sequence having at least about 96% identity to SEQ ID NO: 20. In some cases, the left recombinase sequence includes a sequence having at least about 97% identity to SEQ ID NO: 20. In some cases, the left recombinase sequence comprises a sequence having at least about 98% identity to SEQ ID NO: 20. In some cases, the left recombinase sequence comprises a sequence having at least about 99% identity to SEQ ID NO: 20. In some cases, the left recombinase sequence comprises a sequence having 100% identity to SEQ ID NO: 20.

[0271] In some cases, the right recombinase sequence includes a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NO: 21. In some cases, the right recombinase sequence includes a sequence having at least about 70% identity to SEQ ID NO: 21. In some cases, the right recombinase sequence includes a sequence having at least about 75% identity to SEQ ID NO: 21. In some cases, the right recombinase sequence includes a sequence having at least about 80% identity to SEQ ID NO: 21. In some cases, the right recombinase sequence includes a sequence having at least about 85% identity to SEQ ID NO: 21. In some cases, the right recombinase sequence includes a sequence having at least about 90% identity to SEQ ID NO: 21. In some cases, the right recombinase sequence includes a sequence having at least about 91% identity to SEQ ID NO: 21. In some cases, the right recombinase sequence includes a sequence having at least about 92% identity to SEQ ID NO: 21. In some cases, the right recombinase sequence includes a sequence having at least about 93% identity to SEQ ID NO: 21. In some cases, the right recombinase sequence includes a sequence having at least about 94% identity to SEQ ID NO: 21. In some cases, the right recombinase sequence includes a sequence having at least about 95% identity to SEQ ID NO: 21. In some cases, the right recombinase sequence includes a sequence having at least about 96% identity to SEQ ID NO: 21. In some cases, the right recombinase sequence includes a sequence having at least about 97% identity to SEQ ID NO: 21. In some cases, the right recombinase sequence comprises a sequence having at least about 98% identity to SEQ ID NO: 21. In some cases, the right recombinase sequence comprises a sequence having at least about 99% identity to SEQ ID NO: 21. In some cases, the right recombinase sequence comprises a sequence having 100% identity to SEQ ID NO: 21.

[0272] In some cases, the class 2 type V Cas effector and Tn7-type transposase complex is encoded by a polynucleotide sequence comprising less than about 20 kilobases, less than about 15 kilobases, less than about 10 kilobases, or less than about 5 kilobases.

[0273] MG64 System

[0274] In some embodiments, provided herein is a MG64 system for transposing a cargo nucleotide sequence into a target nucleic acid site. In some embodiments, the system includes a double-stranded nucleic acid including a cargo nucleotide sequence. In some embodiments, the cargo nucleotide sequence is configured to interact with a Tn7 type or Tn5053 type transposase complex. In some embodiments, the system includes a Cas effector complex. In some embodiments, the Cas effector complex includes 2 types of V-type Cas effectors and an engineered guide polynucleotide configured to hybridize with a target nucleotide sequence. In some embodiments, the system includes a Tn7 type or Tn5053 type transposase complex configured to bind to a Cas effector complex. In some embodiments, 2 types of V-type Cas effectors include a RuvC domain.

[0275] In some cases, the cargo nucleotide sequence is flanked by a left transposase recognition sequence. In some cases, the cargo nucleotide sequence is flanked by a right transposase recognition sequence. In some cases, the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence.

[0276] In some cases, the target nucleic acid includes a target nucleic acid site. In some cases, the target nucleic acid includes a PAM sequence compatible with the Cas effector complex adjacent to the target nucleic acid site. In some cases, the PAM sequence is located at the 3' of the target nucleic acid site. In some cases, the PAM sequence is located at the 5' of the target nucleic acid site. In some cases, the PAM sequence includes 5'-nGTn-3' or 5'-nGTt-3'.

[0277] In some cases, the engineered guide polynucleotide is configured to bind to the Class 2 type V Cas effector. In some cases, the Class 2 type V Cas effector includes a polypeptide comprising a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 70% identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 75% identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 80% identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 85% identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 90% identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 91% identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689. In some cases, the Class 2-type V Cas effector includes a polypeptide comprising a sequence at least about 92% identical to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689.In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 93% identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 94% identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 95% identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 96% identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 97% identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 98% identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689. In some cases, the class 2 type V Cas effector includes a polypeptide comprising a sequence having at least about 99% identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689. In some cases, the class 2 type V Cas effector includes a polypeptide comprising a sequence having 100% identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689.

[0278] In some cases, the Tn7-type transposase complex includes at least one polypeptide (e.g., at least 1, 2, 3, 4, 5, 6, or more than 6 polypeptides) comprising a polypeptide corresponding to SEQ ID Any of NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347 has a sequence that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence at least about 70% identical to any one of SEQ ID NOs: 23-25, 27, -29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence at least about 75% identical to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence at least about 80% identical to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence at least about 85% identical to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence at least about 90% identical to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347.In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence at least about 91% identical to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence at least about 92% identical to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence at least about 93% identical to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence at least about 94% identical to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence at least about 95% identical to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence at least about 96% identical to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence at least about 97% identical to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence at least about 98% identical to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347.In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence having at least about 99% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence having 100% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some embodiments, the Tn7-type transposase complex includes TnsB, TnsC, and TniQ.

[0279] In some cases, the Tn7-type transposase complex comprises at least a first polypeptide and a second polypeptide, wherein the first polypeptide and the second polypeptide each independently comprise a polypeptide corresponding to SEQ ID Any of NOs: 23-25, 27, -29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347 has a sequence that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 70% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 75% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 80% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 85% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347.In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 90% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 91% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 92% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 93% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 94% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 95% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347.In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 96% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 97% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 98% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 99% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, wherein the first polypeptide and the second polypeptide each independently include a sequence with 100% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347.

[0280] In some embodiments, the systems disclosed herein include at least one engineered guide polynucleotide, such as a gRNA.

[0281] In some embodiments, provided herein are engineered guide polynucleotides, such as guide RNA (gRNA).

[0282] In some cases, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739. In some cases, the engineered guide polynucleotide comprises a sequence comprising at least 46-80 contiguous nucleotides having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 46-80 consecutive nucleotides at least about 70% identical to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 46-80 consecutive nucleotides at least about 75% identical to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 46-80 consecutive nucleotides at least about 80% identical to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 46-80 contiguous nucleotides that is at least about 85% identical to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739.In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 46-80 consecutive nucleotides at least about 90% identical to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 46-80 consecutive nucleotides at least about 91% identical to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 46-80 consecutive nucleotides at least about 92% identical to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 46-80 consecutive nucleotides at least about 93% identical to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 46-80 consecutive nucleotides at least about 94% identical to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 46-80 consecutive nucleotides at least about 95% identical to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 46-80 consecutive nucleotides at least about 96% identical to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 46-80 consecutive nucleotides at least about 97% identical to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 46-80 consecutive nucleotides at least about 98% identical to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739.In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 46-80 consecutive nucleotides that is at least about 99% identical to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least 46-80 consecutive nucleotides that is 100% identical to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739.

[0283] In some cases, the engineered guide polynucleotide includes a sequence comprising non-degenerate nucleotides of any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492 that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to the non-degenerate nucleotides of any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492.

[0284] In some cases, the engineered guide polynucleotide includes a sequence that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 70% identical to any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 75% identical to any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 80% identical to any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 85% identical to any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 90% identical to any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 91% identical to any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 92% identical to any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 93% identical to any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492.In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 94% identical to any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 95% identical to any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 96% identical to any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 97% identical to any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 98% identical to any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 99% identical to any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492. In some embodiments, the engineered guide polynucleotide comprises a sequence that is 100% identical to any one of SEQ ID NOs: 111-114, 201-204, 262, 263, 348, 350-353, and 473-492.

[0285] In some embodiments, the guide RNA comprises synthetic nucleotides or modified nucleotides. In some embodiments, the guide RNA comprises one or more internucleoside linkers modified by natural phosphodiester. In some embodiments, all internucleoside linkers of the guide RNA or its continuous nucleotide sequence are modified. For example, in some embodiments, the internucleoside bond comprises sulfur (S), such as a thiophosphate internucleoside bond.

[0286] In some embodiments, the guide RNA includes modifications to ribose sugar or nucleobase. In some embodiments, the guide RNA includes one or more nucleosides, the nucleosides including modified sugar moieties, wherein when compared to the ribose sugar moieties present in deoxyribonucleic acid (DNA) and RNA, the modified glucose moieties are modifications of sugar moieties. In some embodiments, the modification is within the ribose ring structure. Exemplary modifications include but are not limited to substitution with a hexose ring (HNA), a bicyclic ring (e.g., locked nucleic acid (LNA)) having a diradical bridge between the C2 carbon and the C4 carbon on the ribose ring, or an unconnected ribose ring (e.g., UNA) that lacks a bond between the C2 carbon and the C3 carbon. In some embodiments, sugar-modified nucleosides include bicyclic hexose nucleic acids or tricyclic nucleic acids. In some embodiments, modified nucleosides include nucleosides in which the sugar moiety is replaced by a non-sugar moiety, such as a peptide nucleic acid (PNA) or a morpholino nucleic acid.

[0287] In some embodiments, the guide RNA includes one or more modified sugars. In some embodiments, sugar modifications include modifications by changing the substituents on the ribose ring to groups other than hydrogen or 2'-OH groups naturally present in DNA and RNA nucleosides. In some embodiments, the substituents are introduced at 2', 3', 4' or 5' positions or combinations thereof. In some embodiments, nucleosides with modified sugar moieties include 2' modified nucleosides, such as 2' substituted nucleosides. In some embodiments, 2' sugar-modified nucleosides are nucleosides with substituents other than -H or -OH (2' substituted nucleosides) or including 2' connected diradicals at 2' positions, and include 2' substituted nucleosides and LNA (2'-4' diradical bridged) nucleosides. Examples of 2'-substituted modified nucleosides include, but are not limited to, 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-fluoro-RNA and 2'-F-ANA nucleosides. In some embodiments, the modification in the ribose group comprises a modification at the 2' position of the ribose group. In some embodiments, the modification at the 2' position of the ribose group is selected from the group consisting of: 2'-O-methyl, 2'-fluoro, 2'-deoxy, and 2'-O-(2-methoxyethyl).

[0288] In some embodiments, the guide RNA includes one or more modified sugars. In some embodiments, the guide RNA includes only modified sugars. In certain embodiments, the guide RNA includes greater than about 10%, 25%, 50%, 75% or 90% modified sugars. In some embodiments, the modified sugar is a bicyclic sugar. In some embodiments, the modified sugar includes 2'-O-methoxyethyl. In some embodiments, the guide RNA includes both internucleoside linker modifications and nucleoside modifications.

[0289] In some cases, the guide RNA includes a sequence complementary to a eukaryotic, fungal, plant, mammalian or human genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a eukaryotic genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a fungal genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a plant genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a mammalian genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a human genome polynucleotide sequence.

[0290] In some embodiments, the guide RNA is 30-250 nucleotides in length. In some embodiments, the guide RNA is more than 90 nucleotides in length. In some embodiments, the guide RNA is less than 245 nucleotides in length. In some embodiments, the guide RNA is 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, or more than 240 nucleotides in length. In some embodiments, the guide RNA is about 30 to about 40, about 30 to about 50, about 30 to about 60, about 30 to about 70, about 30 to about 80, about 30 to about 90, about 30 to about 100, about 30 to about 120, about 30 to about 140, about 30 to about 160, about 30 to about 180, about 30 to about 200, about 30 to about 220, about 30 to about 240, about 50 to about 60, about 50 to about 70, about 50 to about 80, about 50 to about 90, about 50 to about 100, about 30 to about 120, about 30 to about 140, about 30 to about 160, about 30 to about 180, about 30 to about 200, about 30 to about 220, about 30 to about 240, about 50 to about 60, about 50 to about 70, about 50 to about 80, about 50 to about 90, about 50 to about 100 In the present invention, the present invention relates to a polypeptide having at least one nucleotide sequence and at least one nucleotide sequence. In the present invention, the present invention relates to a polypeptide having at least one nucleotide sequence and at least one nucleotide sequence. In the present invention, the present invention relates to a polypeptide having at least one nucleotide sequence and at least one nucleotide sequence.

[0291] In some cases, the left recombinase sequence comprises a sequence that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467. In some cases, the left recombinase sequence comprises a sequence having at least about 70% identity to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467. In some cases, the left recombinase sequence comprises a sequence having at least about 75% identity to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467. In some cases, the left recombinase sequence comprises a sequence having at least about 80% identity to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467. In some cases, the left recombinase sequence comprises a sequence having at least about 85% identity to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467. In some cases, the left recombinase sequence comprises a sequence having at least about 90% identity to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467. In some cases, the left recombinase sequence comprises a sequence having at least about 91% identity to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467. In some cases, the left recombinase sequence includes a sequence that is at least about 92% identical to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467.In some cases, the left recombinase sequence comprises a sequence having at least about 93% identity to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467. In some cases, the left recombinase sequence comprises a sequence having at least about 94% identity to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467. In some cases, the left recombinase sequence comprises a sequence having at least about 95% identity to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467. In some cases, the left recombinase sequence comprises a sequence having at least about 96% identity to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467. In some cases, the left recombinase sequence comprises a sequence having at least about 97% identity to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467. In some cases, the left recombinase sequence comprises a sequence having at least about 98% identity to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467. In some cases, the left recombinase sequence comprises a sequence having at least about 99% identity to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467. In some cases, the left recombinase sequence comprises a sequence having 100% identity to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467.

[0292] In some cases, the right recombinase sequence comprises a sequence that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466, and 468. In some cases, the right recombinase sequence comprises a sequence having at least about 70% identity to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466, and 468. In some cases, the right recombinase sequence comprises a sequence having at least about 75% identity to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466, and 468. In some cases, the right recombinase sequence comprises a sequence having at least about 80% identity to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466, and 468. In some cases, the right recombinase sequence comprises a sequence having at least about 85% identity to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466, and 468. In some cases, the right recombinase sequence comprises a sequence having at least about 90% identity to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466, and 468. In some cases, the right recombinase sequence comprises a sequence having at least about 91% identity to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466, and 468. In some cases, the right recombinase sequence includes a sequence that is at least about 92% identical to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466, and 468.In some cases, the right recombinase sequence comprises a sequence having at least about 93% identity to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466, and 468. In some cases, the right recombinase sequence comprises a sequence having at least about 94% identity to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466, and 468. In some cases, the right recombinase sequence comprises a sequence having at least about 95% identity to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466, and 468. In some cases, the right recombinase sequence comprises a sequence having at least about 96% identity to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466, and 468. In some cases, the right recombinase sequence comprises a sequence having at least about 97% identity to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466, and 468. In some cases, the right recombinase sequence comprises a sequence having at least about 98% identity to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466, and 468. In some cases, the right recombinase sequence comprises a sequence having at least about 99% identity to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466, and 468. In some cases, the right recombinase sequence comprises a sequence having 100% identity to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466, and 468.

[0293] In some cases, the class 2 type V Cas effector and Tn7-type transposase complex is encoded by a polynucleotide sequence comprising less than about 20 kilobases, less than about 15 kilobases, less than about 10 kilobases, or less than about 5 kilobases.

[0294] MG108 System

[0295] In some embodiments, provided herein is the MG108 system for transposing a cargo nucleotide sequence into a target nucleic acid site. Figure 8. In some embodiments, the system includes a double-stranded nucleic acid comprising a cargo nucleotide sequence. In some embodiments, the cargo nucleotide sequence is configured to interact with a Tn7-type transposase complex. In some embodiments, the system includes a Cas effector complex. In some embodiments, the Cas effector complex includes 2 types of V-type Cas effectors and an engineered guide polynucleotide configured to hybridize with a target nucleotide sequence. In some embodiments, the 2 types of V-type Cas effectors include a RuvC domain. In some embodiments, the system includes a Tn7-type transposase complex configured to bind to the Cas effector complex. In some cases, the Tn7-type transposase complex includes TnsB and TnsC components, but does not include TnsA and / or TniQ components.

[0296] In some cases, the cargo nucleotide sequence is flanked by a left transposase recognition sequence. In some cases, the cargo nucleotide sequence is flanked by a right transposase recognition sequence. In some cases, the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence.

[0297] In some cases, the target nucleic acid includes a target nucleic acid site. In some cases, the target nucleic acid includes a PAM sequence that is compatible with the Cas effector complex adjacent to the target nucleic acid site. In some cases, the PAM sequence is located at 3' of the target nucleic acid site. In some cases, the PAM sequence is located at 5' of the target nucleic acid site.

[0298] In some cases, the engineered guide polynucleotide is configured to bind to the Class 2 type V Cas effector. In some cases, the Class 2 type V Cas effector includes a polypeptide comprising a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NO: 38 or SEQ ID NO: 108. In some cases, the Class 2 type V Cas effector includes a polypeptide comprising a sequence having at least about 70% identity to SEQ ID NO: 38 or SEQ ID NO: 108. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 75% identity to SEQ ID NO: 38 or SEQ ID NO: 108. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 80% identity to SEQ ID NO: 38 or SEQ ID NO: 108. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 85% identity to SEQ ID NO: 38 or SEQ ID NO: 108. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 90% identity to SEQ ID NO: 38 or SEQ ID NO: 108. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 91% identity to SEQ ID NO: 38 or SEQ ID NO: 108. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 92% identity to SEQ ID NO: 38 or SEQ ID NO: 108. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 93% identity to SEQ ID NO: 38 or SEQ ID NO: 108. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 94% identity to SEQ ID NO: 38 or SEQ ID NO: 108. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 95% identity to SEQ ID NO: 38 or SEQ ID NO: 108. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 96% identity to SEQ ID NO: 38 or SEQ ID NO: 108.In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 97% identity to SEQ ID NO: 38 or SEQ ID NO: 108. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 98% identity to SEQ ID NO: 38 or SEQ ID NO: 108. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having at least about 99% identity to SEQ ID NO: 38 or SEQ ID NO: 108. In some cases, the class 2 type V Cas effector comprises a polypeptide comprising a sequence having 100% identity to SEQ ID NO: 38 or SEQ ID NO: 108.

[0299] In some cases, the Tn7-type transposase complex includes at least one polypeptide (e.g., at least 1, 2, 3, 4, 5, 6, or more than 6 polypeptides) that includes a sequence that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 70% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 75% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 80% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 85% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 90% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 91% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 92% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 93% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence at least about 94% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344.In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 95% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 96% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 97% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence that is at least about 98% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence at least about 99% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence 100% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344.

[0300] In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, each independently comprising a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 70% identity to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 75% identity to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 80% identity to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 85% identity to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 90% identity to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 91% identity to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently including a sequence at least about 92% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344.In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 93% identity to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 94% identity to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 95% identity to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 96% identity to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 97% identity to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 98% identity to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having at least about 99% identity to any one of SEQ ID NOs: 39-40, 109-110, and 344. In some cases, the Tn7-type transposase complex includes at least a first polypeptide and a second polypeptide, the first polypeptide and the second polypeptide each independently include a sequence having 100% identity to any one of SEQ ID NOs: 39-40, 109-110, and 344.

[0301] In some cases, the Tn7-type transposase complex includes a TnsB component comprising a sequence at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 40 and 109. In some cases, the Tn7-type transposase complex includes at least one TnsB component comprising a sequence at least about 70% identical to any one of SEQ ID NOs: 40 and 109. In some cases, the Tn7-type transposase complex includes at least one TnsB component including a sequence that is at least about 75% identical to any one of SEQ ID NOs: 40 and 109. In some cases, the Tn7-type transposase complex includes at least one TnsB component including a sequence that is at least about 80% identical to any one of SEQ ID NOs: 40 and 109. In some cases, the Tn7-type transposase complex includes at least one TnsB component including a sequence that is at least about 85% identical to any one of SEQ ID NOs: 40 and 109. In some cases, the Tn7-type transposase complex includes at least one TnsB component including a sequence that is at least about 90% identical to any one of SEQ ID NOs: 40 and 109. In some cases, the Tn7-type transposase complex includes at least one TnsB component including a sequence that is at least about 91% identical to any one of SEQ ID NOs: 40 and 109. In some cases, the Tn7-type transposase complex includes at least one TnsB component including a sequence that is at least about 92% identical to any one of SEQ ID NOs: 40 and 109. In some cases, the Tn7-type transposase complex includes at least one TnsB component including a sequence that is at least about 93% identical to any one of SEQ ID NOs: 40 and 109. In some cases, the Tn7-type transposase complex includes at least one TnsB component including a sequence that is at least about 94% identical to any one of SEQ ID NOs: 40 and 109. In some cases, the Tn7-type transposase complex includes at least one TnsB component including a sequence that is at least about 95% identical to any one of SEQ ID NOs: 40 and 109. In some cases, the Tn7-type transposase complex includes at least one TnsB component including a sequence that is at least about 96% identical to any one of SEQ ID NOs: 40 and 109.In some cases, the Tn7-type transposase complex includes at least one TnsB component including a sequence that is at least about 97% identical to any one of SEQ ID NOs: 40 and 109. In some cases, the Tn7-type transposase complex includes at least one TnsB component including a sequence that is at least about 98% identical to any one of SEQ ID NOs: 40 and 109. In some cases, the Tn7-type transposase complex includes at least one TnsB component including a sequence that is at least about 99% identical to any one of SEQ ID NOs: 40 and 109. In some cases, the Tn7-type transposase complex includes at least one TnsB component including a sequence that is 100% identical to any one of SEQ ID NOs: 40 and 109.

[0302] In some cases, the Tn7-type transposase complex includes a TnsC component comprising a sequence at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 39 and 110. In some cases, the Tn7-type transposase complex includes at least one TnsC component comprising a sequence at least about 70% identical to any one of SEQ ID NOs: 39 and 110. In some cases, the Tn7-type transposase complex includes at least one TnsC component including a sequence that is at least about 75% identical to any one of SEQ ID NOs: 39 and 110. In some cases, the Tn7-type transposase complex includes at least one TnsC component including a sequence that is at least about 80% identical to any one of SEQ ID NOs: 39 and 110. In some cases, the Tn7-type transposase complex includes at least one TnsC component including a sequence that is at least about 85% identical to any one of SEQ ID NOs: 39 and 110. In some cases, the Tn7-type transposase complex includes at least one TnsC component including a sequence that is at least about 90% identical to any one of SEQ ID NOs: 39 and 110. In some cases, the Tn7-type transposase complex includes at least one TnsC component including a sequence that is at least about 91% identical to any one of SEQ ID NOs: 39 and 110. In some cases, the Tn7-type transposase complex includes at least one TnsC component including a sequence having at least about 92% identity to any one of SEQ ID NOs: 39 and 110. In some cases, the Tn7-type transposase complex includes at least one TnsC component including a sequence having at least about 93% identity to any one of SEQ ID NOs: 39 and 110. In some cases, the Tn7-type transposase complex includes at least one TnsC component including a sequence having at least about 94% identity to any one of SEQ ID NOs: 39 and 110. In some cases, the Tn7-type transposase complex includes at least one TnsC component including a sequence having at least about 95% identity to any one of SEQ ID NOs: 39 and 110. In some cases, the Tn7-type transposase complex includes at least one TnsC component including a sequence having at least about 96% identity to any one of SEQ ID NOs: 39 and 110.In some cases, the Tn7-type transposase complex includes at least one TnsC component including a sequence at least about 97% identical to any one of SEQ ID NOs: 39 and 110. In some cases, the Tn7-type transposase complex includes at least one TnsC component including a sequence at least about 98% identical to any one of SEQ ID NOs: 39 and 110. In some cases, the Tn7-type transposase complex includes at least one TnsC component including a sequence at least about 99% identical to any one of SEQ ID NOs: 39 and 110. In some cases, the Tn7-type transposase complex includes at least one TnsC component including a sequence 100% identical to any one of SEQ ID NOs: 39 and 110.

[0303] In some cases, the Tn7-type transposase complex includes TnsB and TnsC components comprising a sequence at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 40 and 39 or 109 and 110. In some cases, the Tn7-type transposase complex includes TnsB and TnsC components comprising a sequence substantially identical to any one of SEQ ID NOs: 40 and 39 or 109 and 110, respectively, or variants thereof.

[0304] In some embodiments, the systems disclosed herein include at least one engineered guide polynucleotide, such as a gRNA.

[0305] In some embodiments, provided herein are engineered guide polynucleotides, such as guide RNA (gRNA).

[0306] In some cases, the engineered guide polynucleotide includes a sequence comprising at least about 46-80 contiguous nucleotides having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NOs: 118, 182, 183, 235, and 236. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides at least 70% identical to any one of SEQ ID NOs: 118, 182, 183, 235, and 236. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides at least 75% identical to any one of SEQ ID NOs: 118, 182, 183, 235, and 236. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides at least 80% identical to any one of SEQ ID NOs: 118, 182, 183, 235, and 236. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides at least 85% identical to any one of SEQ ID NOs: 118, 182, 183, 235, and 236. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides at least 90% identical to any one of SEQ ID NOs: 118, 182, 183, 235, and 236. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides at least 91% identical to any one of SEQ ID NOs: 118, 182, 183, 235, and 236. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides at least 92% identical to any one of SEQ ID NOs: 118, 182, 183, 235, and 236. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides at least 93% identical to any one of SEQ ID NOs: 118, 182, 183, 235, and 236. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides that is at least 94% identical to any one of SEQ ID NOs: 118, 182, 183, 235, and 236.In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides at least 95% identical to any one of SEQ ID NOs: 118, 182, 183, 235, and 236. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides at least 96% identical to any one of SEQ ID NOs: 118, 182, 183, 235, and 236. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides at least 97% identical to any one of SEQ ID NOs: 118, 182, 183, 235, and 236. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides at least 98% identical to any one of SEQ ID NOs: 118, 182, 183, 235, and 236. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides at least 99% identical to any one of SEQ ID NOs: 118, 182, 183, 235, and 236. In some embodiments, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides 100% identical to any one of SEQ ID NOs: 118, 182, 183, 235, and 236.

[0307] In some cases, the engineered guide polynucleotide comprises a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to the non-degenerate nucleotides of any one of SEQ ID NOs: 115-116, 205-206, and 493. In some cases, the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides substantially identical to the non-degenerate nucleotides of any one of SEQ ID NOs: 115-116, 205-206, and 493, or variants thereof.

[0308] In some cases, the engineered guide polynucleotide comprises a sequence that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 115-116, 205-206, and 493. In some embodiments, the engineered guide polynucleotide comprises a sequence that is at least about 70% identical to any one of SEQ ID NOs: 115-116, 205-206, and 493. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 75% identical to any one of SEQ ID NOs: 115-116, 205-206, and 493. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 80% identical to any one of SEQ ID NOs: 115-116, 205-206, and 493. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 85% identical to any one of SEQ ID NOs: 115-116, 205-206, and 493. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 90% identical to any one of SEQ ID NOs: 115-116, 205-206, and 493. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 91% identical to any one of SEQ ID NOs: 115-116, 205-206, and 493. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 92% identical to any one of SEQ ID NOs: 115-116, 205-206, and 493. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 93% identical to any one of SEQ ID NOs: 115-116, 205-206, and 493. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 94% identical to any one of SEQ ID NOs: 115-116, 205-206, and 493. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 95% identical to any one of SEQ ID NOs: 115-116, 205-206, and 493. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 96% identical to any one of SEQ ID NOs: 115-116, 205-206, and 493.In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 97% identical to any one of SEQ ID NOs: 115-116, 205-206, and 493. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 98% identical to any one of SEQ ID NOs: 115-116, 205-206, and 493. In some embodiments, the engineered guide polynucleotide comprises a sequence at least about 99% identical to any one of SEQ ID NOs: 115-116, 205-206, and 493. In some embodiments, the engineered guide polynucleotide comprises a sequence 100% identical to any one of SEQ ID NOs: 115-116, 205-206, and 493.

[0309] In some embodiments, the guide RNA comprises synthetic nucleotides or modified nucleotides. In some embodiments, the guide RNA comprises one or more internucleoside linkers modified by natural phosphodiester. In some embodiments, all internucleoside linkers of the guide RNA or its continuous nucleotide sequence are modified. For example, in some embodiments, the internucleoside bond comprises sulfur (S), such as a thiophosphate internucleoside bond.

[0310] In some embodiments, the guide RNA includes modifications to ribose sugar or nucleobase. In some embodiments, the guide RNA includes one or more nucleosides, the nucleosides including modified sugar moieties, wherein when compared to the ribose sugar moieties present in deoxyribonucleic acid (DNA) and RNA, the modified glucose moieties are modifications of sugar moieties. In some embodiments, the modification is within the ribose ring structure. Exemplary modifications include but are not limited to substitution with a hexose ring (HNA), a bicyclic ring (e.g., locked nucleic acid (LNA)) having a diradical bridge between the C2 carbon and the C4 carbon on the ribose ring, or an unconnected ribose ring (e.g., UNA) that lacks a bond between the C2 carbon and the C3 carbon. In some embodiments, sugar-modified nucleosides include bicyclic hexose nucleic acids or tricyclic nucleic acids. In some embodiments, modified nucleosides include nucleosides in which the sugar moiety is replaced by a non-sugar moiety, such as a peptide nucleic acid (PNA) or a morpholino nucleic acid.

[0311] In some embodiments, the guide RNA includes one or more modified sugars. In some embodiments, sugar modifications include modifications by changing the substituents on the ribose ring to groups other than hydrogen or 2'-OH groups naturally present in DNA and RNA nucleosides. In some embodiments, the substituents are introduced at 2', 3', 4' or 5' positions or combinations thereof. In some embodiments, nucleosides with modified sugar moieties include 2' modified nucleosides, such as 2' substituted nucleosides. In some embodiments, 2' sugar-modified nucleosides are nucleosides with substituents other than -H or -OH (2' substituted nucleosides) or including 2' connected diradicals at 2' positions, and include 2' substituted nucleosides and LNA (2'-4' diradical bridged) nucleosides. Examples of 2'-substituted modified nucleosides include, but are not limited to, 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-fluoro-RNA and 2'-F-ANA nucleosides. In some embodiments, the modification in the ribose group comprises a modification at the 2' position of the ribose group. In some embodiments, the modification at the 2' position of the ribose group is selected from the group consisting of: 2'-O-methyl, 2'-fluoro, 2'-deoxy, and 2'-O-(2-methoxyethyl).

[0312] In some embodiments, the guide RNA includes one or more modified sugars. In some embodiments, the guide RNA includes only modified sugars. In certain embodiments, the guide RNA includes greater than about 10%, 25%, 50%, 75% or 90% modified sugars. In some embodiments, the modified sugar is a bicyclic sugar. In some embodiments, the modified sugar includes 2'-O-methoxyethyl. In some embodiments, the guide RNA includes both internucleoside linker modifications and nucleoside modifications.

[0313] In some cases, the guide RNA includes a sequence complementary to a eukaryotic, fungal, plant, mammalian or human genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a eukaryotic genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a fungal genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a plant genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a mammalian genome polynucleotide sequence. In some cases, the guide RNA includes a sequence complementary to a human genome polynucleotide sequence.

[0314] In some embodiments, the guide RNA is 30-250 nucleotides in length. In some embodiments, the guide RNA is more than 90 nucleotides in length. In some embodiments, the guide RNA is less than 245 nucleotides in length. In some embodiments, the guide RNA is 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, or more than 240 nucleotides in length. In some embodiments, the guide RNA is about 30 to about 40, about 30 to about 50, about 30 to about 60, about 30 to about 70, about 30 to about 80, about 30 to about 90, about 30 to about 100, about 30 to about 120, about 30 to about 140, about 30 to about 160, about 30 to about 180, about 30 to about 200, about 30 to about 220, about 30 to about 240, about 50 to about 60, about 50 to about 70, about 50 to about 80, about 50 to about 90, about 50 to about 100, about 30 to about 120, about 30 to about 140, about 30 to about 160, about 30 to about 180, about 30 to about 200, about 30 to about 220, about 30 to about 240, about 50 to about 60, about 50 to about 70, about 50 to about 80, about 50 to about 90, about 50 to about 100 In the present invention, the present invention relates to a polypeptide having at least one nucleotide sequence and at least one nucleotide sequence. In the present invention, the present invention relates to a polypeptide having at least one nucleotide sequence and at least one nucleotide sequence. In the present invention, the present invention relates to a polypeptide having at least one nucleotide sequence and at least one nucleotide sequence.

[0315] In some cases, the left recombinase sequence comprises a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to SEQ ID NO: 134. In some cases, the left recombinase sequence comprises a sequence having at least about 70% identity to SEQ ID NO: 134. In some cases, the left recombinase sequence comprises a sequence having at least about 75% identity to SEQ ID NO: 134. In some cases, the left recombinase sequence comprises a sequence having at least about 80% identity to SEQ ID NO: 134. In some cases, the left recombinase sequence includes a sequence having at least about 85% identity to SEQ ID NO: 134. In some cases, the left recombinase sequence includes a sequence having at least about 90% identity to SEQ ID NO: 134. In some cases, the left recombinase sequence includes a sequence having at least about 91% identity to SEQ ID NO: 134. In some cases, the left recombinase sequence includes a sequence having at least about 92% identity to SEQ ID NO: 134. In some cases, the left recombinase sequence includes a sequence having at least about 93% identity to SEQ ID NO: 134. In some cases, the left recombinase sequence includes a sequence having at least about 94% identity to SEQ ID NO: 134. In some cases, the left recombinase sequence includes a sequence having at least about 95% identity to SEQ ID NO: 134. In some cases, the left recombinase sequence includes a sequence having at least about 96% identity to SEQ ID NO: 134. In some cases, the left recombinase sequence includes a sequence having at least about 97% identity to SEQ ID NO: 134. In some cases, the left recombinase sequence comprises a sequence having at least about 98% identity to SEQ ID NO: 134. In some cases, the left recombinase sequence comprises a sequence having at least about 99% identity to SEQ ID NO: 134. In some cases, the left recombinase sequence comprises a sequence having 100% identity to SEQ ID NO: 134.

[0316] In some cases, the right recombinase sequence comprises a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to SEQ ID NO: 135. In some cases, the right recombinase sequence comprises a sequence having at least about 70% identity to SEQ ID NO: 135. In some cases, the right recombinase sequence comprises a sequence having at least about 75% identity to SEQ ID NO: 135. In some cases, the right recombinase sequence comprises a sequence having at least about 80% identity to SEQ ID NO: 135. In some cases, the right recombinase sequence includes a sequence having at least about 85% identity to SEQ ID NO: 135. In some cases, the right recombinase sequence includes a sequence having at least about 90% identity to SEQ ID NO: 135. In some cases, the right recombinase sequence includes a sequence having at least about 91% identity to SEQ ID NO: 135. In some cases, the right recombinase sequence includes a sequence having at least about 92% identity to SEQ ID NO: 135. In some cases, the right recombinase sequence includes a sequence having at least about 93% identity to SEQ ID NO: 135. In some cases, the right recombinase sequence includes a sequence having at least about 94% identity to SEQ ID NO: 135. In some cases, the right recombinase sequence includes a sequence having at least about 95% identity to SEQ ID NO: 135. In some cases, the right recombinase sequence includes a sequence having at least about 96% identity to SEQ ID NO: 135. In some cases, the right recombinase sequence includes a sequence having at least about 97% identity to SEQ ID NO: 135. In some cases, the right recombinase sequence comprises a sequence that is at least about 98% identical to SEQ ID NO: 135. In some cases, the right recombinase sequence comprises a sequence that is at least about 99% identical to SEQ ID NO: 135. In some cases, the right recombinase sequence comprises a sequence that is 100% identical to SEQ ID NO: 135.

[0317] In some cases, the class 2 type V Cas effector and Tn7-type transposase complex is encoded by a polynucleotide sequence comprising less than about 20 kilobases, less than about 15 kilobases, less than about 10 kilobases, or less than about 5 kilobases.

[0318] MG110 System

[0319] In some embodiments, the present invention provides a MG110 system for transposing a cargo nucleotide sequence into a target nucleic acid site. In some embodiments, the system includes a double-stranded nucleic acid including a cargo nucleotide sequence. In some embodiments, the cargo nucleotide sequence is configured to interact with a Tn7 transposase complex. In some embodiments, the system includes a Cas effector complex. In some embodiments, the Cas effector complex includes a Class I type I Cas effector and an engineered guide polynucleotide configured to hybridize with a target nucleotide sequence. In some embodiments, the system includes a Tn7 transposase complex configured to bind to a Cas effector complex.

[0320] In some cases, the cargo nucleotide sequence is flanked by a left transposase recognition sequence. In some cases, the cargo nucleotide sequence is flanked by a right transposase recognition sequence. In some cases, the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence.

[0321] In some cases, the target nucleic acid includes a target nucleic acid site. In some cases, the target nucleic acid includes a PAM sequence that is compatible with the Cas effector complex adjacent to the target nucleic acid site. In some cases, the PAM sequence is located at 3' of the target nucleic acid site. In some cases, the PAM sequence is located at 5' of the target nucleic acid site.

[0322] In some cases, the engineered guide polynucleotide is configured to bind a Class 1, Type I Cas effector. In some cases, the Class 1, Type I Cas effector includes a polypeptide comprising a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NOs: 41-43 and 48-50. In some cases, the class 1 type I Cas effector includes a polypeptide comprising a sequence having at least about 70% identity to any one of SEQ ID NOs: 41-43 and 48-50. In some cases, the class 1 type I Cas effector includes a polypeptide comprising a sequence having at least about 75% identity to any one of SEQ ID NOs: 41-43 and 48-50. In some cases, the class 1 type I Cas effector includes a polypeptide comprising a sequence having at least about 80% identity to any one of SEQ ID NOs: 41-43 and 48-50. In some cases, the class 1 type I Cas effector includes a polypeptide comprising a sequence having at least about 85% identity to any one of SEQ ID NOs: 41-43 and 48-50. In some cases, the class 1 type I Cas effector includes a polypeptide comprising a sequence having at least about 90% identity to any one of SEQ ID NOs: 41-43 and 48-50. In some cases, the class 1 type I Cas effector includes a polypeptide comprising a sequence having at least about 91% identity to any one of SEQ ID NOs: 41-43 and 48-50. In some cases, the class 1 type I Cas effector includes a polypeptide comprising a sequence having at least about 92% identity to any one of SEQ ID NOs: 41-43 and 48-50. In some cases, the class 1 type I Cas effector includes a polypeptide comprising a sequence having at least about 93% identity to any one of SEQ ID NOs: 41-43 and 48-50. In some cases, the class 1 type I Cas effector includes a polypeptide comprising a sequence having at least about 94% identity to any one of SEQ ID NOs: 41-43 and 48-50. In some cases, the class 1 type I Cas effector includes a polypeptide comprising a sequence having at least about 95% identity to any one of SEQ ID NOs: 41-43 and 48-50. In some cases, the Class 1 type I Cas effector includes a polypeptide comprising a sequence at least about 96% identical to any one of SEQ ID NOs: 41-43 and 48-50.In some cases, the class 1 type I Cas effector comprises a polypeptide comprising a sequence having at least about 97% identity to any one of SEQ ID NOs: 41-43 and 48-50. In some cases, the class 1 type I Cas effector comprises a polypeptide comprising a sequence having at least about 98% identity to any one of SEQ ID NOs: 41-43 and 48-50. In some cases, the class 1 type I Cas effector comprises a polypeptide comprising a sequence having at least about 99% identity to any one of SEQ ID NOs: 41-43 and 48-50. In some cases, the class 1 type I Cas effector comprises a polypeptide comprising a sequence having 100% identity to any one of SEQ ID NOs: 41-43 and 48-50.

[0323] In some cases, the engineered guide polynucleotide is configured to bind a Class 1, Type I Cas effector. In some cases, the Class 1, Type I Cas effector includes Cas6, Cas7, and Cas8 effectors comprising a sequence having at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to any one of SEQ ID NOs: 41-43 and 48-50. In some cases, the Class 1 Type I Cas effectors include Cas6, Cas7, and Cas8 effectors comprising a sequence substantially identical to any one of SEQ ID NOs: 41-43 and 48-50.

[0324] In some cases, the Tn7-type transposase complex includes at least one polypeptide (e.g., at least 1, 2, 3, 4, 5, 6, or more than 6 polypeptides) that includes a sequence that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs:44-47 and 51-54. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence having at least about 70% identity to any one of SEQ ID NOs: 44-47 and 51-54. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence having at least about 75% identity to any one of SEQ ID NOs: 44-47 and 51-54. In some cases, the Tn7-type transposase complex includes at least one polypeptide including a sequence having at least about 80% identity to a...

Claims

1. A system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a) a Cas effector complex comprising 2 class II type Cas effectors, a small prokaryotic ribosomal protein subunit S15, and an engineered guide polynucleotide configured to hybridize to the target nucleic acid site; b) a recombinase or transposase complex configured to bind to the Cas effector complex; as well as c) a double-stranded nucleic acid configured to interact with the recombinase or transposase complex and comprising the cargo nucleotide sequence.

2. The system of claim 1, wherein the Cas effector complex is non-covalently bound to the recombinase or transposase complex.

3. The system of claim 1, wherein the Cas effector complex is covalently linked to the recombinase or transposase complex.

4. The system of claim 1, wherein the Cas effector complex is fused to the recombinase or transposase complex.

5. The system according to any one of claims 1 to 4, wherein the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence recognized by the recombinase or transposase complex.

6. The system of claim 5, wherein the left recombinase sequence comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 17-18.

7. The system of any one of claim 5, wherein the right recombinase sequence comprises a sequence having at least 80% identity to SEQ ID NO:

19.

8. The system of claims 1 to 7, wherein the target nucleic acid comprises a PAM sequence that is compatible with the Cas effector complex.

9. The system of claim 8, wherein the PAM sequence is located about 50 to about 70 base pairs from the target nucleic acid site.

10. The system of claim 9, wherein the PAM sequence is located 3' to the target nucleic acid site.

11. The system of claim 9, wherein the PAM sequence is located 5' to the target nucleic acid site.

12. The system of any one of claims 1 to 11, wherein the Class 2 type II Cas effector is not a Cas12k effector.

13. The system of any one of claims 1 to 11, wherein the Class 2 Type II Cas effector comprises a polypeptide comprising a sequence at least 80% identical to SEQ ID NO:

1.

14. The system of any one of claims 1 to 11, wherein the Class 2 Type II Cas effector comprises a polypeptide comprising a sequence at least 90% identical to SEQ ID NO:

1.

15. The system of any one of claims 1 to 11, wherein the Class 2 type II Cas effector comprises a polypeptide comprising the sequence of SEQ ID NO:

1.

16. The system of any one of claims 1 to 15, wherein the recombinase or transposase complex comprises at least one polypeptide comprising a sequence at least 80% identical to any one of SEQ ID NOs: 2-5.

17. The system of any one of claims 1 to 15, wherein the recombinase or transposase complex comprises at least one polypeptide comprising a sequence at least 90% identical to any one of SEQ ID NOs: 2-5.

18. The system of any one of claims 1 to 17, wherein the recombinase or transposase complex comprises at least one polypeptide comprising the sequence of any one of SEQ ID NOs: 2-5.

19. The system of any one of claims 1 to 18, wherein the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides having at least 80% identity to SEQ ID NO:

12.

20. The system of any one of claims 1 to 18, wherein the engineered guide polynucleotide comprises a sequence having at least 80% sequence identity to SEQ ID NO:

11.

21. The system of any one of claims 1 to 20, wherein the small prokaryotic ribosomal protein subunit S15 comprises a sequence having at least 80% sequence identity to any one of any one of SEQ ID NOs: 494-659.

22. The system of any one of claims 1 to 21, wherein the 2 class II type Cas effectors and the recombinase or transposase complex are encoded by a polynucleotide sequence comprising less than about 10 kilobases.

23. A system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a) a Cas effector complex comprising 2 type V Cas effectors, a small prokaryotic ribosomal protein subunit S15, and an engineered guide polynucleotide configured to hybridize to the target nucleic acid site; b) a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsA, TnsB, TnsC and TniQ components; as well as c) a double-stranded nucleic acid configured to interact with the Tn7-type transposase complex and comprising the cargo nucleotide sequence.

24. The system of claim 23, wherein the Cas effector complex is non-covalently associated with the Tn7-type transposase complex.

25. The system of claim 23, wherein the Cas effector complex is covalently linked to the Tn7-type transposase complex.

26. The system of claim 23, wherein the Cas effector complex is fused to the Tn7-type transposase complex.

27. The system of any one of claims 23 to 26, wherein the cargo nucleotide sequence is flanked by a left transposase recognition sequence and a right transposase recognition sequence recognized by the recombinase or transposase complex.

28. The system of claim 27, wherein the left recombinase sequence comprises a sequence having at least 80% identity to any one of SEQ ID NO:

20.

29. The system of claim 27, wherein the right recombinase sequence comprises a sequence having at least 80% identity to SEQ ID NO:

21.

30. The system of any one of claims 23 to 29, wherein the target nucleic acid comprises a PAM sequence that is compatible with the Cas effector complex.

31. The system of claim 30, wherein the PAM sequence is located about 50 to about 70 base pairs from the target nucleic acid site.

32. The system of claim 31, wherein the PAM sequence is located 3' to the target nucleic acid site.

33. The system of claim 31, wherein the PAM sequence is located 5' to the target nucleic acid site.

34. The system of any one of claims 23 to 33, wherein the Class 2 type V Cas effector is not a Cas12k effector.

35. The system of any one of claims 23 to 34, wherein the TnsA component comprises a polypeptide comprising a sequence at least 80% identical to SEQ ID NO:

7.

36. The system of any one of claims 23 to 25, wherein the Tn7-type transposase complex comprises at least one polypeptide comprising a sequence at least 80% identical to any one of SEQ ID NOs: 8-10.

37. The system of any one of claims 23 to 36, wherein the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides having at least 80% identity to any one of SEQ ID NOs: 13-16.

38. The system of any one of claims 23 to 37, wherein the small prokaryotic ribosomal protein subunit S15 comprises a sequence having at least 80% sequence identity to any one of any one of SEQ ID NOs: 494-659.

39. The system of any one of claims 23 to 38, wherein the 2 class II type Cas effectors and the recombinase or transposase complex are encoded by a polynucleotide sequence comprising less than about 10 kilobases.

40. A system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a) a Cas effector complex comprising a class 1 IF-type Cas effector, a small prokaryotic ribosomal protein subunit S15, and an engineered guide polynucleotide configured to hybridize to the target nucleic acid site; b) a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsA, TnsB, TnsC and TniQ components; as well as c) a double-stranded nucleic acid configured to interact with the Tn7-type transposase complex and comprising a cargo nucleotide sequence.

41. The system of claim 40, wherein the Cas effector complex is non-covalently associated with the Tn7-type transposase complex.

42. The system of claim 40, wherein the Cas effector complex is covalently linked to the Tn7-type transposase complex.

43. The system of claim 40, wherein the Cas effector complex is fused to the Tn7-type transposase complex.

44. The system of any one of claims 40 to 43, wherein the cargo nucleotide sequence is flanked by a left-side transposase recognition sequence and a right-side transposase recognition sequence recognized by the recombinase or transposase complex.

45. The system of claim 44, wherein the left recombinase sequence comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 136 and 138.

46. ​​The system of any one of claims 44, wherein the right recombinase sequence comprises a sequence having at least 80% identity to SEQ ID NOs: 137 and 139.

47. The system of claims 40 to 46, wherein the target nucleic acid comprises a PAM sequence that is compatible with the Cas effector complex.

48. The system of claim 47, wherein the PAM sequence is located about 50 to about 70 base pairs from the target nucleic acid site.

49. The system of claim 48, wherein the PAM sequence is located 3' to the target nucleic acid site.

50. The system of claim 48, wherein the PAM sequence is located 5' to the target nucleic acid site.

51. The system of any one of claims 40 to 50, wherein the Class 1 IF-type Cas effector comprises a polypeptide comprising a sequence at least 80% identical to any one of SEQ ID NOs: 41-43 and 48-50.

52. The system of any one of claims 40 to 50, wherein the Class 1 IF-type Cas effector comprises a polypeptide comprising a sequence at least 90% identical to any one of SEQ ID NOs: 41-43 and 48-50.

53. The system of any one of claims 40 to 50, wherein the Class 1 IF-type Cas effector comprises a polypeptide comprising the sequence of any one of SEQ ID NOs: 41-43 and 48-50.

54. The system of any one of claims 40 to 53, wherein the Tn7-type transposase complex comprises at least one polypeptide comprising a sequence at least 80% identical to any one of SEQ ID NOs: 44-47 and 51-54.

55. The system of any one of claims 40 to 53, wherein the Tn7-type transposase complex comprises at least one polypeptide comprising a sequence at least 90% identical to any one of SEQ ID NOs: 44-47 and 51-54.

56. The system of any one of claims 40 to 53, wherein the Tn7-type transposase complex comprises at least one polypeptide comprising the sequence of any one of SEQ ID NOs: 44-47 and 51-54.

57. The system of any one of claims 40 to 56, wherein the small prokaryotic ribosomal protein subunit S15 comprises a sequence having at least 80% sequence identity to any one of any one of SEQ ID NOs: 494-659.

58. The system of any one of claims 40 to 57, wherein the 2 class II type Cas effectors and the recombinase or transposase complex are encoded by a polynucleotide sequence comprising less than about 10 kilobases.

59. A system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a) a Cas effector complex configured to hybridize to the target nucleic acid site and comprising: i) a Class 2 type V Cas effector comprising a polypeptide having a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 90-93, 111-114, 117, 151, 156-181, 201-204, 209-234, 255-258, 262, 263, 348, 350-353, 417-460, 491-492, and 715-739; b) a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsB, TnsC, and TniQ components, wherein the TnsB, TnsC, or TniQ components comprise a sequence having at least 80% identity to any one of SEQ ID NOs: 23-25, 27-29, 31-33, 35-37, 101-103, 105-107, 148-150, 305-343, and 345-347; and c) a double-stranded nucleic acid configured to interact with the Tn7-type transposase complex and comprising, in 5' to 3' order: i) a left recombinase sequence comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 123, 125, 127, 129, 131, 133, 153, 354-358, 461, 463, 465, and 467; ii) the cargo nucleotide sequence; and iii) a right recombinase sequence comprising a sequence that is at least 80% identical to any one of SEQ ID NOs: 124, 126, 128, 130, 132, 154, 155, 359-363, 462, 464, 466 and 468.

60. A system for transposing a cargo nucleotide sequence into a target nucleic acid site, the system comprising: a) a Cas effector complex configured to hybridize to the target nucleic acid site and comprising: i) a Class 2 type V Cas effector comprising a polypeptide having a sequence having at least 80% sequence identity to SEQ ID NO: 22; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 90, 112, and 202; b) a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsB, TnsC, and TniQ components, wherein the TnsB, TnsC, or TniQ components comprise a sequence having at least 80% identity to any one of SEQ ID NOs: 23-25; and c) a double-stranded nucleic acid configured to interact with the Tn7-type transposase complex and comprising, in 5' to 3' order: i) a left recombinase sequence, the left recombinase sequence comprising a sequence having at least 80% sequence identity to SEQ ID NO: 125; ii) the cargo nucleotide sequence; and iii) a right recombinase sequence comprising a sequence that is at least 80% identical to any one of SEQ ID NOs: 126 and 155.

61. A system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a) a Cas effector complex configured to hybridize to the target nucleic acid site and comprising: i) a class 2 type V Cas effector comprising a polypeptide having a sequence having at least 80% sequence identity to SEQ ID NO: 26; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 91, 113, 156, 203, and 209; b) a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsB, TnsC, and TniQ components, wherein the TnsB, TnsC, or TniQ components comprise a sequence having at least 80% identity to any one of SEQ ID NOs: 27-29; and c) a double-stranded nucleic acid configured to interact with the Tn7-type transposase complex and comprising, in 5' to 3' order: i) a left recombinase sequence, the left recombinase sequence comprising a sequence having at least 80% sequence identity to SEQ ID NO: 127; ii) the cargo nucleotide sequence; and iii) a right recombinase sequence, the right recombinase sequence comprising a sequence having at least 80% identity to SEQ ID NO:

128.

62. A system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a) a Cas effector complex configured to hybridize to the target nucleic acid site and comprising: i) a class 2 type V Cas effector comprising a polypeptide having a sequence having at least 80% sequence identity to SEQ ID NO: 60; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 117, 119, 161, and 214; b) a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsB, TnsC, and TniQ components, wherein the TnsB, TnsC, or TniQ components comprise a sequence having at least 80% identity to any one of SEQ ID NOs: 101-103; and c) a double-stranded nucleic acid configured to interact with the Tn7-type transposase complex and comprising, in 5' to 3' order: i) a left recombinase sequence, the left recombinase sequence comprising a sequence having at least 80% sequence identity to SEQ ID NO: 131; ii) the cargo nucleotide sequence; and iii) a right recombinase sequence, the right recombinase sequence comprising a sequence having at least 80% identity to SEQ ID NO:

132.

63. A system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a) a Cas effector complex configured to hybridize to the target nucleic acid site and comprising: i) a class 2 type V Cas effector comprising a polypeptide having a sequence having at least 80% sequence identity to SEQ ID NO: 147; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 151, 181, and 234; b) a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsB, TnsC, and TniQ components, wherein the TnsB, TnsC, or TniQ components comprise a sequence having at least 80% identity to any one of SEQ ID NOs: 148-150; and c) a double-stranded nucleic acid configured to interact with the Tn7-type transposase complex and comprising, in 5' to 3' order: i) a left recombinase sequence comprising a sequence having at least 80% sequence identity to SEQ ID NO: 153; ii) the cargo nucleotide sequence; and iii) a right recombinase sequence, the right recombinase sequence comprising a sequence having at least 80% identity to SEQ ID NO:

154.

64. A system for transposing a cargo nucleotide sequence into a target nucleic acid site, the system comprising: a) a Cas effector complex configured to hybridize to a target nucleic acid site in a target nucleic acid site and comprising: i) a class 2 type V Cas effector comprising a polypeptide having a sequence having at least 80% sequence identity to SEQ ID NO: 34; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 93, 114, 157, 204, and 210; b) a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsB, TnsC, and TniQ components, wherein the TnsB, TnsC, or TniQ components comprise a sequence having at least 80% identity to any one of SEQ ID NOs: 148-150; and c) a double-stranded nucleic acid configured to interact with the Tn7-type transposase complex and comprising, in 5' to 3' order: i) a left recombinase sequence comprising a sequence having at least 80% sequence identity to SEQ ID NO: 129; ii) the cargo nucleotide sequence; and iii) a right recombinase sequence, the right recombinase sequence comprising a sequence having at least 80% identity to SEQ ID NO:

130.

65. A system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a) a Cas effector complex configured to hybridize to the target nucleic acid site and comprising: i) a class 2 type V Cas effector comprising a polypeptide having a sequence having at least 80% sequence identity to SEQ ID NO: 30; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 92, 111, and 201; b) a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsB, TnsC, and TniQ components, wherein the TnsB, TnsC, or TniQ components comprise a sequence having at least 80% identity to any one of SEQ ID NOs: 31-33; and c) a double-stranded nucleic acid configured to interact with the Tn7-type transposase complex and comprising, in 5' to 3' order: i) a left recombinase sequence, the left recombinase sequence comprising a sequence having at least 80% sequence identity to SEQ ID NO: 123; ii) the cargo nucleotide sequence; and iii) a right recombinase sequence, the right recombinase sequence comprising a sequence having at least 80% identity to SEQ ID NO:

124.

66. A system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a) a Cas effector complex configured to hybridize to the target nucleic acid site and comprising: i) a class 2 type V Cas effector comprising a polypeptide having a sequence having at least 80% sequence identity to SEQ ID NO: 38; and ii) an engineered guide polynucleotide comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 98, 115-116, 182, 205-206, 235, and 493; b) a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsB, TnsC, and TniQ components, wherein the TnsB, TnsC, or TniQ components comprise a sequence having at least 80% identity to any one of SEQ ID NOs: 39 and 40; and c) a double-stranded nucleic acid configured to interact with the Tn7-type transposase complex and comprising, in 5' to 3' order: i) a left recombinase sequence, the left recombinase sequence comprising a sequence having at least 80% sequence identity to SEQ ID NO: 134; ii) the cargo nucleotide sequence; and iii) a right recombinase sequence, the right recombinase sequence comprising a sequence having at least 80% identity to SEQ ID NO:

135.

67. The system of any one of claims 59 to 66, wherein the class 2 type V Cas effector is a Cas12k effector.

68. The system of any one of claims 59 to 67, wherein the target nucleic acid comprises a PAM sequence that is compatible with the Cas effector complex.

69. The system of claim 68, wherein the PAM sequence is located 5' of the target nucleic acid site.

70. The system of any one of claims 68 to 69, wherein the PAM sequence comprises 5'-nGTn-3' or 5'-nGTt-3'.

71. The system of any one of claims 59 to 70, wherein the Cas effector complex further comprises a small prokaryotic ribosomal protein subunit S15.

72. The system of claim 71, wherein the small prokaryotic ribosomal protein subunit S15 comprises a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 494-659.

73. The system of claim 71, wherein the class 2 type V Cas effector and the Tn7-type transposase complex are encoded by a polynucleotide sequence comprising less than about 10 kilobases.

74. A system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a) a Cas effector complex comprising 2 type V Cas effectors, a small prokaryotic ribosomal protein subunit S15, and an engineered guide polynucleotide configured to hybridize to the target nucleic acid site; b) a Tn7-type transposase complex configured to bind to the Cas effector complex and comprising TnsB and TnsC components but not TnsA and / or TniQ components; as well as c) a double-stranded nucleic acid configured to interact with the Tn7-type transposase complex and comprising the cargo nucleotide sequence.

75. The system of claim 74, wherein the Cas effector complex is non-covalently associated with the Tn7-type transposase complex.

76. The system of claim 74, wherein the Cas effector complex is covalently linked to the Tn7-type transposase complex.

77. The system of claim 74, wherein the Cas effector complex is fused to the Tn7-type transposase complex.

78. The system of any one of claims 74 to 77, wherein the cargo nucleotide sequence is flanked by a left-side transposase recognition sequence and a right-side transposase recognition sequence recognized by the recombinase or transposase complex.

79. The system of claim 78, wherein the left recombinase sequence comprises a sequence at least 80% identical to any one of SEQ ID NO:

134.

80. The system of claim 78, wherein the right recombinase sequence comprises a sequence that is at least 80% identical to SEQ ID NO:

135.

81. The system of any one of claims 74 to 80, wherein the target nucleic acid comprises a PAM sequence that is compatible with the Cas effector complex.

82. The system of claim 81, wherein the PAM sequence is located about 50 to about 70 base pairs from the target nucleic acid site.

83. The system of claim 82, wherein the PAM sequence is located 3' to the target nucleic acid site.

84. The system of claim 82, wherein the PAM sequence is located 5' of the target nucleic acid site.

85. The system of any one of claims 74 to 84, wherein the Class 2, Type V Cas effector is a Cas12k effector.

86. The system of any one of claims 74 to 85, wherein the Class 2 type V Cas effector comprises a polypeptide comprising a sequence at least 80% identical to any one of SEQ ID NOs: 38 and 108.

87. The system of any one of claims 74 to 85, wherein the Class 2 type V Cas effector comprises a polypeptide comprising a sequence at least 90% identical to any one of SEQ ID NOs: 38 and 108.

88. The system of any one of claims 74 to 85, wherein the Class 2 type V Cas effector comprises a polypeptide comprising the sequence of any one of SEQ ID NOs: 38 and 108.

89. The system of any one of claims 74 to 88, wherein the TnsB subunit comprises a polypeptide comprising a sequence at least 80% identical to SEQ ID NO:40 or 109.

90. The system of any one of claims 74 to 89, wherein the TnsC subunit comprises a polypeptide comprising a sequence at least 80% identical to SEQ ID NO:39 or 110.

91. The system of any one of claims 74 to 90, wherein the Tn7-type transposase complex comprises at least one polypeptide comprising a sequence at least 80% identical to any one of SEQ ID NOs: 39-40, 109-110, and 344.

92. The system of any one of claims 74 to 91, wherein the engineered guide polynucleotide comprises a sequence at least 80% identical to any one of SEQ ID NOs: 115, 116, 205, 206, 261, 235, 260, and 236.

93. The system of any one of claims 74 to 91, wherein the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides having at least 80% identity to any one of SEQ ID NOs: 118, 182, 183, 235, and 236.

94. The system of any one of claims 74 to 93, wherein the small prokaryotic ribosomal protein subunit S15 comprises a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 494-659.

95. The system of any one of claims 74 to 94, wherein the 2 Class II type Cas effectors and the recombinase or transposase complex are encoded by a polynucleotide sequence comprising less than about 10 kilobases.

96. A system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a) a Cas effector complex comprising two class II type Cas effectors, a small prokaryotic ribosomal protein subunit S15, and an engineered guide polynucleotide, wherein the engineered guide polynucleotide is capable of hybridizing to the target nucleic acid; b) a recombinase or transposase complex, the recombinase or transposase complex being operably linked to the Cas effector complex; as well as c) a double-stranded nucleic acid, which comprises, in 5' to 3' order: i) left recombinase recognition sequence; ii) the cargo nucleotide sequence; and iii) a right recombinase recognition sequence, wherein the left recombinase recognition sequence and the right recombinase recognition sequence can be recognized by the recombinase or transposase complex.

97. A system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a) a Cas effector complex, the Cas effector complex comprising 2 types of V-type Cas effectors, a small prokaryotic ribosomal protein subunit S15, and an engineered guide polynucleotide, wherein the engineered guide polynucleotide is capable of hybridizing to the target nucleic acid; b) a Tn7-type transposase complex, which is operably linked to the Cas effector complex and includes TnsA, TnsB, TnsC and TniQ components; as well as c) a double-stranded nucleic acid, which comprises, in 5' to 3' order: i) left recombinase recognition sequence; ii) the cargo nucleotide sequence; and iii) a right recombinase recognition sequence, wherein the left recombinase recognition sequence and the right recombinase recognition sequence can be recognized by the Tn7-type transposase complex.

98. A system for transposing a cargo nucleotide sequence into a target nucleic acid site in a target nucleic acid, the system comprising: a) a Cas effector complex comprising a class 1 IF-type Cas effector, a small prokaryotic ribosomal protein subunit S15, and an engineered guide polynucleotide, wherein the engineered guide polynucleotide is capable of hybridizing to the target nucleic acid; b) a Tn7-type transposase complex, which is operably linked to the Cas effector complex and includes TnsA, TnsB, TnsC and TniQ components; as well as c) a double-stranded nucleic acid, which comprises, in 5' to 3' order: i) left recombinase recognition sequence; ii) the cargo nucleotide sequence; and iii) a right recombinase recognition sequence, wherein the left recombinase recognition sequence and the right recombinase recognition sequence can be recognized by the Tn7-type transposase complex.

99. An engineered nuclease system comprising: An endonuclease comprising a RuvC domain and a HNH domain, wherein the endonuclease is derived from an uncultured microorganism, wherein the endonuclease is a Class 2 Type II endonuclease comprising a sequence having at least 80% identity to SEQ ID NO: 1; and An engineered guide polynucleotide, wherein the engineered guide RNA is configured to form a complex with the endonuclease, and the engineered guide RNA comprises a spacer sequence configured to hybridize to a target nucleic acid sequence.

100. The engineered nuclease system of claim 99, wherein the engineered guide polynucleotide comprises at least 60-80 contiguous nucleotides having at least 80% identity to SEQ ID NO:

12.

101. The engineered nuclease system of claim 99, wherein the engineered guide polynucleotide comprises a sequence at least 80% identical to SEQ ID NO:

11.

102. An engineered nuclease system comprising: An endonuclease comprising a RuvC domain, wherein the endonuclease is derived from an uncultured microorganism, and wherein the endonuclease is a Class 2 V-type endonuclease having at least 80% identity to SEQ ID NO: 6; and An engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease, and the engineered guide RNA comprises a spacer sequence configured to hybridize to a target nucleic acid sequence.

103. The engineered nuclease system of claim 102, wherein the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides having at least 80% identity to any one of SEQ ID NOs: 13-16.

104. An engineered nuclease system comprising: An endonuclease comprising a RuvC domain, wherein the endonuclease is derived from an uncultured microorganism, and wherein the endonuclease is a Class 2 VK-type endonuclease having at least 80% identity to any one of SEQ ID NOs: 22, 26, 30, 34, 55-89, 104, 147, 264-304, and 660-689; and An engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease, and the engineered guide RNA comprises a spacer sequence configured to hybridize to a target nucleic acid sequence.

105. The engineered nuclease system of claim 104, wherein the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides having at least 80% identity to any one of SEQ ID NOs: 90-93, 117, 151, 156-181, 209-234, 417-460, and 715-739.

106. The engineered nuclease system of claim 104 or 105, wherein the engineered guide polynucleotide comprises a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 111-114, 201-206, 209, 210, 255-258, 262, 263, 348, 350-353, and 473-492.

107. An engineered nuclease system comprising: An endonuclease comprising a RuvC domain, wherein the endonuclease is derived from an uncultured microorganism, and wherein the endonuclease is a Class 2 VK-type endonuclease having at least 80% identity to SEQ ID NO: 38 or SEQ ID NO: 108; and An engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease, and the engineered guide RNA comprises a spacer sequence configured to hybridize to a target nucleic acid sequence.

108. The engineered nuclease system of claim 107, wherein the engineered guide polynucleotide comprises a sequence comprising at least about 46-80 consecutive nucleotides having at least 80% identity to any one of SEQ ID NOs: 118, 182, 183, 235, and 236.

109. The engineered nuclease system of claim 107, wherein the engineered guide polynucleotide comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 111-114, 115, 116, 201-206, 209, 210, 235, 236, 255-258, 260-263, 348, and 350-353.

110. An engineered nuclease system comprising: A Class 1 IF-type Cas endonuclease comprising at least one Cas6, Cas7 or Cas8 polypeptide comprising a sequence at least 80% identical to any one of SEQ ID NOs: 41-43 and 48-50; as well as An engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease, and the engineered guide RNA comprises a spacer sequence configured to hybridize to a target nucleic acid sequence.

111. The engineered nuclease system of claim 110, wherein the engineered guide polynucleotide comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 121, 122, 207, and 208.

112. A method for transposing a cargo nucleotide sequence into a target nucleic acid site, the method comprising introducing into a cell the system according to any one of claims 1 to 111.

113. A cell comprising the system according to any one of claims 1 to 111.

114. The cell of claim 113, wherein the cell is a eukaryotic cell.

115. The cell of claim 113, wherein the cell is a mammalian cell.

116. The cell of claim 113, wherein the cell is an immortalized cell.

117. The cell of claim 113, wherein the cell is an insect cell.

118. The cell of claim 113, wherein the cell is a yeast cell.

119. The cell of claim 113, wherein the cell is a plant cell.

120. The cell of claim 113, wherein the cell is a fungal cell.

121. The cell of claim 113, wherein the cell is a prokaryotic cell.

122. The cell of claim 113, wherein the cell is A549, HEK-293, HEK-293T, BHK, CHO, HeLa, MRC5, Sf9, Cos-1, Cos-7, Vero, BSC 1, BSC 40, BMT 10, WI38, HeLa, Saos, C2C12, L cell, HT1080, HepG2, Huh7, K562, a primary cell, or a derivative thereof.

123. The cell of claim 113, wherein the cell is an engineered cell.

124. The cell of claim 113, wherein the cell is a stable cell.